Induction, execution and clinical relevance of TNf- and TRAIL-induced necroptosis by Voigt, Susann
  
Induction, execution and clinical relevance of 
TNF- and TRAIL-induced necroptosis 
 
 
 
 
Dissertation 
 
zur Erlangung des Doktorgrades 
 
der Mathematisch-Naturwissenschaftlichen Fakultät 
 
der Christian-Albrechts-Universität zu Kiel 
 
 
vorgelegt von 
 
Susann Voigt 
 
Kiel 
2014 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Erster Gutachter:   Prof. Dr. Dieter Adam 
 
Zweiter Gutachter:   Prof. Dr. Dr. Thomas C. G. Bosch 
 
Tag der mündlichen Prüfung:  01.07.2014 
 
Zum Druck genehmigt:  01.07.2014   
 
gez. Prof. Dr. Wolfgang J. Duschl, Dekan 
  
 
 
 
 
 
 
 
 
Meinem Großvater 
Walter Bronkalla 
(1932-2011) 
Table of contents 
i 
 
I. Table of contents 
I. Table of contents i 
II. Abbreviations iv 
III. List of Figures viii 
IV. List of Tables x 
 
1. Summary 1 
1.1 Zusammenfassung 3 
 
2. Introduction 5 
2.1 Caspase-dependent programmed cell death – apoptosis ................................................... 5 
2.2 Caspase-independent programmed cell death – regulated necrosis .................................. 8 
2.2.1 Necroptosis ....................................................................................................................... 9 
2.2.1.1 Initiation of necroptosis .................................................................................................. 10 
2.2.1.2 Execution of necroptosis ................................................................................................. 12 
2.2.2 Regulated necrosis in health and disease ........................................................................ 14 
2.3 Death receptors ............................................................................................................... 16 
2.3.1 The TNF superfamily...................................................................................................... 16 
2.3.2 The death receptor TNF-R1 ............................................................................................ 16 
2.3.3 The complex signaling pathways of TNF-R1 ................................................................. 17 
2.3.4 The death receptors TRAIL-R1 and TRAIL-R2 ............................................................. 20 
2.4 Acid sphingomyelinase and its product ceramide .......................................................... 21 
2.4.1 Biological role and function of ceramide........................................................................ 21 
2.4.2 Biological functions and activation of acid sphingomyelinase ....................................... 22 
 
3. Aims of the presented dissertation 26 
 
4. Materials and Methods 28 
4.1 Materials ......................................................................................................................... 28 
4.1.1 Technical equipment ....................................................................................................... 28 
4.1.2 Chemicals and reagents .................................................................................................. 30 
4.1.3 Plasmids and siRNAs ..................................................................................................... 32 
4.1.4 Antibodies ....................................................................................................................... 34 
4.1.5 Cell lines ......................................................................................................................... 35 
4.2 Methods .......................................................................................................................... 37 
4.2.1 Cytotoxicity assays ......................................................................................................... 37 
4.2.1.1 Trypan blue staining ....................................................................................................... 37 
4.2.1.2 Measurement of intracellular ATP levels ....................................................................... 37
Table of contents 
ii 
 
4.2.1.3 Crystal violet staining ..................................................................................................... 37 
4.2.1.4 Propidium iodide staining ............................................................................................... 37 
4.2.2 Clonogenic survival assays ............................................................................................. 38 
4.2.3 Transfection .................................................................................................................... 38 
4.2.3.1 Nucleofection .................................................................................................................. 38 
4.2.3.2 Electroporation ............................................................................................................... 38 
4.2.3.3 Reverse transfection with siPORT™ Amine Transfection Agent .................................. 39 
4.2.3.4 Stable transfection of L929Ts cells ................................................................................ 39 
4.2.4 High-throughput RNA interference screen procedure with HT-29 cells ........................ 40 
4.2.5 Staining of cell surface molecules .................................................................................. 41 
4.2.5.1 Internalization studies of TNF-R1 .................................................................................. 41 
4.2.5.2 Cell surface staining of TRAIL receptors ....................................................................... 41 
4.2.6 Caspase activity assay ..................................................................................................... 42 
4.2.7 Intracellular ceramide quantification .............................................................................. 42 
4.2.8 A-SMase activity assay ................................................................................................... 43 
4.2.9 Preparation of cellular extracts ....................................................................................... 44 
4.2.10 Protein quantification ...................................................................................................... 44 
4.2.11 SDS-PAGE and Western blot analysis ........................................................................... 44 
4.2.12 Two-dimensional PAGE (2D-PAGE) ............................................................................ 45 
4.2.13 Two-dimensional difference gel electrophoresis (2D-DIGE) ......................................... 45 
4.2.14 In-gel tryptic digestion and MALDI-TOF/TOF MS analysis ......................................... 46 
4.2.15 Protein enrichment and analysis ..................................................................................... 47 
4.2.15.1 Immunoprecipitation ....................................................................................................... 47 
4.2.15.2 Electrospray ionization ................................................................................................... 47 
4.2.15.3 Purification of TNF ligands ............................................................................................ 49 
4.2.15.4 Preparation of magnetically labeled TNF receptors and isolation of TNF receptor 
magnetic fractions ........................................................................................................... 49 
4.2.16 Microscopy ..................................................................................................................... 51 
4.2.16.1 Documentation of cell morphology ................................................................................ 51 
4.2.16.2 Immunofluorescence analysis of suspension cells .......................................................... 51 
4.2.16.3 Immunofluorescence analysis of adherent cells ............................................................. 52 
4.2.17 Transformation of E. coli and plasmid purification ........................................................ 52 
4.2.18 Statistical analysis ........................................................................................................... 53 
 
5. Results 54 
 New model cell lines to study regulated necrosis: U-937 and HT-29 cells .................... 54 
 Conclusion ...................................................................................................................... 57 
5.1 TNF and PARP-1 elicit distinct routes to regulated necrosis ......................................... 57 
 Conclusion ...................................................................................................................... 64 
5.2 Proteolysis is crucial for the regulation of TNF-induced necroptosis ............................ 65
Table of contents 
iii 
 
5.2.1 Identification of HtrA2/Omi, PSA1, PMPCA and Lon protease as TFCK-sensitive 
proteases mediating necroptosis ..................................................................................... 65 
 Conclusion ...................................................................................................................... 72 
5.2.2 RNAi screen to identify proteases that regulate necroptosis .......................................... 73 
 Conclusion ...................................................................................................................... 80 
5.2.3 Identification of new proteins that are cleaved or differentially expressed during 
necroptosis as potential candidate regulators of necroptosis .......................................... 80 
 Conclusion ...................................................................................................................... 94 
5.2.4 The potentially pro-necroptotic protein PGAM5 is constitutively degraded in healthy 
cells ................................................................................................................................. 95 
 Conclusion ...................................................................................................................... 98 
5.2.5 Acid sphingomyelinase is proteolytically activated during TNF-induced necroptosis .. 99 
 Conclusion .................................................................................................................... 107 
5.2.6 The role of presenilin and the presenilin homologue signal-peptide-peptidase-like 
(SPPL) during TNF-induced necroptosis...................................................................... 108 
5.3 TRAIL-induced necroptosis is a novel approach to eliminate tumor cells ................... 110 
 Conclusion .................................................................................................................... 118 
 
6. Discussion 119 
6.1 TNF-induced necroptosis and PARP-1-mediated necrosis elicit distinct routes to 
regulated necrosis ......................................................................................................... 119 
6.2 Identification of proteases and proteolytic substrates involved in  TNF-induced 
necroptosis .................................................................................................................... 121 
6.2.1 HtrA2/Omi, Lon protease 1, PSA1 and PMPCA are TFCK-sensitive serine  proteases 
identified during necroptosis ........................................................................................ 122 
6.2.2 Five novel proteases enhance TNF-induced necroptosis .............................................. 124 
6.2.3 Newly identified signaling components of TNF-induced necroptosis .......................... 126 
6.2.4 PGAM5 is constitutively degraded under physiological conditions ............................. 129 
6.2.5 A-SMase is proteolytically cleaved during necroptosis ................................................ 130 
6.2.6 Presenilins are indispensable for TNF-induced necroptosis ......................................... 132 
6.3 TRAIL induces regulated necrosis in clinically relevant tumor cell lines .................... 133 
6.4 Conclusions and biological relevance of the above observations ................................. 136 
 
7. References 139 
8. Appendix 157 
9. List of publications 162 
10. Eidesstattliche Erklärung 163 
11. Danksagung 164 
12. Wissenschaftlicher Werdegang 165 
 
Abbreviations 
iv 
 
II. Abbreviations 
AAA    ATPases associated with diverse cellular activities 
ABC    ammonium bicarbonate 
ACN    acetonitrile 
ac-zDEVD-afc   benzyloxycarbonyl-Asp-Glu-Val-Asp-7-   
    aminotrifluoromethylcoumarin 
ac-zIETD-afc   benzyloxycarbonyl-Ile-Glu-Thr-Asp-aminotrifluoromethylcoumarin 
ADAMTS18   a disintegrin and metalloproteinase with thrombospondin motifs 18 
AIF    apoptosis inducing factor 
ANT    adenine nucleotide translocase 
Apaf-1    apoptotic protease activating factor-1 
AP-Q    aminopeptidase Q 
ASC    apoptosis-associated speck-like protein containing a CARD 
A-SMase   acid sphingomyelinase 
ATCC    American Type Culture Collection 
ATP    adenosine-5'-triphosphate 
Bcl-2    B-cell CLL/lymphoma-2 
BSA    bovine serum albumin 
CARD    caspase activation and recruitment domain 
Cas    cellular apoptosis susceptibility 
Caspase   cysteine-aspartate protease 
CASP8    caspase-8 
CAT    catalase 
CBPQ    carboxypeptidase Q 
CFLAR   caspase 8 and FADD-like apoptosis regulator 
CFL-1    cofilin-1 
c-FLIP    cellular FLICE-inhibitory protein 
CHX    cycloheximide 
cIAP    cellular inhibitor of apoptosis protein 
CID    collision-induced dissociation 
COXIV    cytochrome c oxidase subunit 4 
CrmA    cytokine response modifier protein A 
Ctr    control 
CYLD    cylindromatosis 
CypD    cyclophilin D 
DAG    diacylglycerol 
DAMPs   damage associated molecular patterns 
DAPK    death-associated protein kinase 
dATP    deoxyadenosine triphosphate 
DD    death domain 
DESC    transmembrane protease serine 11E 
DIABLO   direct inhibitor of apoptosis protein binding protein with low pI 
DIE    insulysin 
DISC    death inducing signaling complex 
DKO    double knock-out 
DMF    dimethylformamide 
DNML1   dynamin 1-like protein 
DPP8    dipeptidyl peptidase 8 
DPYL    dihydropyrimidinase-related protein 
Abbreviations 
v 
 
DPYSL4   dihydropyrimidinase-like 4 
DRs    death receptors 
Drp-1    dynamin 1-like protein 
dsRNA    double-stranded RNA 
DTT    dithiothreitol 
DUBs    deubiquitinating enzymes 
EDAR    ectodysplasin A receptor 
ENO1    alpha-enolase 
ER    endoplasmatic reticulum 
ESI    electrospray ionization 
ET    extracellular trap 
FA    formic acid 
FADD    Fas-associated protein with death domain 
FBP2    fructose-1,6-bisphosphatase 2 
FCS    fetal calf serum 
FFCK    fluorescently labeled N-tosyl-L-phenylalanine chloromethyl ketone-
    derivative 
FH    fumarate hydratase 
FLICE    FADD-like IL-1β-converting enzyme 
FLIPL    FLICE-like inhibitory protein long isoform 
G6P    glucose-6-phosphate 
Gas2    growth arrest-specific protein 2 
GDIA2    Rho GDP-dissociation inhibitor 2 
GFP    green fluorescent protein 
GGT1    gamma-glutamyltransferase 1 
GLT25D1   glycosyltransferase 25 domain-containing 1 
GLUD1   glutamate dehydrogenase 1 
GLUL    glutamate-ammonia ligase 
HAX-1    HCLS1-associated protein X-1 
HB    homogenization buffer 
HCD    higher-energy collisional dissociation 
HNRNP   heterogeneous nuclear ribonucleoprotein 
HPLC    high performance liquid chromatography 
HRP    horseradish peroxidase 
HSPB1    heat shock protein beta-1 
HtrA    high temperature requirement protein A 
IAP    inhibitor of apoptosis protein 
I-CLIPs   intramembrane-cleaving proteases 
IDH1    isocitrate dehydrogenase 1 
IEF    isoelectric focusing 
IF    immunofluorescence 
IFN    interferon 
IKK    IκB kinase 
IL    interleukin 
IMPDH2   inosine-5’-monophosphate dehydrogenase 2 
iTRAQ    isobaric tag for relative and absolute quantification 
JNK    c-Jun N-terminal kinases 
LAMP    lysosome-associated membrane glycoprotein 
LARD    lymphocyte-associated receptor of death 
LB    lysogeny broth 
LC    liquid chromatography 
LF    lung fibroblast 
LMP    lysosomal membrane permeabilization 
LONM    Lon protease 1 
LONP1    Lon protease 1 
LPS    lipopolysaccharide 
Abbreviations 
vi 
 
LUBAC   linear ubiquitin chain assembly complex 
MALDI   matrix-associated laser desorption/ionization 
MEF    mouse embryonic fibroblast 
MEP1B   meprin β 
MLKL    mixed lineage kinase domain-like 
MMP3    metalloproteinase 3 or stromelysin-1 
MMS    methyl methanesulfonate 
MNNG    1-methyl-3-nitro-1-nitrosoguanidine 
MOMP    mitochondrial outer membrane permeabilization 
MS    mass spectrometry 
MSN    moesin 
MTT    3-[4,5-dimethylthiazol-2yl]-2,5-diphenylterazolium bromide 
M6P    mannose-6-phosphate 
NAD    nicotinamide adenine dinucleotide 
NADPH   nicotinamide adenine dinucleotide phosphate 
Nec-1    necrostatin 1 
NEMO    NF-κB essential modulator 
NET    neutrophil extracellular trap 
NF-κB    nuclear factor-κB 
NGFR    nerve growth factor receptor 
NIK    NF-κB-inducing kinase 
NOD    nucleotide-binding oligomerization domain 
Nox1    NADPH oxidase-1 
NSA    necrosulfonamide 
N-SMase   neutral sphingomyelinase 
OPA1    optic atrophy 1 
OPG    osteoprotegerin 
PAGE    polyacrylamide gel electrophoresis 
PAK2    p21 activated kinase 2 
PARP    poly (ADP-ribose)-polymerase 
PBS    phosphate buffered saline 
PCD    programmed cell death 
PDIA6    protein disulfide isomerase A6 
Pea-15    phosphoprotein enriched in astrocytes 15 
PFA    paraformaldehyde 
PGAM    phosphoglycerate mutase family member 
PHGDH   D-3-phosphoglycerate dehydrogenase 
PI    propidium iodide 
PKC    protein kinase C 
PKM    pyruvate kinase isozymes M1/M2 
PKR2    cAMP-dependent protein kinase type II-alpha regulatory subunit 
PLA2    phospholipase A2 
PMPCA   mitochondrial processing peptidase alpha 
POD    alkaline phosphatase 
PRPF8    pre-mRNA processing factor 8 
PSA1    proteasome subunit, alpha type-1 
PSMA1   proteasome subunit, alpha type-1 
PTPC    permeability transition pore complex 
PYGL    glycogen phosphorylase 
Rab    Ras-related protein 
RHIM    RIPK homotypic interaction motif 
RIPK    receptor-interacting serine-threonine protein kinase 
RNAi    RNA interference 
ROCK-1   Rho-associated, coiled-coil containing protein kinase 1 
ROS    reactive oxygen species 
RT    room temperature 
Abbreviations 
vii 
 
SDS    sodium dodecyl sulphate 
siRNA    small interfering RNA 
SM    Smac mimetic/sphingomyelin 
Smac    second mitochondria-derived activator of caspases 
SMase    sphingomyelinase 
SPH    sphingosine 1-phosphate 
SPP    signal peptide peptidase 
SPPL    signal peptide peptidase-like 
S-SMase   secretory sphingomyelinase 
STMN1   stathmin 
SV40    simian virus 40 
TAB    transforming growth factor-β-activated kinase-binding protein 
tAIF    truncated apoptosis inducing factor 
TAILS    terminal amine isotopic labeling of substrates 
TAK1    TAB kinase 1 
TARD    tumor necrosis factor-receptor-related apoptosis-mediating protein 
TCA    trichloroacetic acid 
TFA    trifluoroacetic acid 
TFCK    N-tosyl-L-phenylalanine chloromethyl ketone 
TLR    Toll-like receptor 
TMPRSS11E   transmembrane protease serine 11E 
TNF    tumor necrosis factor 
TNF-R    TNF-receptor 
TOF    time-of-flight 
TR3    TNF-receptor-like 3 
TRADD   TNF-R1-associated protein with death domain 
TRAF2    TNF-R-associated factor 2 
TRAIL    TNF-related apoptosis inducing ligand 
TRAIL-R   TRAIL-receptor 
TRMP    transient receptor potential channels of the melastatin-like family 
TRMP7   transient receptor potential cation channel, subfamily M, member 7 
TUBA1B   tubulin alpha-1B chain 
VDAC    voltage-dependent anion channel 
wt    wild-type 
YME1L1   YME1-like ATPase 
zVAD-fmk   benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone 
2D-PAGE   two-dimensional polyacrylamide gel electrophoresis 
2D-DIGE   two-dimensional difference gel electrophoresis 
Commonly used abbreviations are not listed. 
List of Figures 
viii 
 
III. List of Figures 
Figure 1: Apoptosis, the caspase-dependent programmed cell death pathway. 
Figure 2: TNF-R1-mediated necroptosis. 
Figure 3: TNF-R1-mediated signaling pathways. 
Figure 4: Regulation of ceramide levels and its biological role. 
Figure 5: High-throughput siRNA screen for proteases participating in necroptosis. 
Figure 6: Treatment with TNF/zVAD/CHX or TRAIL/zVAD/CHX elicits necroptosis in U-937 
  and HT-29 cells. 
Figure 7: Characterization of necroptosis elicited by TNF in U-937 cells. 
Figure 8: Intracellular ceramide levels of U-937 and HT-29 cells increase in response to  
  treatment with TNF/zVAD/CHX or TRAIL/zVAD/CHX. 
Figure 9: TNF and MNNG elicit regulated necrosis in L929 cells. 
Figure 10: MNNG but not TNF(/zVAD/CHX) induces rapid ATP depletion. 
Figure 11: PARP-1 inhibitors affect MNNG-induced regulated necrosis but not TNF-induced 
  necroptosis. 
Figure 12: JNK do not participate in TNF-induced necroptosis. 
Figure 13: Cathepsin D plays no role in either TNF-induced necroptosis or the PARP pathway. 
Figure 14: RIPK3 is a crucial mediator of TNF-induced necroptosis, but not in the PARP  
  pathway. 
Figure 15: Inhibition of cathepsin or calpain/cysteine proteases and metalloproteases does not 
  protect U-937 cells from TNF-induced necroptosis. 
Figure 16: TFCK-specific serine proteases have an impact on TNF-induced necroptosis. 
Figure 17: Labeling of L929Ts cells with a fluorescent active-site-directed serine protease  
  inhibitor (FFCK). 
Figure 18: HtrA2/Omi is a candidate serine protease involved in necroptosis. 
Figure 19: Identification of the mitochondrial ATP-dependent protease Lon as a candidate serine 
  protease involved in necroptosis. 
Figure 20: The serine protease HtrA2/Omi mediates TNF-induced necroptosis. 
Figure 21: High-throughput siRNA screen for proteases participating in necroptosis. 
Figure 22: Exemplary control experiment for the validation of candidate proteases in HT-29  
  cells. 
Figure 23: Validation of 13 candidate proteases in HT-29 cells. 
Figure 24: Validation of 13 candidate proteases in U-937 cells. 
Figure 25: Role of MEP1B during necroptosis. 
Figure 26: Biological activity of TNF ligands. 
Figure 27: Determination of TNF-R1 internalization by flow cytometry. 
Figure 28: TNF-R1 is internalized upon induction of necroptosis. 
Figure 29: Stimulation with TNF leads to co-localization of internalized TNF-R1 with RIPK1. 
Figure 30: Immunofluorescence of TNF-R1-localization. 
Figure 31: TNF-dependent accumulation of proteins to necroptotic TNF-R1 magnetic fractions. 
Figure 32: TNF-dependent accumulation of proteins to the necroptotic TNF-R1 magnetic  
  fractions isolated from U-937 cells. 
Figure 33: Stathmin was identified by 2D-DIGE analysis and is potentially cleaved during TNF-
  induced necroptosis. 
Figure 34: Characterization of magnetically isolated TNF-R1-containing vesicles prior to 2D-
  DIGE analysis. 
List of Figures 
ix 
 
Figure 35: 2D gel and examples of spots identified after TNF60-Fc/zVAD stimulation in isolated 
  TNF-R1 magnetic fractions. 
Figure 36: Western blot of mitochondria-free necroptotic TNF-R1 magnetic and non-magnetic 
  fractions and 2D-DIGE analysis of the magnetic fractions. 
Figure 37: MLKL is a mediator of TNF-induced necroptosis. 
Figure 38: L929Ts cell lines overexpressing PGAM5-FLAG. 
Figure 39: Serine proteases (HtrA2/Omi) and the proteasome are physiological regulators of 
  PGAM5. 
Figure 40: A-SMase is cleaved after TNF/zVAD stimulation. 
Figure 41: Proteolytic activation of A-SMase in necroptosis. 
Figure 42: TNF/zVAD-induced A-SMase cleavage and activation occurs downstream of RIPK1. 
Figure 43:  A-SMase cleavage and activation in L929Ts cells occurs downstream of MLKL and is 
  inhibited by dynasore. 
Figure 44: A-SMase activity after TNF-induced necroptosis in wild-type and caspase-7 deficient 
  MEFs. 
Figure 45: Enrichment of full-length and processed V5-A-SMase. 
Figure 46: Sequence coverage of full-length and processed A-SMase during TNF-induced  
  necroptosis. 
Figure 47: Comparison of sequence coverage of processed V5-A-SMase isolated from cells  
  undergoing TNF-induced necroptosis or TNF-induced apoptosis. 
Figure 48: The role of SPPLs and presenilin in TNF-induced necroptosis. 
Figure 49: Induction of regulated necrosis by TRAIL in human tumor cell lines. 
Figure 50: Birinapant enhances TRAIL-induced necroptosis. 
Figure 51: RIPK1 and RIPK3 are mediators of TRAIL-induced regulated necrosis. 
Figure 52: MLKL is a mediator of TRAIL-induced regulated necrosis. 
Figure 53: A-SMase activity is crucial for TRAIL- and TNF-induced regulated necrosis in human 
  tumor cell lines. 
Figure 54: Ceramide mediates TNF/zVAD-induced regulated necrosis downstream of RIPK3. 
Figure 55: TRAIL- and TNF-induced regulated necrosis reduces clonogenic survival of tumor 
  cells. 
Figure 56: TRAIL-induced regulated necrosis synergizes with chemotherapy in the elimination 
  of tumor cells. 
Figure 57: A general model of selected signaling pathways in regulated necrosis based on the 
  results obtained in the study presented here. 
List of Tables 
x 
 
IV. List of Tables 
Table 1: List of all siRNAs used. 
Table 2: List of all applied primary and secondary antibodies and their working dilutions. 
Table 3: Electroporation settings for U-937, HEK293T and L929Ts cells. 
Table 4: Proteases identified to have a positive or negative effect on TNF-induced necroptosis. 
Table S1: The 40 candidate proteases identified in the first siRNA screen whose down- 
  regulation either positively or negatively affects TNF-induced necroptosis in HT-29 
  cells. 
Table S2: Soluble proteins differentially regulated after induction of necroptosis which were 
  identified by MS analysis. 
Table S3: Proteins differentially regulated during necroptosis identified by MS analysis. 
Summary 
1 
 
1. Summary 
Regulated necrosis is important in many (patho)physiological settings. In contrast to apoptosis, the 
molecular mechanisms of the induction and execution of regulated necrosis are only marginally 
understood. This thesis therefore presents detailed analyses of different aspects of regulated necrosis: 
the characterization of distinct routes to regulated necrosis, the identification of novel proteins 
involved in the execution of necroptosis and the study of the applicability of tumor necrosis factor 
(TNF)-related apoptosis inducing ligand (TRAIL)-induced regulated necrosis in clinically relevant 
systems. 
In the first part of the thesis, it is shown that TNF-induced necroptosis and induction of the poly 
(ADP-ribose)-polymerase (PARP) pathway by DNA-damaging agents such as MNNG represent 
distinct and independent routes to regulated necrosis. The interruption of the PARP pathway by 
PARP-1 inhibitors prevented MNNG- but not TNF-induced necroptosis and the genetic interference 
with JNK kinases and the protease cathepsin D as further components of the PARP pathway did not 
affect TNF-induced necroptosis. Likewise, the interference with components important for TNF-
induced necroptosis such as the kinase RIPK3 did not prevent regulated necrosis through the PARP 
pathway. 
In the course of the work of this doctoral thesis, new components of the execution signaling 
mechanisms of TNF-induced necroptosis could be discovered. Experiments aimed at the identification 
of serine protease(s), which appear to be crucial in this pathway, found the serine protease HtrA2/Omi 
as a promising candidate. Pharmacological inhibition or genetic deletion of HtrA2/Omi protected from 
TNF-induced necroptosis, further substantiating its functional impact on necroptosis. In addition to 
HtrA2/Omi, the proteases Lon protease 1, PSA1 and PMPCA were identified as further potential 
components of the TNF-induced necroptotic pathway. By RNA interference screens using siRNAs 
targeting all proteases encoded by the human genome, 16 proteases were identified whose down-
regulation affects necroptosis in HT-29 cells. The impact of the candidate proteases CYLD, CASP8, 
DESC, GGT1, DPYL4, PRPF8, MMP3 and CFLAR on TNF-induced necroptosis could be also 
verified in U-937 cells. Additionally, the comparison of the proteomes of healthy cells or cells 
undergoing TNF-induced necroptosis via 2D-DIGE in combination with mass spectrometry revealed 
differentially expressed proteins (TUBA1B, PKM, CFL-1, IMPDH2, PHGDH, CAT) and possible 
substrates for proteolytic cleavage during necroptosis (moesin, stathmin). Furthermore, it was shown 
that acid sphingomyelinase (A-SMase) is proteolytically cleaved and activated in TNF-induced 
necroptosis. Besides the proteolytic regulation of A-SMase, it could be demonstrated that the 
potentially pro-necroptotic protein PGAM5 is constitutively degraded by yet unknown proteases in 
healthy cells and that this degradation is blocked upon induction of TNF-induced necroptosis. 
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Additionally, presenilins, which are parts of the catalytic core of the γ-secretase protease complex, 
were found to be involved in the execution of necroptosis. 
In the third part of the thesis, new and additional information on the potential of TRAIL-induced 
necroptosis in clinically relevant tumor cell lines of wide-ranging origin was obtained. Eight out of 14 
tumor cell lines were spontaneously sensitive to TRAIL-induced regulated necrosis and Smac 
mimetics could further enhance TRAIL-induced regulated necrosis. Clonogenic survival was reduced 
in all sensitive and even one resistant cell lines tested and TRAIL synergized with chemotherapeutics 
in killing resistant cell lines by regulated necrosis. At the molecular level, the obtained data point to a 
relation of the kinases RIPK3 and MLKL as primary targets for resistance or susceptibility of the 
analyzed tumor cells to regulated necrosis. Finally, the pharmacological inhibition of the ceramide 
generating-enzyme A-SMase showed protection against TRAIL- and TNF-induced necroptosis in 
multiple tumor cell lines, extending the previously established role of ceramide as a pivotal 
downstream mediator of death receptor-induced regulated necrosis and thus as a potential target for 
future therapy of cancer patients. 
Altogether, the data presented in this thesis substantiate the hypothesis that there are several 
independent pathways to regulated necrosis. The study provides a more detailed picture of necroptosis 
with newly identified proteins involved in the execution of necroptosis and it provides evidence that 
TRAIL-induced regulated necrosis represents a feasible approach for the elimination of tumor cells. In 
the long term, a better understanding of necroptosis and the distinct pathways of regulated necrosis 
may help to define potential targets for future therapies for diseases that arise from deregulated 
necrosis. 
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1.1 Zusammenfassung 
Die regulierte Nekrose stellt einen wichtigen Mechanismus in physiologischen und 
pathophysiologischen Szenarien dar. Im Gegensatz zur Apoptose sind die Induktions- und 
Wirkungsmechanismen der regulierten Nekrose nur ansatzweise erforscht. Die vorliegende Arbeit 
präsentiert daher detaillierte Analysen über relevante Aspekte der regulierten Nekrose: die 
Charakterisierung verschiedener Wege zur regulierten Nekrose, die Beschreibung neuer Proteine, die 
an der Ausführung der TNF-induzierten Nekroptose beteiligt sind und die Untersuchung ob TRAIL-
induzierte Nekroptose auch in klinisch relevanten Systemen angewendet werden kann. 
Die Ergebnisse aus dem ersten Teil dieser Arbeit zeigen, dass die TNF-induzierte Nekroptose und die 
Induktion der PARP-vermittelten regulierten Nekrose durch DNA-schädigende Agenzien wie MNNG 
zwei verschiedene und völlig voneinander unabhängige Wege der regulierten Nekrose darstellen. Die 
Blockierung der PARP-vermittelten regulierten Nekrose durch PARP-1 Inhibitoren verhinderte die 
MNNG-vermittelte, jedoch nicht die TNF-induzierte regulierte Nekrose. Die genetische Deletion 
nachgeschalteter Komponenten der PARP-vermittelten regulierten Nekrose (JNK Kinasen oder die 
Protease Cathepsin D) hatte keinen Effekt auf die TNF-induzierte regulierte Nekrose. Gleichermaßen 
hatte eine Inhibition der TNF-induzierten Nekroptose durch die Blockierung der für die Nekroptose 
essentiellen Proteinkinase RIPK3 keine Auswirkung auf die Aktivierung der PARP-vermittelten 
regulierten Nekrose. 
In der vorliegenden Arbeit konnten neue Komponenten der exekutiven Signaltransduktion der TNF-
vermittelten Nekroptose identifiziert werden. Experimente zur Identifizierung von Serinproteasen, 
welche wichtig für die Weiterleitung des nekroptotischen Signals zu sein scheinen, konnten 
HtrA2/Omi als vielversprechenden Kandidaten identifizieren. Ein Aktivitätsverlust von HtrA2/Omi 
durch die pharmakologische Inhibition oder genetische Ablation blockierte die TNF-induzierte 
Nekroptose, was als ein weiterer Beleg für eine wichtige Rolle von HtrA2/Omi in der Nekroptose 
gewertet werden kann. Neben HtrA2/Omi konnten außerdem die Proteasen Lon protease 1, PSA1 und 
PMPCA als weitere potentielle Komponenten der TNF-induzierten Nekroptose identifiziert werden. In 
einem komplementären Ansatz wurden alle im humanen Genom kodierten Proteasen mittels eines 
„small interfering“ siRNA Screens auf ihre Relevanz in der TNF-induzierten Nekroptose untersucht. 
In humanen HT-29 Zellen konnten 16 Proteasen ermittelt werden, deren Inhibition Effekte auf die 
TNF-induzierte Nekroptose zeigte. Die Bedeutung bestimmter Proteasen (CYLD, CASP8, DESC, 
GGT1, DPYL4, PRPF8, MMP3 und CFLAR) konnte auch in einem weiteren Zellsystem, humanen U-
937 Zellen, bestätigt werden. Zusätzlich konnten während des Vergleiches der Proteome von gesunden 
und nekroptotischen Zellen im 2D-DIGE Verfahren und nachfolgender Massenspektrometrie 
differenziell exprimierte Proteine (TUBA1B, PKM, CFL-1, IMPDH2, PHGDH, CAT) und mögliche 
Substratproteine für proteolytische Spaltung (Moesin, Stathmin) in nekroptotischen Zellen 
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nachgewiesen werden. Weiterhin konnte eine proteolytische Spaltung und die damit verbundene 
Aktivierung der sauren Sphingomyelinase (A-SMase) während der TNF-induzierten Nekroptose 
erstmals beschrieben werden. Neben der proteolytischen Aktivierung der A-SMase wurde eine 
proteolytische Degradierung des potentiell Nekroptose-vermittelnden Proteins PGAM5 in gesunden 
Zellen durch noch unbekannte Proteasen nachgewiesen. Dieser Abbau von PGAM5 wird durch die 
Einleitung der Nekroptose gehemmt. Weiterhin wurden Anhaltspunkte gefunden, dass Präseniline, die 
einen Teil des γ-Sekretase-Komplexes bilden, in der Nekroptose eine Rolle spielen.  
Im dritten Teil dieser Arbeit wurden neue und vielversprechende Informationen über die Induktion 
von nekroptotischen regulierten Zelltod durch TRAIL in klinisch relevanten Tumorzelllinien 
gewonnen. Acht der 14 untersuchten Zelllinien zeigten eine Sensibilität für nekroptotischen TRAIL-
vermittelten Zelltod. Diese Reaktion konnte durch die Zugabe von Smac-nachahmenden Molekülen 
noch verstärkt werden. Die Behandlung der Tumorzelllinien mit TRAIL ging einher mit dem Verlust 
der Klonogenität der sensitiven Tumorzelllinien und darüber hinaus auch einer resistenten 
Tumorzelllinie. Des Weiteren konnte gezeigt werden, dass die gemeinsame Behandlung mit TRAIL 
und Chemotherapeutika in den meisten resistenten Tumorzelllinien in Synergie regulierte Nekrose 
induziert. Auf molekularer Ebene zeigten die generierten Daten, dass RIPK3 und MLKL primäre 
Faktoren für die Resistenz oder Empfindlichkeit einzelner Zelllinien darstellen. Die pharmakologische 
Inaktivierung des Ceramid-produzierenden Enzyms A-SMase führte ebenfalls zu einer Blockierung 
der TRAIL- und TNF-vermittelten Nekroptose. Schlussfolgernd stellt Ceramid damit ein 
Schlüsselmolekül in der Todesrezeptor-vermittelten regulierten Nekrose dar und kann somit als 
potentielles Zielmolekül für eine zukünftige Therapie von Krebspatienten angesehen werden. 
Zusammenfassend untermauern die Ergebnisse der vorliegenden Arbeit die Existenz verschiedener, 
voneinander unabhängiger Signalwege der regulierten Nekrose. Die vorliegende Studie liefert ein 
detaillierteres Bild über neu identifizierte Proteine, die in die Prozesse der regulierten Nekrose 
eingebunden sind und liefert Belege, dass die TRAIL-vermittelte regulatorische Nekrose einen 
sinnvollen Ansatz für die Eliminierung von Tumorzellen darstellt. Langfristig kann ein verbessertes 
Verständnis der Nekroptose und der verschiedenen Signalwege der regulierten Nekrose dabei helfen, 
neue Zielmoleküle zu identifizieren, welche für die Entwicklung zukünftiger Behandlungsstrategien 
von Krankheiten wichtig sein könnten, die durch deregulierten Zelltod verursacht werden. 
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2. Introduction 
The balance between cell survival and cell death is a fundamental concept in biology, regulating the 
development and homeostasis of every organism. Already in 1842, the process of natural cell death 
was described by Carl Vogt. While studying tadpoles and their metamorphosis, he realized that the 
resorption and replacement of the notochord by the vertebrae must be a physiological process 
involving the death of certain cells (Vogt, 1842). Programmed cell death (PCD), first described in 
1964 by Lockshin and Williams, was defined as an important regulated cellular mechanism (Lockshin 
and Williams, 1964), likely involved in many human pathologies from viral infections to tumor 
formation or neurodegenerative diseases. PCD not only influences development: it is also involved in 
regulating tissue homeostasis by eliminating unwanted and harmful cells (Degterev and Yuan, 2008). 
Experiments using Caenorhabditis elegans unraveled, amongst others, the genetic program of 
apoptosis (Ellis and Horvitz, 1986). Apoptosis is defined by the induction of PCD through the 
activation of caspases (Galluzzi et al. 2012a), which is the classical and most studied primary route to 
death in most cell types. Historically, apoptosis was regarded to be the only form of PCD, whereas 
necrosis was considered to be an accidental, uncontrolled cell death as a consequence of extreme 
physicochemical stress. However, in the last 20 years, increasing evidence has accumulated showing 
that PCD can also occur independent from caspases and that different regulated types of necrosis exist. 
For example, it was shown that caspase inhibition can switch the toxic response evoked by TNF from 
apoptosis to necrosis (Vercammen et al. 1998a). In 2000, Holler and coworkers reported that the death 
receptor CD95 is, in some cell types, able to trigger necrotic-like cell death. This process is 
independent of caspases but dependent on both the adaptor protein Fas-associated protein with death 
domain (FADD) and receptor-interacting serine-threonine kinase 1 (RIPK1; Holler et al. 2000). The 
discovery of chemical inhibitors of necrosis led to the accumulation of additional lines of evidence for 
regulated types of necrosis (Degterev et al. 2005; Sun et al. 2012). The mechanisms of necrosis have 
been intensively investigated, revealing the existence of multiple pathways of regulated necrosis 
(discussed in detail in chapter 2.2). In the future, a better understanding of these pathways could be 
directly translated into improved therapies, for e.g., cancer, stroke or neurodegenerative diseases 
(Degterev and Yuan, 2008; Vandenabeele et al. 2010). 
2.1 Caspase-dependent programmed cell death – apoptosis 
The first study on the biochemical mechanisms of apoptosis was published in 1972 (Kerr et al. 1972) 
and opened the way to explore the relevance of this mode of PCD in fundamental processes such as 
tissue remodeling, homeostasis and the development of multi-cellular organisms. Apoptosis is 
characterized by the activation of cysteine-aspartate proteases (caspases). Caspase-dependent PCD 
(apoptosis) is defined by an ensemble of morphological features, including membrane blebbing, 
chromatin condensation and DNA cleavage, resulting in the fragmentation of dying cells into 
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apoptotic bodies (Taylor et al. 2008). These apoptotic bodies can be phagocytized by macrophages or 
neighboring cells, resulting in the uptake of apoptotic corpses without the release of intracellular 
material into the environment, thereby avoiding an inflammatory response (Savill and Fadok, 2000). 
In the absence of a phagocytic system, apoptotic bodies lose their integrity which leads to the release 
of their content into the extracellular microenvironment, resulting in an inflammatory answer. This 
process is called secondary necrosis. 
There are two main pathways of apoptosis, i.e. the extrinsic apoptosis pathway triggered by 
extracellular inducers and the intrinsic apoptosis pathway initiated mainly by stress factors. In the 
extrinsic apoptotic pathway, activation of caspases occurs through stimulation of death receptors 
(DRs) which belong to the TNF-receptor (TNF-R) superfamily. Upon binding of the corresponding 
ligand and stimulation of the DR, trimerization of the receptor molecules is induced with clustering of 
their cytoplasmic death domain (DD) and the formation of the death-inducing signaling complex 
(DISC). Distinct adaptor proteins e.g. TNF-R1-associated protein with death domain (TRADD) and 
FADD are recruited to the receptor and this interaction results in the recruitment of pro-caspase-8 and 
-10 to the DISC and subsequently to their auto-catalytical activation. Caspase-8 and -10 in turn 
proteolytically activate effector caspases such as caspase-3 (Figure 1; Galluzzi et al. 2012a) and 
initiate subsequent steps of proteolytic cleavage of, for example, substrate proteins that participate in 
cellular blebbing (gelsolin, Rho-associated, coiled-coil containing protein kinase 1 (ROCK-1), p21 
activated kinase 2 (PAK2)), determine cell shape (cytokeratin-18, vimentin, growth arrest-specific 
protein 2 (Gas2) and plectin, fodrin, focal adhesion kinase, cellular apoptosis susceptibility (Cas) 
proteins or paxillin) or influence nuclear architecture. This altogether leads then to the ordered demise 
of the cell (Fischer et al. 2003). Downstream of caspase-8 activation, apoptosis can occur via two 
distinct mechanisms. In so-called type I cells, massive auto-proteolytic activation of caspase-8 leads to 
sufficient activation of subsequent effector caspases, e.g. caspase-3, whereas in type II cells only small 
quantities of cleaved, active caspase-8 are produced at the DISC. To ensure apoptosis in type II cells, 
apoptosis is in part dependent on the cleavage of the mitochondrial protein Bid to its truncated form 
tBid by caspase-8 (Figure 1; Scaffidi et al. 1998). 
The intrinsic pathway is mainly initiated in response to non-receptor stimuli, including DNA damage, 
cytokine deprivation, hypoxia, oxidative stress and other types of severe cell stress (Galluzzi et al. 
2012b). Proteins of the B-cell CLL/lymphoma-2 (Bcl-2) protein family which exhibit pro-survival and 
pro-apoptotic features control the intrinsic pathway by aggregation of pro-apoptotic Bcl-2 family 
members (e.g. BAX and BAK). Activated BAX and BAK initiate mitochondrial outer membrane 
permeabilization (MOMP) which leads to the swelling of mitochondria and to the loss of the 
mitochondrial inner transmembrane potential. Subsequently, this results in the release of 
mitochondrial intermembrane space proteins like cytochrome c, Smac (second mitochondria-derived 
activator of caspase)/DIABLO (direct inhibitor of apoptosis protein (IAP) binding protein with low 
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pI), HtrA2/Omi (high temperature requirement protein A2), apoptosis inducing factor (AIF) and 
endonuclease G into the cytoplasm. Cytoplasmic cytochrome c together with deoxyadenosine 
triphosphate (dATP) and the adaptor protein apoptotic protease activating factor 1 (Apaf-1) form a 
protein complex named apoptosome (Figure 1). The apoptosome activates the initiator caspase-9 
resulting in the cleavage and activation of the effector caspases-3, -6 and -7 (Galluzzi et al. 2012a). 
Figure 1: Apoptosis, the caspase-dependent programmed cell death pathway. Apoptosis can be induced by two distinct 
routes: the extrinsic and the intrinsic apoptosis pathway. The extrinsic apoptotic pathway is induced by binding of cell 
surface death receptors (TNF-R1, CD95 (or Fas), TRAIL-R1/R2) to their respective ligands. This leads to the activation of 
initiator caspase-8, which in turn activates the effector caspase-3. Activation of caspase-3 results in cleavage of intracellular 
proteins and the ordered demise of the cell. On the other hand, the intrinsic apoptotic pathway is induced by UV-irradiation, 
growth factor deprivation or various other stress stimuli and results in the activation of pro-apoptotic BH3-only Bcl-2-family 
members. The BH3-only proteins inhibit their anti-apoptotic Bcl-2-family members and release or directly activate the pro-
apoptotic proteins BAX and BAK. Once activated, the proteins BAK and BAX promote MOMP and the release of 
cytochrome c from the mitochondria. The apoptosome, which activates caspase-3, is built by association of cytochrome c, 
Apaf-1 and caspase-9. In addition to cytochrome c release and MOMP, the factors Smac/DIABLO and HtrA2/Omi are also 
released from the mitochondria. These proteins promote apoptosis by inhibiting the action of IAPs. In type II cells, the 
intrinsic and the extrinsic apoptotic pathway are interconnected by Bid. Bid is cleaved by caspase-8 to its truncated form 
tBid, translocates to the mitochondria where it interacts directly with BAX to promote MOMP and finally apoptosis. 
Abbreviations: apoptotic protease activating factor 1 (Apaf-1), B-cell CLL/lymphoma-2 (Bcl-2), high temperature 
requirement protein A2 (HtrA2/Omi) inhibitor of apoptosis proteins (IAPs), mitochondrial outer membrane permeabilization 
(MOMP), second mitochondria-derived activator of caspase / direct IAP binding protein with low pI (Smac/DIABLO), tumor 
necrosis factor-receptor 1 (TNF-R1), TNF-related apoptosis inducing ligand-receptor (TRAIL-R) 
(Scheme was taken from Brenner and Mak (2009) Curr Opin Cell Biol 21, p. 872) 
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To circumvent the accidental activation of the deadly caspase cascade under conditions favoring cell 
survival, caspases are suppressed by inhibitor of apoptosis proteins (IAPs). During apoptosis, 
mitochondrial factors are released into the cytosol to, e.g. interfere with IAPs or to trigger DNA 
fragmentation. The proteins Smac/DIABLO and HtrA2/Omi bind to and neutralize IAPs and thereby 
release the caspases from the IAPs (Figure 1; Wu et al. 2000). Upon induction of apoptosis, the 
mitochondrial factors AIF and endonuclease G translocate to the nucleus and trigger there large-scale 
DNA fragmentation in a caspase-independent manner (Sevrioukova, 2011). 
Both apoptotic pathways, extrinsic and intrinsic, are functionally linked. Caspase-3 and -8, 
components of the extrinsic apoptotic pathway, cleave the pro-apoptotic protein Bid (Scaffidi et al., 
1998). The truncated form tBid causes then the release of cytochrome c from mitochondria, an 
important component of the intrinsic pathway, and the subsequent activation of caspase-9 and  
caspase-3 (Figure 1). 
2.2 Caspase-independent programmed cell death – regulated necrosis 
While caspase-dependent apoptosis (described above) represents the major physiologic pathway by 
which PCD is mediated, regulated necrosis can act as a backup system when the apoptotic machinery 
fails or is inactivated (Leist and Jäättelä, 2001). Cytoplasmic granulation and cellular swelling which 
culminate in the breakdown of the plasma membrane are morphological features of regulated necrosis. 
Different cellular stimuli (e.g. TNF, CD95 ligand, TRAIL, double-stranded (ds)RNA, interferon-γ 
(IFN-γ), ATP depletion, ischemia-reperfusion injury and pathogens) have been shown to induce 
necrotic PCD (Vanlangenakker et al. 2012). 
Several modes of regulated necrosis have been already defined based on their underlying signaling 
pathways, such as ferroptosis, NETosis, ETosis, pyroptosis, pyronecrosis, parthanatos and necroptosis 
(Vanden Berghe et al. 2014). All these processes share morphological hallmarks but are characterized 
by individual aspects of cell death. For example, ferroptosis depends on intracellular iron and is 
typically observed in the context of cancer and neurodegeneration (Vanden Berghe et al. 2014). The 
lethal small molecule erastin triggers this unique iron-dependent form of cell death which is 
morphologically, biochemically and genetically distinct from apoptosis, necrosis and autophagy 
(Dixon et al. 2012). NETosis is a specialized form of neutrophil death occurring with the release of 
neutrophil extracellular traps (NETs). These NETs are composed of DNA associated with histones, 
granular, and cytoplasmic proteins enabling neutrophils to immobilize and kill bacteria (Remijsen et 
al. 2011). In addition to neutrophils, other cell types, such as eosinophils, mast cells, and 
macrophages, can also die by NETosis (Remijsen et al. 2011). Therefore, NETosis was re-named as 
the more generalized term ETosis (Wartha and Henriques-Normark, 2008). Pyroptosis has been 
described as an atypical death of macrophages and dendritic cells but may also occur in other cell 
types. Pyroptosis appears as a result from osmotic pressure generated by caspase-1 (but not caspase-3, 
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the central executioner of apoptosis)-dependent formation of membrane pores and is characterized by 
the rapid release of cytosolic contents (von Moltke et al. 2013). Another necrosis-like cell death 
process is pyronecrosis and has been described in response to Shigella flexneri. Pyronecrosis occurs 
independently of caspase-1 and -11, but is dependent on the inflammasome-adaptor ASC (apoptosis-
associated speck-like protein containing a CARD) and the lysosomal protein cathepsin B (Willingham 
et al. 2007). Parthanatos was named after Thanatos, the personification of death in Greek mythology, 
and describes a particular mode of regulated necrosis involving the DNA damage-responsive enzyme 
PARP-1, in particular the (hyper)activation of PARP-1 (Galluzzi et al. 2014a). Regulated necrosis is 
considered as parthanatic when cell death depends on early PARP-1 activation and depletion of 
nicotinamide adenine dinucleotide (NAD+), which has a dramatic bioenergetic impact (Chiarugi, 
2005). Furthermore, PARP-1 dependent regulated necrosis relies on the release of AIF from the 
mitochondrial intermembrane space and its translocation to the nucleus (Yu et al. 2002; Andrabi et al. 
2008). Finally, necroptosis represents the currently best understood and molecularly most well 
characterized form of regulated necrosis. Necroptosis is defined as a RIPK-dependent molecular 
cascade promoting necrotic-like cell death (Vanden Berghe et al. 2014; see 2.2.1) and will be the main 
focus of the study presented here. 
Currently, regulated necrosis is intensively studied and in the focus of scientific interest because 
induction of regulated necrosis plays a significant role in both physiological settings (e.g. embryonic 
development) as well as in pathological scenarios (e.g. neurodegeneration). Therefore, the modulation 
of regulated necrosis may result in novel or additional options for the treatment of patients affected by 
disorders related to regulated necrosis (Galluzzi et al. 2014a; see 2.2.2).  
2.2.1 Necroptosis 
The term “necroptosis” was introduced in 2005 to describe a mode of regulated necrosis induced by 
TNF when caspase activity was blocked (Degterev et al. 2005). Later, necroptosis was redefined as 
being dependent on RIPK1 activity (Degterev et al. 2008). In the following years, necroptosis was 
classified as a PCD pathway mediated by signaling components that depend on the functional 
interactions of RIPK1 with its homolog RIPK3 (Cho et al. 2009; He et al. 2009; Zhang et al. 2009). 
RIPK3 was proposed to be the major initiator of necroptosis because RIPK3 can also trigger 
necroptosis independent from RIPK1 (Zhang et al. 2009; Upton et al. 2010). Later on, in 2012, the 
substrate of RIPK3 mixed lineage kinase domain-like (MLKL) was discovered as a crucial mediator of 
necroptosis downstream of RIPK3 (Sun et al. 2012). The induction of necroptosis can be inhibited by 
the RIPK1 inhibitor necrostatin 1 (Nec-1) or the inhibitor necrosulfonamide (NSA) which acts only on 
human, but not mouse MLKL (Figure 2; Degterev et al. 2008; Sun et al. 2012). 
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2.2.1.1 Initiation of necroptosis 
The induction of necroptosis can be exemplified by the TNF signaling pathway. Under caspase-
inhibitory conditions (e.g. in the presence of caspase inhibitors or virally expressed proteins), TNF 
induces the recruitment of RIPK1 to the TNF-R1 complex I (described in detail in 2.3.3) where RIPK1 
is deubiquitinated by deubiquitinating enzymes (DUBs) such as cylindromatosis (CYLD), A20 or 
cezanne (Hitomi et al. 2008; Shembade et al. 2010; Enesa et al. 2008). The inhibition of RIPK1 
ubiquitination by DUBs or Smac mimetics leads to the formation of a protein complex containing 
RIPK1 and its homolog RIPK3 which is termed “necrosome” (Figure 2; Declercq et al. 2009; Vanden 
Berghe et al. 2014). Both kinases possess an N-terminal kinase domain and a C-terminal RIPK 
homotypic interaction motif (RHIM) which appears to be critical for the activation of the necrosome 
(Sun et al. 2002; Galluzzi et al. 2014a). Recently, it was reported that the RIPK1-RIPK3-necrosome 
aggregates in microfilament-like complexes mediated by the RHIMs of RIPK1 and RIPK3. These 
heterodimeric filamentous structures exhibited classical characteristics of β-amyloids and the 
inhibition of the formation of RIPK1-RIPK3 amyloid-like structures represses the signal transduction 
of necroptosis (Li et al. 2012). The finely regulated crosstalk between RIPK1 and RIPK3 is regulated 
by phosphorylation of RIPK1 and RIPK3. For example, the autophosphorylation of RIPK1 at serine 
161 (S161) and the direct and indirect RIPK3-mediated phosphorylation of RIPK1 generate pro-
necroptotic signals (Cho et al. 2009; Degterev et al. 2008; He et al. 2009). The phosphorylation site at 
S199 of RIPK3 was reported to be a pro-necroptotic phosphorylation target site (Cho et al. 2009). 
Phosphorylation of RIPK3 is crucial for the recruitment of MLKL (Chen et al. 2014), a pseudokinase 
that binds ATP but is catalytically inactive (Sun et al. 2012). RIPK3-dependent phosphorylation of 
MLKL results in c-Jun N-terminal kinase (JNK) activation, reactive oxygen species (ROS) production 
and the execution of necroptosis (Zhao et al. 2012). Human MLKL is phosphorylated by human 
RIPK3 at threonine 357 (T357) and S358 (Sun et al. 2012), whereas mouse MLKL is phosphorylated 
at positions S345, S347, S352 and T349 by mouse RIPK3 (Figure 2; Xie et al. 2013). Wang and 
coworkers proposed that the phosphorylation of MLKL promotes the activation and association of the 
mitochondrial protein phosphatase phosphoglycerate mutase family member 5 (PGAM5). PGAM5 in 
turn recruits the mitochondrial fission factor dynamin-1-like protein (Drp-1) leading to the execution 
of necroptosis (Wang et al. 2012). However, accumulating evidence indicates that both PGAM5 and 
Drp-1 may be dispensable for the pro-necroptotic effects of MLKL (Galluzzi et al. 2014a). Recently, 
two independent studies demonstrated that MLKL appears to form oligomers upon phosphorylation by 
RIPK3 and that this results in the re-localization of MLKL to the plasma membrane in the course of 
necroptotic cell death (Figure 2; Cai et al. 2014; Chen et al. 2014). However, the existing data are still 
inconsistent regarding the molecular events of how MLKL regulates necrotic plasma membrane 
permeabilization and the execution of necroptosis (Galluzzi et al. 2014b; see 2.2.1.2). 
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Figure 2: TNF-R1-mediated necroptosis. Necroptosis is induced by TNF (inducer) when caspases are inhibited, e.g. by the 
pan-caspase inhibitor zVAD-fmk. The signal transduction starts with the assembly of the TNF-R1 complex I and the 
subsequent deubiquitination of RIPK1 by SMs or DUBs such as CYLD leads to the formation of the necrosome. The 
necrosome contains phosphorylated and activated RIPK1 and RIPK3 associated in amyloid-like structures. The 
phosphorylation of RIPK1 and RIPK3 leads to the recruitment of MLKL. MLKL is phosphorylated by RIPK3 and forms 
oligomers resulting in the re-localization of MLKL to the plasma membrane where it interferes with membrane integrity and 
induces necroptosis. The assembly of the necrosome culminates in multiple executioner pathways which all lead to 
necroptosis (outcome). Necroptosis can be blocked by Nec-1 which inhibits RIPK1, and by NSA which blocks human 
MLKL. Abbreviations: cylindromatosis (CYLD), deubiquitinating enzymes (DUBs), mixed-lineage kinase domain-like 
(MLKL), necrostatin 1 (Nec-1), necrosulfonamide (NSA), phosphorylation (P), receptor-interacting protein kinase (RIPK), 
Smac mimetic (SM), tumor necrosis factor (TNF), TNF-receptor 1 (TNF-R1). 
(Modified from Moriwaki and Chan (2013) Cytokine Growth Factor Rev 25, p. 170) 
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Necroptosis, triggered by the ligation of TNF to the TNF-R1 (Figure 2), is also the most extensively 
investigated model which will be the main focus of the thesis presented here. Nevertheless, 
necroptosis can also be triggered by other members of the TNF receptor family, e.g. CD95 (Holler et 
al. 2000); TNF-R2 (Chan et al. 2003) and TRAIL-R1 and -R2 (Vercammen et al. 1998b; Thon et al. 
2006; Voigt et al. 2014) as well as by Toll-like receptors (TLR) 3 and 4 (Holler et al. 2000; Chan et al. 
2003) and DNA and/or RNA sensors (Kaczmarek et al. 2013). 
2.2.1.2 Execution of necroptosis 
The list of mechanisms implicated in the execution of regulated necrosis is constantly growing, but 
detailed insights into these mechanisms, and especially those involved in the execution of necroptosis 
downstream of MLKL are sparse. It is currently unclear whether the execution mechanisms are 
exclusive for necroptosis or whether they also participate in other modes of regulated necrosis 
described above (see 2.2). Therefore, this chapter describes common execution mechanisms of 
regulated necrosis, which may also turn out to be relevant for necroptosis. 
The signals required for necroptotic cell death downstream of MLKL remain uncertain. Recent reports 
show that MLKL forms trimers and translocates to the plasma membrane to facilitate calcium influx in 
response to TNF-induced regulated necrosis (Cai et al. 2014). The transient receptor potential cation 
channel, subfamily M, member 7 (TRPM7) seems to represent the central voltage-sensitive channel 
facilitating calcium influx, because blockade of TRPM7 inhibited regulated necrosis (Cai et al. 2014). 
Consequently, the influx of calcium ions into the cytoplasm disrupts osmotic homeostasis leading to 
the death of the cell (Cai et al. 2014). Furthermore, the generation of ROS may be another 
consequence in response of MLKL activation promoting necroptotic cell death (Moriwaki and Chan, 
2013).  
The accumulation of ROS during necrotic cell death was discovered even before the discovery of the 
necrosome (Schulze-Osthoff et al. 1992). The kinase RIPK3 links TNF-R1 signaling to metabolic 
enzymes and the production of ROS by building a complex with glycogen phosphorylase (PYGL), 
glutamate-ammonia ligase (GLUL), glutamate dehydrogenase 1 (GLUD1), fructose-1,6-
bisphosphatase 2 (FBP2), fumarate hydratase (FH), glycosyltransferase 25 domain containing 1 
(GLT25D1), and isocitrate dehydrogenase 1 (IDH1). PYGL, GLUL and GLUD1 can directly interact 
with RIPK3. The knock-down of any of these enzymes reduced TNF-induced accumulation of ROS, 
correlating with reduced cell death (Zhang et al. 2009). GLUL, a cytosolic enzyme that condensates 
glutamate and free ammonia into glutamine, and GLUD1, a mitochondrial enzyme converting 
glutamate into α-ketoglutarate, are hyperactivated by RIPK3. This hyperactivation results in increased 
glutaminolysis and excessive generation of α-ketoglutarate and lactate overproduction (Mates et al. 
2009). PYGL catalyzes one step of glycogenolysis, the breakdown of glycogen into glucose-1-
phosphate and subsequent conversation to glucose-6-phosphate (G6P). G6P stimulates glycolysis 
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contributing to ROS production and generation of cytotoxic methylglyoxal (Van Herreweghe et al. 
2002). Altogether, there are several mechanisms by which enhanced glycogenolysis, glycolysis and 
glutaminolysis can contribute to the respiratory burst that characterizes necrotic cell death. A non-
mitochondrial source of ROS is the plasma membrane-associated NADPH oxidase-1 (Nox1). The 
activation of TNF-R1 signaling rapidly activates Nox1 through RIPK1-dependent signaling, leading to 
a burst of Nox1-derived ROS (Morgan et al. 2008). 
Profound depletion of ATP levels triggered by overconsumption of NAD+ in ADP ribosylation 
reactions (e.g. by PARP-1 hyperactivation) is a hallmark of some forms of regulated necrosis. In 
addition to ROS production, mitochondria also contribute to the abrupt decrease in ATP. Temkin and 
coworkers reported that binding of TNF to TNF-R1 leads to the RIPK1-mediated inhibition of the 
mitochondrial adenine nucleotide translocase (ANT; Temkin et al. 2006) which is an ATP/ADP 
antiporter. ANT was shown to interact with other mitochondrial proteins like voltage-dependent anion 
channel (VDAC) and cyclophilin D (CypD) leading to the assembly of a permeability transition pore 
complex (PTPC; Vanlangenakker et al. 2008). Pro-apoptotic and anti-apoptotic members of the Bcl-2 
family were also shown to interact with the PTPC (Brenner et al. 2000). In response to cytotoxic 
stimuli such as ROS and cytosolic Ca2+ overload, the PTPC rearranges its conformation, allowing the 
entry of unwanted solutes and water into the mitochondrial matrix, the so-called mitochondrial 
permeability transition leading to the rupture of the mitochondria and to cell death (Vanlangenakker et 
al. 2008). Mitochondria appear to be important activators of regulated necrosis signals; however, 
recent studies claimed that mitochondria are dispensable for the execution of necroptosis in response 
to MLKL activation (Tait et al. 2013). 
Lysosomal membrane permeabilization (LMP) was also found to contribute to the execution of 
regulated necrosis (Vanlangenakker et al. 2008). During this process, excess ROS production 
overcomes the antioxidant defenses of the cell leading to the destabilization of other intracellular 
membranes, e.g. of the endoplasmatic reticulum (ER), mitochondria or lysosomes. LMP can be a 
consequence of the activation of several signaling pathways. For example, TNF-R1 engagement leads 
to the activation of cytosolic phospholipase A2 (PLA2). PLA2 is known to generate arachidonic acid 
which is transformed by lipoxygenase into lipid hydroperoxides. These lipids are characterized by a 
high membrane-damaging potential (Burke and Dennis, 2009). Another signaling pathway following 
after TNF binding to TNF-R1 results in the activation of the lysosomal enzyme acid sphingomyelinase 
(A-SMase) and membranous neutral sphingomyelinases (N-SMase). Both enzymes convert 
sphingomyelin into ceramide. Ceramide is a substrate for ceramidases, producing sphingosine as an 
inducer of LMP (Kagedal et al. 2001). Of note, ceramide is implicated to play an additional, much 
more important role in mediating necroptosis elicited by TNF or TRAIL (Strelow et al. 2000; Thon et 
al. 2005, Thon et al. 2006) which will be the focus of chapter 2.4. Membrane destabilization at the 
mitochondrial level has multiple consequences like inhibition of ATP synthesis, inner membrane 
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permeabilization and altered Ca2+ buffering (Galluzzi et al. 2011). Destabilization of the ER 
membrane promotes the accumulation of cytosolic Ca2+. As additional inducers of LMP, cytotoxic 
hydrolases such as Ca2+-dependent calpains (calcium activated neutral proteases) destabilize lysosomal 
membranes. Calpain-triggered LMP results in the release of cytotoxic lysosomal cathepsins leading to 
the cytoskeletal protein breakdown and cell death (Vanlangenakker et al. 2008). 
Proteolysis of regulatory proteins, leading to either activation or inactivation of downstream signaling 
cascades is a further potential critical execution mechanism during regulated necrosis and especially 
necroptosis. During apoptosis, hundreds of proteins are specifically cleaved by proteolysis as part of 
the apoptotic program. The family of caspases is involved in many of these proteolytic events which 
are essential for the cleavage of substrate proteins, initiation and execution of PCD and thus for the 
survival and homeostasis of multicellular organisms (Degterev and Yuan, 2008). During regulated 
necrosis, proteolysis appears to be equally important. For example, necroptosis is negatively regulated 
by caspase-8 which cleaves and inactivates RIPK1 (Mocarski et al. 2011). During regulated necrosis, 
alternative proteolytic molecules such as lysosomal proteases (calpains, cathepsins and granzymes), 
serine proteases, the proteasome and metalloproteases might substitute for caspases (Leist and Jäättelä, 
2001; Schrader et al. 2010). The ability of non-caspase proteases to cleave at least some of the classic 
caspase substrates implicates that non-caspase proteases might be essential for regulated necrosis. For 
example, cathepsins are responsible for the translocation of Bax to the mitochondrion in the complete 
absence of caspase activation (Bidere et al. 2003). The cleavage and translocation of Bid as well as the 
cleavage and release of AIF are cathepsin-mediated events which do not need caspase activity 
(Lorenzo and Susin, 2007). Similar to cathepsins, calpains can also cleave AIF in the absence of 
caspases (Lorenzo and Susin, 2007). Moreover, the serine protease granzyme B was shown to cleave 
and activate Bid to its truncated product gtBid. During regulated necrosis, gtBid translocates to the 
mitochondrion, integrates into the mitochondrial membrane and thereby releases cytochrome c 
(Heibein et al. 2000). Furthermore, the proteolytic activity of the mitochondrial serine protease 
HtrA2/Omi has been implicated to mediate necrotic-like cell death of human neutrophils (Blink et al. 
2004). 
Taken together, the above described events like ROS overproduction, mitochondrial dysfunction and 
proteolysis may play a major role in the execution of regulated necrosis. Besides its suggested role 
during healthy development, regulated necrosis has been described to additionally trigger 
pathophysiological alterations, e.g. in stroke, Alzheimer’s, Huntington’s and Parkinson’s disease 
(Vandenabeele et al. 2010). 
2.2.2 Regulated necrosis in health and disease 
Regulated necrosis has physiological and pathophysiological consequences. Regulated necrosis occurs 
in vital processes such as regulation of bone growth by participating in the physiological cell death of 
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chondrocytes (Roach and Clarke, 2000) and in adult tissue homeostasis where colonocytes in the 
lower regions of intestinal crypts undergo necrotic cell death (Barkla and Gibson, 1999). The 
homeostasis of T-cell populations is another physiological relevant response (Jäättelä and Tschopp, 
2003). Furthermore, regulated necrosis is reported to be relevant for the negative selection of 
lymphocytes, embryonic removal of interdigital webs, ovulation, termination of immune responses, 
hyperacute shock in response to TNF, or the autonomous death of activated T-cells (Festjens et al. 
2006). 
As described above, regulated necrosis plays a major role as a backup cell death mechanism, when 
apoptosis is disabled. For example, viral and bacterial proteins can efficiently suppress caspase 
activity and thus the cell initiates regulated necrosis as an alternative mechanism to limit viral and 
bacterial infections (Kaczmarek et al. 2013). Studying RIPK3-deficient mice revealed that these mice 
are more susceptible to viral infection than their wild-type counterparts (Cho et al. 2009). In addition, 
Upton and coworkers demonstrated that the murine cytomegalovirus M45 protein interferes with the 
necrosome (Upton et al. 2010). In summary, these findings support the antiviral and antibacterial 
properties of necroptosis.  
In addition, regulated necrosis has been shown to play a role in many human pathologies like 
hyperacute shock (Cauwels et al. 2003), pancreatitis (He et al. 2009; Zhang et al. 2009), cerebral and 
myocardial ischemia-reperfusion injury (Linkermann et al. 2013), Crohn’s disease (Günther et al. 
2011), Alzheimer’s disease (Lin and Beal, 2006) and photoreceptor cell loss (Viringipurampeer et al. 
2014). Moreover pathogens such as HIV, vaccinia virus, Shigella and Salmonella (Festjens et al. 2006; 
Cho et al. 2009) can destruct cells in a caspase-independent manner. Rapid plasma permeabilization 
due to necrotic triggers leads to the release of damage associated molecular patterns (DAMPs) from 
the cell. These necrosis-dependent DAMPs can contribute to sensitization of necroptosis in 
neighboring cells or modulate the fate of inflammation (Kaczmarek et al. 2013). 
Genetic studies of knock-out mice revealed that RIPK1-deficient mice are not viable, whereas kinase-
dead mutant RIPK1D138N mice are viable (Newton et al. 2014). The pharmacological inhibition of 
RIPK1 with Nec-1 or geldanamycin showed cytoprotective effects in vitro (Vandenabeele et al. 2010). 
Moreover, the inhibition of RIPK1 activity in vivo attenuates neurodegenerative diseases (Yuan et al. 
2003), adult brain ischemia (Degterev et al. 2005), myocardial infarction (Lim et al. 2007) and 
photoreceptor degeneration of retina disorders (Trichonas et al. 2010; Viringipurampeer et al. 2014). 
The genetic deletion of RIPK1 functionally complemented the impaired lymphocyte proliferation in 
FADD-deficient mice (Zhang et al. 2011). This and the above findings are consistent with a critical 
role for the kinase activity of RIPK1 in pathological cell death. RIPK3 deficient mice displayed 
reduced pancreatitis (He et al. 2009; Zhang et al. 2009). The absence of any phenotypic change in 
unchallenged RIPK3-deficient mice suggests that RIPK3 is not involved in embryogenesis and 
homeostasis (Newton et al. 2014). However, genetic deletion of RIPK3 rescues caspase-8-deficient 
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mice from early embryonic death, revealing that during development apoptotic regulatory mechanisms 
counteract RIPK3-dependent necroptosis (Kaiser et al. 2011). Genetic deletion of both caspase-8 and 
RIPK3 lead to progressive lymphoaccumulative disease in adult mice (Oberst et al. 2011). These 
studies clearly demonstrate that apoptotic mechanisms block the necrotic pathway in diverse 
physiological ways. 
2.3 Death receptors 
2.3.1 The TNF superfamily 
As outlined above, members of the TNF superfamily are central inducers of necroptosis. Cellular 
processes such as immune responses, cell proliferation, hematopoiesis and cell death are regulated by 
the family of TNF receptor-related molecules (Aggarwal, 2003). So far, 19 different ligands belonging 
to the TNF superfamily have been identified. These 19 ligands mediate their cellular response via 29 
different receptors all belonging to the TNF receptor superfamily. These receptors have a cysteine-rich 
domain in the extracellular portion of the receptor (Aggarwal, 2003). Within the members of the TNF-
receptor superfamily, DRs have been shown to induce both caspase-dependent as well as caspase-
independent pathways leading to PCD (Leist and Jäättelä, 2001). At present, eight members of the DR 
family have been identified: TNF-R1 (also known DR1/CD120a/p55/p60), CD95 (named also Fas-
receptor, DR2, or APO-1), DR3 (also termed as APO-3, lymphocyte-associated receptor of death 
(LARD), TNF-R-related apoptosis-mediating protein (TARD), WS-1, TNF-receptor-like 3 (TR3), 
TNF receptor superfamily member 25 (TNFRSF25)), TRAIL-receptor 1 (TRAIL-R1; or APO-2 and 
DR4), TRAIL-R2 (also known as TRICK2, TNFRSF10B, DR5, KILLER), DR6 (or TNFRSF21), 
ectodysplasin A receptor (EDAR) and nerve growth factor receptor (NGFR) (Mahmood and Shukla, 
2010). 
With focus on regulated necrosis, members of the DR family are able to induce cell death independent 
of caspases. For example, Holler and coworkers showed that activated primary T cells were killed by 
CD95 ligand in the absence of caspases (Holler et al. 2005). Human and murine TRAIL-receptors 
(TRAIL-R) are also able to induce regulated necrosis (Holler et al. 2000; Guo et al. 2005; Thon et al. 
2006). TNF-R1 is as well capable of inducing necroptosis as described above (see 2.2.1.1) and the 
most extensively investigated model of necroptosis is triggered by the activation of TNF-R1 signaling 
(Figure 2 and 3). 
2.3.2 The death receptor TNF-R1 
Two different types of TNF receptors have been characterized. TNF-R1 (also referred to as type I or 
p55 or p60) is expressed by almost all cell types, whereas TNF-R2 (also known as type II or p75 or 
p70) was shown to be expressed by endothelial cells as well as by cells of the immune system 
(Aggarwal and Natarajan, 1996). TNF-R1 belongs to the DR subgroup of the TNF superfamily, 
whereas TNF-R2 contains no DD. The latter interacts with the adaptor protein TNF receptor-
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associated factor-2 (TRAF2) leading to the proteasomal degradation of TRAF2 and inhibition of TNF-
R1-induced activation of nuclear factor-κB (NF-κB; Wu et al. 2005). In 2009, TRAF1 was shown to 
inhibit TNF-R2-induced proteasomal degradation of TRAF2 and thereby modifies TNF-R1-TNF-R2 
cooperation shifting signaling from apoptosis to proinflammatory NF-κB signaling (Wicovsky et al. 
2009). Typically, cells expressing TNF-R2 also express TNF-R1 and thereby regulate the balance 
between cellular survival and cell death. TNF-R1 stimulation usually induces cytokine generation, 
inflammation, and cell survival, unless the cytotoxic potential of TNF-R1 is unmasked by inhibiting 
these survival pathways. However, the potential usefulness of TNF in clinical oncology is severely 
limited by its strong side effects. 
2.3.3 The complex signaling pathways of TNF-R1 
The balance between pro-survival and pro-cell death signals depends on intracellular interactors of 
TNF-R1. Additionally, the existence of different protein complexes is very critical to determine which 
signaling pathway will be induced upon TNF ligation to TNF-R1 (Figure 3). Binding of TNF to TNF-
R1 can, for example, induce the formation of a membrane-proximal supra-molecular complex termed 
“TNF-R1 complex I”. Complex I is responsible for the activation of pro-survival signals favoring the 
canonical pathway of activation of the transcription factor NF-κB and up-regulating anti-apoptotic 
genes such as A20 and FLICE-like inhibitory protein long isoform (FLIPL) (Micheau and Tschopp, 
2003). The ligand-bound TNF-R1 trimers recruit TRADD, RIPK1, cellular (c)IAP1 and cIAP2, 
TRAF2 and TRAF5 (Micheau and Tschopp, 2003). The cIAP-mediated polyubiquitination of RIPK1 
(Bertrand et al. 2008) recruits downstream adaptors such as transforming growth factor-β-activated 
kinase 1 (TAK1), TAK1-binding protein 2 (TAB2) and TAB3 as well as inhibitor of NF-κB kinase 
(IKK) complex which together trigger the canonical NF-κB activation (Figure 3a). The activation of 
NF-κB is enhanced by recruitment of the linear ubiquitin chain assembly complex (LUBAC). LUBAC 
activity results in linear ubiquitination of RIPK1 and the NF-κB essential modulator (NEMO) protein 
(Walczak, 2011). 
Upon endocytosis of TNF-R1, the TRADD-dependent “TNF-R1 complex IIa” is generated by a 
rearrangement of the molecular composition of complex I (Figure 3b). Here, the dissociation of RIPK1 
from TNF-R1 by CYLD-mediated deubiquitination (O’Donnell et al. 2007; Hitomi et al. 2008) is 
crucial for the transition from complex I to the lethal complex II which has also been termed DISC. 
Complex IIa is composed of pro-caspase-8 and FLIPL heterodimers as well as TRADD and FADD. 
Upon activation of caspase-8 several substrates including Bid and caspase-3 are activated. RIPK1, 
RIPK3 and CYLD are cleaved by the caspase-8/FLIPL heterodimer leading to their inactivation, 
thereby preventing necroptosis (Lin et al. 1999; Feng et al. 2007) and instead leading to execution of 
caspase-dependent apoptosis (Figure 3b and see 2.1).  
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When cIAPs are inhibited, through for example Smac/DIABLO, a distinct signaling cascade occurs 
(Vanlangenakker et al. 2011a). Here, the degradation of cIAPs reduces the canonical NF-κB activation 
of complex I (Bertrand et al. 2008). This leads to an up-regulation of NF-κB-inducing kinase (NIK) 
and facilitates non-canonical NF-κB signaling (Figure 3d; Varfolomeev et al. 2007). Moreover, a 
TRADD-independent cytosolic complex is supposed to be formed between non-ubiquitinylated 
RIPK1, RIPK3, FADD and the caspase-8/FLIPL heterodimer. This second lethal complex II is 
referred to as RIPK1-dependent complex IIb or “ripoptosome” (Figure 3e; Feoktistova et al. 2011). 
The ripoptosome is necessary but not sufficient to induce cell death because caspase-8 activity is 
controlled by c-FLIP (Feoktistova et al. 2011). Similar as described for complex IIa, RIPK1 and 
RIPK3 are inactivated through cleavage mediated by caspase-8/FLIPL heterodimers, leading to the 
induction of apoptosis by the release of caspase-8 homodimers. 
However, the deletion of FADD or caspase-8 as well as inhibition of caspase-8 by cytokine response 
modifier protein A (CrmA), a potent viral inhibitor of caspase-8 or pharmacologically with zVAD-fmk 
can lead to the formation of the necrosome, a pro-necrotic complex (Vercammen et al. 1998a; Holler 
et al. 2000). This complex is comprised of and dependent on active RIPK1-RIPK3 and MLKL (Figure 
3c and Figure 2; Vandenabeele et al. 2010; see chapter 2.2.1.1). Whether FADD or TRADD are 
strictly required to assemble the necrosome remains unclear. 
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Figure 3: TNF-R1-mediated signaling pathways. Stimulation of TNF-R1 by the TNF ligand results in (a) the recruitment 
of TRADD, RIPK1, cIAP1, cIAP2, TRAF2 and TRAF5 and in the assembly of complex I. cIAP1 and cIAP2 in turn poly-
ubiquitinylate RIPK1, allowing recruitment of the TAK1-TAB2/3 complex as well as the IKK/NEMO complex. The 
assembly of this complex leads to the activation of the canonical NF-κB pathway which is enhanced by the recruitment of the 
LUBAC. (b) TRADD-dependent complex IIa is built after de-ubiquitination of RIPK1 by CYLD, allowing RIPK1 to 
dissociate from the plasma membrane. Here, RIPK1 interacts with TRADD, FAAD, pro-caspase-8 and FLIP. Pro-caspase-8 
and FLIPL cleave and inactivate RIPK1, RIPK3 and CYLD (dashed ovals) to inhibit necroptosis. Homodimerized, active 
caspase-8 in turn activates executioner caspases resulting in apoptosis. (c) When caspase-8 is inactive, the RHIM domains of 
RIPK1 and RIPK3 associate in RIPK1-RIPK3 amyloid-like microfilaments (necrosome). The phosphorylation of RIPK1 and 
RIPK3 leads to the recruitment of MLKL which can be inhibited by NSA. The RIPK3/MLKL-dependent complex initiates 
regulated necrosis. (d) However, when cIAPs are inhibited by Smac mimetics, RIPK1 is not ubiquitinated. This leads to an 
up-regulation of NIK and the activation of the non-canonical NF-κB pathway. (e) In the absence of cIAPs, a RIPK1-
dependent complex IIb (ripoptosome) comprised of RIPK1, RIPK3, FADD and FLIPL-caspase-8-homodimers is formed. As 
in (b) RIPK1 and RIPK3 are inactivated and apoptosis is induced. Abbreviations: cIAP (cellular inhibitor of apoptosis 
protein), CYLD (cylindromatosis), FADD (Fas-associated death domain), FLIP (FLICE-like inhibitory protein), IKK 
(inhibitor of NF-κB), LUBAC (linear ubiquitin chain assembly complex), MLKL (mixed lineage kinase domain-like), 
NEC1s (necrostatin 1), NEMO (NF-κB essential modulator), NF-κB (nuclear factor-κB), NIK (NF-κB-inducing kinase, NSA 
(necrosulfonamide), RHIM (RIP homotypic interaction motif), RIPK (receptor-interacting protein kinase), SMAC (second 
mitochondria-derived activator of caspase), TAB2 (TAK1 binding protein 2), TAK (transforming growth factor-β-activated 
kinase), TRADD (TNF receptor-associated death domain), TRAF (TNF receptor-associated factor), TNF (tumor necrosis 
factor), TNF-R1 (TNF-receptor 1). 
(Adapted from Vanden Berghe et al. (2014) Nat Rev 15, p. 138) 
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2.3.4 The death receptors TRAIL-R1 and TRAIL-R2 
The ligand TRAIL was first cloned and characterized in 1995 (Wiley et al. 1995). TRAIL is a type II 
transmembrane protein belonging to the TNF superfamily. Five receptors are able to bind TRAIL 
(Wang and El-Deiry, 2003). In humans, TRAIL-R1 and TRAIL-R2 are capable of inducing PCD 
through their DD. Both receptors have cysteine-rich repeats facilitating TRAIL binding. TRAIL also 
binds to the decoy receptor TRAIL-R3 (also known as DcR1, LIT, TRID) and TRAIL-R4 (also termed 
as DcR2, TRUNDD). However, in their cytoplasmic domains, both receptors completely or partially 
lack a DD and are therefore unable to induce apoptosis. For this reason, TRAIL-R3 and TRAIL-R4 are 
regulators rather than inhibitors of TRAIL-mediated PCD (Merino et al. 2006). Osteoprotegerin 
(OPG), the fifth and soluble receptor, has a rather low affinity to the ligand TRAIL. It was suggested 
that the function of OPG and TRAIL is linked to bone metabolism (Emery et al. 1998). To date, only 
one mouse receptor is known, which is homologous to the human TRAIL-R2 (Wu et al. 1999). 
In contrast to TNF, TRAIL has emerged as a most promising molecule for cancer therapy due to its 
ability to selectively induce apoptosis in tumor cells without affecting normal cells (Walczak et al. 
1999). For example, the treatment of patients with human agonistic TRAIL-R antibodies 
Mapatumumab and Lexatumumab can induce apoptosis and have been employed for selective cancer 
therapy (Pukac et al. 2005; Ashkenazi and Herbst, 2008). Similar to TNF-R1, TRAIL-R1 and TRAIL-
R2 are able to induce regulated necrosis independently of their apoptotic capabilities when apoptosis 
induction fails or is inhibited (Holler et al. 2000; Guo et al. 2005; Thon et al. 2006). In contrast to 
TNF-R1 induced necroptosis, a comprehensive picture of the signaling pathways of regulated necrosis 
induced by TRAIL-R1 or TRAIL-R2 is currently lacking. In 2006, the capacity of mTRAIL-R2 to 
induce necroptosis has been demonstrated (Thon et al. 2006). Moreover, cells over-expressing acid 
ceramidase, an enzyme which degrades the second messenger ceramide, showed an increased 
resistance to regulated necrosis elicited by TRAIL (Thon et al. 2006). TRAIL-induced necroptosis 
results in the increase of intracellular ceramide levels in murine L929, NIH3T3 and human Jurkat T 
cells (Voigt, Bachelor Thesis, 2009). To this end, the induction of regulated necrosis by TRAIL may 
represent a novel and additional option for the elimination of tumor cells, and the second messenger 
ceramide seems to play a crucial role in regulated necrosis distinct from apoptosis signaling elicited by 
TRAIL and TNF (see below). 
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2.4 Acid sphingomyelinase and its product ceramide 
2.4.1 Biological role and function of ceramide 
As described above, the lipid ceramide plays a crucial role in mediating regulated necrosis. Ceramide 
is an important second messenger and a structural membrane component and involved in multiple 
biological processes, such as apoptosis, differentiation and cell growth, or bacterial and viral 
pathogenesis (Kolesnick and Krönke, 1998). This pro-apoptotic mediator is generated in response to 
various stimuli including ionizing radiation, chemotherapy and by the DRs TNF-R1, CD95 and 
TRAIL receptors (Figure 4). Ceramide can be produced in mammalian cells either by the de novo 
synthesis in the ER, by the hydrolysis of sphingomyelin to ceramide mediated by sphingomyelin-
specific forms of phospholipase C, called sphingomyelinases (SMases) or by the activity of 
cerebrosidases. The activity of ceramidases, sphingomyelin synthases or glucosylceramide synthases 
is required for further processing of ceramide. The catabolic pathway of ceramide is controlled by the 
activity of SMases which hydrolyze the phosphodiester bond of sphingomyelin yielding ceramide and 
phosphocholine. The cleavage of ceramide at the amino bond resulting in sphingosine and a free fatty 
acid is catalyzed by ceramidases and the reversion by ceramide synthases (Figure 4). Ceramide and its 
metabolites have been shown to influence various cellular processes, including angiogenesis, 
apoptosis, autophagy, differentiation, infection, inflammation, migration, proliferation, protein 
trafficking and senescence (Pettus et al. 2002; Gulbins and Li, 2006). For example, ceramide-rich 
membrane domains may serve as sorting locations for membrane receptors, inhibitors and other 
membrane components involved in signaling (Gulbins et al. 2004). At present, the molecular details, 
involved in preferential sorting and receptor clustering at the ceramide-rich membrane domains, 
remain unknown. The concept of temporal organization of the signaling platform by a specific 
receptor was first shown for CD95. Clustering of CD95 at the plasma membrane amplifies the initial 
signaling and activation of caspase-8 (Grassmé et al. 2003). In addition, ceramide also directly 
interacts with and regulates cathepsin D (Heinrich et al. 1999), phospholipase A2 (Huwiler et al. 
2001), kinase suppressor of Ras (Zhang et al. 1997), ceramide-activated protein phosphatases 
(Saddoughi et al. 2013), and protein kinase C isoforms (Huwiler et al. 1998). Furthermore, ceramide 
regulates the activity of the potassium channel Kv1.3 (Gulbins et al. 1997) and calcium release-
activated calcium channels (Samapati et al. 2012). Apart from this, ceramide molecules can form 
channels in the outer mitochondrial membrane, which might contribute to the induction of cell death 
(Siskind and Colombini, 2000). 
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Figure 4: Regulation of ceramide levels and its biological role. Ceramide levels are controlled by the activity of a variety 
of enzymes that synthesize and catabolize ceramide. The breakdown of sphingomyelin to ceramide is hydrolyzed by 
sphingomyelinases. SM synthase clears ceramide by synthesizing sphingomyelin. The condensation of serine and palmitoyl-
CoA by serine palmitoyltransferase initiates the de novo pathway. 3-ketosphinganine is then reduced, N-acetylated and 
desaturated by addition of a 4-5 trans double bond in a series of enzymatic steps, resulting in the generation of ceramide. 
Ceramidases cleave ceramide at the amide bond, leading to sphingosine and a free fatty acid. Sphingosine 1-phosphate is 
generated by sphingosine kinase. A number of stimuli can induce the production of ceramide and its metabolites (upper 
boxes) and results in biological effects (lower boxes). Abbreviations: sphingomyelin (SM), sphingosine (SPH), sphingosine 
1-phosphate (S1P) 
(Modified from: Pettus et al. (2002) Biochim Biophys Acta 1585, p. 115, and Hannun YA and Obeid LM (2008) Nat Rev Mol 
Cell Biol 9, p. 140) 
2.4.2 Biological functions and activation of acid sphingomyelinase 
SMases are considered to be the most important enzymes in the pathway of ceramide signal 
transduction (Kolesnick and Krönke, 1998). There are five types of SMases known, all are defined by 
their pH optimum: plasma membrane-bound neutral sphingomyelinase (N-SMase-1), N-SMase-2, N-
SMase-3, and endo-lysosomal acid sphingomyelinase (A-SMase) and a secreted form of A-SMase (S-
SMase). 
Acid sphingomyelinase (A-SMase) is an endo-lysosomal protein that hydrolyzes sphingomyelin to 
ceramide and phosphocholine at an acidic pH optimum. Several A-SMase isoforms have been 
identified, although only one transcript has been reported to be catalytically active (Rhein et al. 2012). 
Two types of the metallo-enzyme A-SMase are described based on the common protein precursor and 
direct activation by zinc ions (Schissel et al. 1998). The lysosomal A-SMase is partially depending on 
Zn2+, because the enzyme is exposed to cellular Zn2+ during trafficking to lysosomes and in lysosomes. 
Hence, lysosomal A-SMase is zinc ion-saturated and does not require exogenous Zn2+ ions. In contrast 
to lysosomal A-SMase, the secretory A-SMase (S-SMase) requires exogenous Zn2+ for full activity 
and is released extracellularly (Schissel et al. 1998). 
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Maturation of A-SMase from its initial 75-kDa pre-pro form involves multiple proteolytic processing 
steps (Hurwitz et al. 1994). Using pulse-chase labeling experiments, the maturation of A-SMase was 
unraveled. The processing of the initial 75-kDa pre-pro form of A-SMase to the 72-kDa pro-form was 
seen within 3 h of chase and the formation of the mature 70-kDa form was apparent after 4 to 8 h 
(Hurwitz et al. 1994). The primary mechanism of targeting A-SMase to the lysosome is the mannose-
6-phosphate (M6P) receptor system (Ferlinz et al. 1997) because fibroblasts with mutations in 
enzymes of the M6P machinery showed enhanced A-SMase secretion (Takahashi et al. 2006). 
In humans, mutations in the SMPD1 gene (the gene product is A-SMase) result in the lysosomal 
storage disorder Niemann-Pick disease type A or B. Patients suffering from type A exhibit rapid 
neurodegeneration that leads to early death of the patient (2-3 years of age). In contrast to type A, 
Niemann-Pick disease type B is a milder form and is characterized by hepatosplenomegaly, pulmonary 
insufficiency and cardiovascular disease (Simpson et al. 2010). The different clinical outcome of 
Niemann-Pick disease types A and B are likely due to differences in the amount of residual, functional 
A-SMase activity (Schuchmann, 2010). Patients with Niemann-Pick disease accumulate 
sphingomyelin and other lipids, including cholesterol and gangliosides, leading to many cellular 
abnormalities (Scandroglio et al. 2008). 
The regulation of A-SMase and the underlying molecular mechanisms involving post-translational 
modifications as well as proper trafficking signals are only partially characterized. It was shown that in 
addition to initial cleavage, the enzyme can be further processed to a protein with a size of 57 kDa 
(Hurwitz et al. 1994). Here, proteases, in particular caspases, have been suggested to regulate A-
SMase activity (Brenner et al. 1998; Edelmann et al. 2011). Brenner and coworkers demonstrated in 
initial studies that caspase inhibition (by ac-YVAD-chloromethylketone or transient CrmA 
transfection) prevents A-SMase activation by CD95 (Brenner et al. 1998). Further studies reported 
that TNF triggers the interaction of the TNF-R1 with caspase-7. This interaction results in receptor 
internalization and rapid formation of endosomes (Edelmann et al. 2011). The receptor containing 
endosomes fuse with lysosomes resulting in multivesicular bodies bringing lysosomal A-SMase into 
close contact with caspase-7. Caspase-7 was shown to cleave the 72-kDa pro-form into the 57-kDa A-
SMase fragment and thereby activating the enzyme (Edelmann et al. 2011). Similar activation 
mechanisms of A-SMases by stimuli other than TNF are presently unknown. Additionally, cytosolic 
protein kinase C (PKC) δ-mediated phosphorylation of A-SMase at serine 508 can cause activation of 
A-SMase (Zeidan and Hannun, 2007). Furthermore, the second messenger diacylglycerol (DAG) was 
shown to be able to activate PKC as well as A-SMase (Schütze et al. 1992). The activity of A-SMase 
is also dependent on glycosylation, as there are six predicted N-glycosylation sites in the A-SMase 
polypeptide chain. However, only five are used for glycosylation (asparagine 86 (N86), N175, N335, 
N395, N520; Ferlinz et al. 1997). Mutation of N520 caused the impaired secretion of S-SMase in 
addition to a complete loss of activity, presumably resulting from defective trafficking (Hurwitz et al. 
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1994; Ferlinz et al. 1997). The glycosylation pattern also determines trafficking of the enzyme because 
only M6P glycosylation permits binding to M6P receptors. The M6P receptors target then the enzyme 
to lysosomes (Schissel et al. 1998). 
The translocation of A-SMase to the plasma membrane is triggered, for example, by CD95 and 
TRAIL-R2, or by infection with Pseudomonas aeruginosa, Neisseria gonorrhoeae, Staphylococcus 
aureus or rhinovirus (Stancevic and Kolesnick, 2010). It was demonstrated that A-SMase resides in 
secretory lysosomes that are mobilized upon stimulation to fuse with the cell membrane and that the t-
SNARE protein syntaxin-4 is required for the translocation of A-SMase (Perrotta et al. 2010). Another 
study showed that dysferlin is required for translocation of these vesicles (Han et al. 2012). The 
translocation of A-SMase leads to the fusion of secretory lysosomes with the plasma membrane 
resulting in exposure of A-SMase to the membrane extracellular leaflet of the cell. The hydrolysis of 
sphingomyelin to ceramide at the plasma membrane results in the formation of lipid microdomains as 
described in 2.4.1. 
Apart from receptor-mediated activation, A-SMase can be activated by receptor-independent stimuli, 
like irradiation, UV-light, heat, oxidative stress or chemotherapeutic agents (Hannun and Obeid, 
2008). Irradiation induces A-SMase activation in intact bovine aortic endothelial cells (Haimovitz-
Friedmann et al. 1994). Experiments with A-SMase-deficient mice revealed that endothelial cells 
lacking A-SMase were entirely resistant to apoptotic cell death. Moreover, lymphoblasts from patients 
with Niemann-Pick disease were completely resistant to radiation-induced apoptosis (Santana et al. 
1996). In Jurkat cells, it was shown that there are two distinct mechanisms for A-SMase activation. On 
the one hand, caspases were required and on the other hand, UV-C and ionizing radiation induced 
caspase-independent A-SMase activation (Rotolo et al. 2005). This then leads to the accumulation of 
ceramide-rich platforms, indicating that these membrane platforms may be responsible for irradiation-
induced cell death. However, at present it is still not known how these stimuli can exactly activate A-
SMase. 
It is generally accepted that A-SMase plays a central role in cellular responses, including non-receptor 
mediated signals, infection with various pathogens, ligation of DRs to their respective ligands, and 
chemotherapeutic drugs (Gulbins and Li, 2006). Ceramide, generated by A-SMase, appears to be also 
involved in necroptosis. It was shown that ceramide is involved in necroptosis induced by the DR 
TNF-R1 in murine L929 fibrosarcoma cells, NIH3T3 fibroblasts and human Jurkat T-cells (Strelow et 
al. 2000; Thon et al. 2005). Furthermore, it could be shown that ceramide plays a role in TRAIL-
induced necroptosis in murine L929, NIH3T3 fibroblasts and human Jurkat T cells, but that it is less 
pronounced than in necroptosis induced by the cytokine TNF (Thon et al. 2006; Voigt, Bachelor 
Thesis, 2009). Furthermore, TRAIL-induced necroptosis is effective to eliminate various types of 
human-derived tumor cells mediated by ceramide production (Voigt et al. 2014). 
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Despite the multitude of studies implicating the A-SMase and ceramide pathway in apoptosis, many 
important questions regarding the roles and regulation of A-SMase during necroptosis remain 
unanswered. For example, the molecular mechanism(s) of A-SMase regulation under caspase blocking 
conditions, as well as the cellular pathways involved in regulating A-SMase trafficking, localization 
and activity, are at present unresolved. 
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3. Aims of the presented dissertation 
The specific and detailed knowledge of apoptotic signaling has resulted in the targeted design and 
development of new drugs. This suggests that a comparably detailed functional and structural analysis 
of regulated necrosis signaling pathways holds similar therapeutic potential. To this end, the work plan 
for this thesis was divided into three major parts dealing with different aspects of regulated necrosis 
and especially necroptosis. The main goals were to unravel different molecular aspects of the distinct 
induction (1; chapter 5.1) and execution (2; chapter 5.2) mechanisms of regulated necrosis and 
necroptosis, thereby providing a basis for further translation into new therapeutically options (3; 
chapter 5.3) for, e.g. the elimination of tumor cells or for diseases that are caused by inappropriate 
induction of regulated necrosis. 
(1) As described above, it has been proposed that regulated necrosis can be induced by several 
molecular pathways. One key question was therefore whether individual pathways such as necroptosis 
and PARP-1-induced regulated necrosis depend on common execution mechanisms as part of an 
interacting network. First, the induction of regulated necrosis by TNF or DNA-alkylating agents such 
as 1-methyl-3-nitro-1-nitrosoguanidine (MNNG) or methyl methanesulfonate (MMS) will be analyzed 
morphologically and at the molecular level conducting caspase activity assays and measurements of 
intracellular ATP levels in different model cell lines for necroptosis. These model cell lines were 
either described earlier or will be characterized in the course of the study. Second, the interruption of 
the PARP pathway by PARP-1 inhibitors and genetic interference with JNK and cathepsin proteases 
as further components of the PARP pathway will be addressed to understand the molecular 
mechanisms underlying both modes of regulated necrosis. Third, the role of the kinase RIPK3 for 
initiation and execution of both pathways will be investigated. This will give an overview on potential 
differences between signaling in necroptosis and PARP-1-induced regulated necrosis and thus may 
provide first answers to the recently raised question whether there is one core program or several 
independent pathways of regulated necrosis which are important for the future design of therapeutic 
strategies targeting components of regulated necrosis. 
(2) Moreover, exploring in more detail the contribution of common executioner mechanisms in 
regulated necrosis and especially necroptosis could validate, challenge and disentangle the current 
view of the different execution mechanisms of regulated necrosis (see 2.2.1.2). In apoptosis, cleavage 
of proteins by caspases is essential for the initiation and execution of PCD and thus for the survival 
and homeostasis of multicellular organisms (Degterev and Yuan, 2008). As described above, 
proteolysis appears to be equally important in regulated necrosis, but the underlying mechanisms rely 
on alternative and yet marginally characterized proteolytic events. The second and main purpose of the 
dissertation aims to further define the role of proteolysis in the regulation of death receptor-mediated 
regulated necrosis/necroptosis. High throughput techniques as well as proteomic approaches will be 
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employed to identify known or unknown proteases and their substrates participating in necroptosis. 
One aim will be the identification of new or known serine proteases and their substrates that appear to 
be crucial in necroptosis by employing affinity-labeling of potential candidates with an active-site-
directed inhibitor derivate. As a complementary approach, it is planned to screen all 585 proteases 
encoded by the human genome using an RNA interference (RNAi) approach to define their relevance 
in necroptosis. Subsequently, the immunomagnetic enrichment of necroptotic TNF-R1-containing 
vesicles in combination with proteomic technologies will be conducted to isolate proteolytic substrates 
and to further examine the signaling pathway of necroptosis within the cell. Then, it is planned to 
characterize the proteases and potential substrates identified with the above utilized methods with 
regard to their relevance in TNF- and TRAIL-induced regulated necrosis. As a secondary goal, the 
proteolytic maturation and activation of A-SMase will be investigated during TNF-induced 
necroptosis by conventional Western blot analysis and enzymatic activity measurements. Furthermore, 
it is planned to identify the exact cleavage site of mature, active A-SMase to provide information 
about the so far unknown protease that possibly cleaves A-SMase in a caspase-independent manner. 
(3) The third part of the thesis will provide new and additional information on the potential of 
ceramide-mediated necroptosis in clinically relevant tumor cell lines. A panel of tumor cell lines will 
be analyzed with regard to their sensitivity towards necroptotic stimuli. Successively, the role of 
possible effector proteins of the signaling cascade will be investigated by pharmacological inhibitor 
studies of relevant signaling components. Since TRAIL selectively eliminates tumor cells without 
affecting normal cells, the effectiveness of the induction of necroptosis through TRAIL will be in the 
focus of this part of the study. 
In summary, the study should provide a better understanding of the initial and subsequent steps of 
regulated necrosis and especially necroptosis, with the intention to provide a basis for further 
translation into new therapeutic options for, e.g. elimination of apoptotic-resistant tumors or diseases 
that are caused by inappropriate induction of regulated necrosis. 
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4. Materials and Methods 
4.1 Materials 
4.1.1 Technical equipment 
Company Equipment 
AB SCIEX, Darmstadt, Germany AB SCIEX GPS software, Version 3.6, build 332 
MALDI targets (Opti-TOF, 384 Well Insert) 
MALDI-TOF/TOF 5800, 4000 Series Explorer Software 
 
BD Biosciences, Heidelberg, Germany FACSCalibur flow cytometer 
Software: BD CellQuest™ Pro V. 4.0.2 
PRIMARIA™ cultureware 
5 mL polystyrene round-bottom FACS tubes 
Plastipak™ 1 ml syringe 
 
Beckman Coulter, Krefeld, Germany TL-100 Ultracentrifuge, SW32 rotor 
Ultra centrifuge XL-800, SW60Ti rotor 
Ultra clear™ Centrifuge Tube, 11 x 60 mm 
 
Biometra, Göttingen, Germany Rocking platform WT12 
 
Bio-Rad, Munich, Germany Gene Pulser™ X Cell 
Mini PROTEAN® System Casting Stand 
Glass plates 
1.0 mm, 10-well comb 
Power Pac 3000 protein blotting cell 
Smart SpecTM 3000 spectrometer 
 
Branson Ultrasonics, Danbury, CT, USA W-450 sonication device 
 
Carl Roth, Karlsruhe, Germany Microscope slides 
 
Dionex, Idstein, Germany Acclaim PepMap100 C-18 column 
UltiMate 3000 RS Nano/Cap System 
 
Duran Group, Mainz, Germany Conical glass tubes 
 
Eppendorf, Hamburg, Germany Bench-top centrifuge (5415D) 
Refrigerated centrifuge (5417R) 
Thermomixer compact 
 
GE Healthcare, Munich, Germany Ettan DALTsix large vertical electrophoresis system 
HiTrap™ Protein G HP 1mL columns 
Hyperfilm™ 
Hypercassette™ 18 x 24 cm 
Molecular Dynamic Personal Densitometer SI 
Software: PDSI Scanner Control V5.03 
Typhoon Trio imager 
Software: Image Master 6.0, DeCyder 6.5 
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Company Equipment 
GFL, Wunstorf, Germany Water bath 1003 
Shaker 3033 
Gilson, Middleton, WI, USA Minipuls 3 casing pump 
Pipettes (10, 20, 200 and 1000 µL) 
 
Greiner Bio-One, Frickenhausen , Germany Serological pipettes (1, 5, 10, 25 and 50 mL) 
15 and 50 mL tubes 
 
Heraeus, Osterode, Germany Drying oven T6760 
Lamin Air HA2472GS 
Megafuge 1.0 (R)  
Minifuge RF 
 
Hirschmann Laborgeräte, Eberstadt, 
Germany 
 
Pipetus-Accu 
 
HOOCK, Kiel, Germany Magnetic device: HOKImag 1 
 
Lonza Group, Basel, Switzerland Amaxa® Nucleofector™ Device 
 
Merck, Darmstadt, Germany High-performance thin layer chromatography plates 
 
MSE, London, UK Soniprep 150 (ultrasonic disintegrator) 
 
Nerbe Plus, Winsen/Luhe, Germany ‘V’ bottom 96-well plates 
 
Nikon, Düsseldorf, Germany DS-5M-L1 Digital Sight Camera System 
 
Panasonic, Wiesbaden, Germany Lumix DMC-FS10 digital camera 
 
PeqLab Biotechnologie, Erlangen, 
Germany 
NanoDrop® photospectrometer ND-1000 
Software: ND-100 v. 3.7.9 
 
Sarstedt (DESAGA), Nümbrecht, 
Germany 
Chromatography chamber 
1 mL non-pyrogenic serological pipette 
 
Sigma Zentrifugen, Osterode, Germany Refrigerated centrifuge (6K10) 
 
Sterilin, Caerphilly, UK 40 x 6 mm round base test tube (RT15) 
 
Tecan Group, Männedorf, Germany Freedom Evo 200 robotic platform 
Infinite M200 ELISA Microplate Reader, 
Software: i-Control 1.3 
 
Thermo Scientific, Waltham, MA, USA Cell culture incubator 3336 
Multidrop cell dispenser 
Orbitrap LTQ Velos mass spectrometer 
Proteome Discoverer software (version 1.3 and 1.4): 
Sequest, Mascot and MS Amanda 
SpeedVac centrifuge 
 
VWR International GmbH, Darmstadt, 
Germany 
1.5 x 3 mm silicone tubing 
4 x 6 mm silicone tubing 
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Company Equipment 
Wheaton, Millville, NY, USA 15 mL tissue grinder, dounce 
 
Zeiss, Göttingen, Germany Axiovert 10 microscope 
Axiovert 135 microscope 
Axioskop 510 laserscanning microscope 
Software: AIM LSM Image Browser 
 
4.1.2 Chemicals and reagents 
Unless otherwise stated all basic chemicals were purchased by Merck (Darmstadt, Germany) and 
Sigma-Aldrich (Munich, Germany). 
Company Product 
Alexis Biochemicals, Lörrach, Germany SuperKillerTRAIL™ 
 
AppliChem, Darmstadt, Germany Click-RPMI cell culture medium 
 
Axon, Groningen, The Netherlands Olaparib (PARP-1 inhibitor) 
 
Bachem, Heidelberg, Germany zVAD-fmk 
ac-zDEVD-AFC 
ac-zIETD-AFC 
 
BASF Bioresearch, Ludwigshafen, 
Germany 
 
hTNF 
 
BD Biosciences, Heidelberg, Germany Streptavidin-PE 
Bacto-tryptone 
 
Biochrom, Berlin, Germany 10 X Trypsin/EDTA 
L-glutamine 
PBS 
FCS 
 
Biomol, Hamburg, Germany N-[L-3-trans-(propylcarbamoyl)-oxirane-2-carbonyl]-L-
Ile-L-Pro methyl ester (CA-074 Me) 
 
Bio-Rad, Munich, Germany Flamingo™ Fluorescent gel stain 
Mini-PROTEAN TGX Precast Gels 
 
Cambrex, East Rutherford, NJ, USA 
 
Sea Plaque agarose 
Cell Signaling Technology, Danvers, MA, 
USA 
 
LumiGLO® chemiluminiscent substrate 
ChemieTek, Indianapolis, IN, USA Birinapant (Smac mimetic) 
 
Fermentas, St. Leon-Rot, Germany PageRuler™ protein marker 
 
GE Healthcare, Munich, Germany CyDyes 
DeStreak Rehydration solution 
GammaBind G-sepharose 
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Company Product 
Granovita, Heimertingen, Germany Milk powder 
 
Hartmann Analytic GmbH, Braunschweig, 
Germany 
 
N-methyl-[14C]-sphingomyelin 
ICT, Bloomington, MN, USA FLISP™ Serine Protease Detection Assay Kit 
Imgenex, San Diego, CA, USA FAM-Phe-CMK SerPase™ Kit 
 
Invitrogen, Darmstadt, Germany GIBCO® RPMI 1640 and 
DMEM cell culture medium 
Freestyle™ 293 Expression Medium 
Lysotracker® Red DND 99 
ProLong® Gold antifade reagent with DAPI 
Protein G, Alexa Fluor® 488 conjugate 
 
Life Technologies, Darmstadt, Germany Opti-MEM® medium 
siPORT™ Amine Transfection Agent 
 
Lonza Group, Basel, Switzerland Amaxa® Cell line Nucleofector™ Kit V 
 
Macherey-Nagel, Düren, Germany Porablot nitrocellulose membrane 
 
Miltenyi Biotec, Bergisch-Gladbach, 
Germany 
Protein G micro beads 
Streptavidin micro beads 
 
PAA Laboratories, Pasching, Austria Accutase 
Sodium pyruvate 
G418-sulphate 
 
PeptaNova, Sandhausen, Germany (Z-LL)2-ketone 
 
PeqLab Biotechnologie, Erlangen, 
Germany 
 
peqGOLD agarose 
Promega, Madison, WI, USA Cell Titer-Glo® Luminescent Cell Viability Assay 
 
Qiagen, Hilden, Germany Plasmid Maxi Kit 
 
R&D Systems, Minneapolis, MN, USA Fluorokine® Biotinylated Human TNF-α Kit 
 
Roche, Mannheim, Germany Complete Mini and Maxi – protease inhibitor cocktail 
Pefabloc SC® 
 
Serva, Heidelberg, Germany Acrylamide/bis-Solution 
TEMED 
Trypan blue solution 
Albumin bovine fraction V, pH 7.0 
Sequencing-grade trypsin 
Yeast extract 
 
TCI, Zwijndrecht, Belgium 1-methyl-3-nitro-1-nitrosoguanidine (MNNG) 
3-aminobenzamide (3-AB; PARP-1 inhibitor)  
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Company Product 
Thermo Scientific, Waltham, MA, USA BCA Protein Assay Kit 
BSA standard 
Coomassie based reagent 
Zeba™ Spin Desalting Columns 7K 
 
Tocris Bioscience, Ellisville, MO, USA PJ-34 (PARP-1 inhibitor) 
 
Zinsser Analytic, Frankfurt a.M., Germany Liquid scintillator fluid Aquasafe 300 plus 
 
4.1.3 Plasmids and siRNAs 
The plasmid pEF6.V5/His.aSMasewt (referred to as V5-A-SMase throughout this thesis) coding for a 
human V5-tagged version of full-length A-SMase was obtained from Yusuf A. Hannun (Department 
of Biochemistry and Molecular Biology, Charleston, SC, USA) and described previously (Zeidan and 
Hannun, 2007). The transfection vector BMGneo harboring a neomycin resistance cassette was 
described earlier (Karasuyama and Melchers, 1988) and was used for stable transfection of 
pEF6.V5/His.aSMasewt into L929Ts cells (see 4.2.2.4). Plasmids coding for Fc-tagged TNF variants 
based on the expression vectors pCR™ 3 (TNF60-Fc) and pdg105 (TNFwt-Fc) were obtained from 
Harald Wajant (University Würzburg, Germany) and used to produce the fusion proteins TNF60-Fc 
and TNFwt-Fc (see 4.2.14.3). The transfection-ready DNA of a myc-DDK-tagged ORF clone of Homo 
sapiens phosphoglycerate mutase family member 5 (PGAM5, NM: 001170543.1) in a pCMV6-entry 
vector was purchased from OriGene (catalog number: RC201678, Rockville, MD, USA), used for 
stable transfection of L929Ts cells and is referred to as PGAM5-FLAG throughout this thesis. The 
expression plasmids pPPHβ and pPPHβ E90A were a gift from Christoph Becker-Pauly (Christian-
Albrechts-University, Kiel, Germany) and described earlier (Eldering et al. 1997). These plasmids 
were used to transiently express wild-type meprin β or an inactive meprin β mutant (E90A). 
Table 1: List of all siRNAs used. 
Product Description Catalogue 
number 
Company 
siGENOME Human CASP8 mixture of four siRNAs 
targeting caspase-8 
M-003466-05 Thermo Scientific, 
Waltham, MA, USA 
siGENOME Human CFLAR mixture of four siRNAs 
targeting caspase 8 and FADD-
like apoptosis regulator 
(CFLAR) (also known as c-
FLIP, I-FLICE) 
M-003772-06 Thermo Scientific, 
Waltham, MA, USA 
siGENOME Human CYLD mixture of four siRNAs 
targeting cylindromatosis 
(turban tumor syndrome) 
protein 
M-004609-01 Thermo Scientific, 
Waltham, MA, USA 
Silencer® Select Human 
DNM1L 
individual siRNA targeting 
dynamin 1-like protein (alias 
DRP1) 
S19560 Life Technologies, 
Darmstadt, Germany 
Silencer® Select Mouse Dnm1l individual siRNA targeting 
dynamin 1-like protein (alias 
DRP1) 
S92135 Life Technologies, 
Darmstadt, Germany 
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Product Description Catalogue 
number 
Company 
siGENOME Human DPYSL4 mixture of four siRNAs 
targeting dihydropyrimidase-
like 4 (other known aliases: 
Crmp3, Drp-4) 
 
M-008504-00 Thermo Scientific, 
Waltham, MA, USA 
siGENOME Human GGT1 mixture of four siRNAs 
targeting gamma-
glutamyltransferase 1 
M-005884-02 Thermo Scientific, 
Waltham, MA, USA 
Silencer® Select Human 
HTRA2 
validated siRNA targeting HtrA 
(high temperature requirement 
protein A) serine peptidase 2 or 
Omi stress-regulated 
endoprotease (HtraA2/Omi) 
 
S654 Life Technologies, 
Darmstadt, Germany 
Silencer® Human Druggable 
Genome siRNA library 
Version 3 covering 23,349 
human genes with 3 individual 
siRNAs targeting 7,783 human 
genes 
4391844 Life Technologies, 
Darmstadt, Germany 
siGENOME Human LONP1 individual siRNA targeting Lon 
protease 1 
 
D-003979-01 Thermo Scientific, 
Waltham, MA, USA 
siGENOME Human MEP1B individual siRNA targeting 
meprin A beta alias PPH beta or 
Mep1β 
D-005942-01 Thermo Scientific, 
Waltham, MA, USA 
Silencer® Select Human 
MLKL 
individual siRNA targeting 
mixed lineage kinase domain-
like protein 
42942 Life Technologies, 
Darmstadt, Germany 
Silencer® Select Mouse Mlkl individual siRNA targeting 
mixed lineage kinase domain-
like protein 
S92950 Life Technologies, 
Darmstadt, Germany 
siGENOME Human MMP3 mixture of four siRNAs 
targeting matrix 
metalloproteinase 3 
(stromelysin 1) 
M-005968-03 Thermo Scientific, 
Waltham, MA, USA 
Silencer® Negative Control control #1 siRNA with no 
significant sequence similarity 
to mouse or human genes  
AM4611 Life Technologies, 
Darmstadt, Germany 
siGENOME Non-Targeting 
siRNA Pool # 1 
pool of 4 non-targeting siRNAs, 
control for experiments with 
siGENOME reagents 
D-001206-13 Thermo Scientific, 
Waltham, MA, USA 
Silencer® Select Human 
PGAM5 
individual siRNA targeting 
phosphoglycerate mutase family 
member 5 (serine/threonine 
phosphatase) 
S46938 Life Technologies, 
Darmstadt, Germany 
Silencer® Select Mouse Pgam5 individual siRNA targeting 
phosphoglycerate mutase family 
member 5 (serine/threonine 
phosphatase) 
S91079 Life Technologies, 
Darmstadt, Germany 
siGENOME Human PMPCA individual siRNA targeting 
mitochondrial processing 
peptidase alpha 
D-008734-02 Thermo Scientific, 
Waltham, MA, USA 
siGENOME Human PRPF8 mixture of four siRNAs 
targeting pre-mRNA processing 
factor 8 
M-012252-02 Thermo Scientific, 
Waltham, MA, USA 
siGENOME Human PSMA1 individual siRNA targeting 
proteasome subunit,  
alpha type-1 
D-010123-01 Thermo Scientific, 
Waltham, MA, USA 
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Product Description Catalogue 
number 
Company 
Silencer® Select Human 
RIPK1 
validated siRNA targeting 
receptor-interacting 
serine/threonine kinase 1 
S16653 Life Technologies, 
Darmstadt, Germany 
siGENOME Human RIPK3 validated siRNA targeting 
receptor-interacting 
serine/threonine kinase 3 
D-003534-01 Thermo Scientific, 
Waltham, MA, USA 
Silencer® Select Human 
RIPK3 
individual siRNA targeting 
receptor-interacting 
serine/threonine kinase 3 
S21741 Life Technologies, 
Darmstadt, Germany 
siGENOME Human 
TMPRSS11E 
mixture of four siRNAs 
targeting transmembrane 
protease serine 11E (DESC1) 
M-005847-02 Thermo Scientific, 
Waltham, MA, USA 
Silencer® Select Human 
TNFRSF1A 
validated siRNA targeting TNF-
R1 
S14266 Life Technologies, 
Darmstadt, Germany 
siGENOME Human YME1L1 individual siRNA targeting 
YME1-like ATPase (presenilin 
associated metalloprotease) 
D-006103-02 Thermo Scientific, 
Waltham, MA, USA 
 
4.1.4 Antibodies 
Table 2: List of all applied primary and secondary antibodies and their working dilutions. 
Target and clone Used 
dilution  
Article number Company 
primary antibodies:    
α-Actin, C-11 1:10,000 sc-1615 Santa Cruz Biotechnology, 
Heidelberg, Germany 
β-Actin, AC-15 1:10,000 A1978 Sigma-Aldrich, Munich, Germany 
A-SMase 1:1,000 #3687 Cell Signaling Technology, Danvers, 
MA, USA 
Caspase-7, E22 1:1,000 Ab32522 Abcam, Cambridge, UK 
cleaved Caspase-7, D198 1:1,000 #9491 Cell Signaling Technology, Danvers, 
MA, USA 
Caspase-8, IC12, human 
Caspase-8, murine 
1:1,000 
1:1,000 
#9746 
#4927 
Cell Signaling Technology, Danvers, 
MA, USA 
COXIV 1:10,000 #4850 Cell Signaling Technology, Danvers, 
MA, USA 
Drp-1, H-300 1:1,000 sc-32898 Santa Cruz Biotechnology, 
Heidelberg, Germany 
FLAG, M2 1:1,000 035K6196 Sigma-Aldrich, Munich, Germany 
HtrA2/Omi, E55 1:1,000 ab32092 Abcam, Cambridge, UK 
IgG1 fluorescence control 1:5 349040 BD Biosciences, Heidelberg, 
Germany 
JNK1, G151-333 1:1,000 554286 BD Biosciences, Heidelberg, 
Germany 
JNK2, A-7 1:1,000 sc-271133 Santa Cruz Biotechnology, 
Heidelberg, Germany 
Lamp-1 1:500 611043 BD Biosciences, Heidelberg, 
Germany 
Lamp-1, supernatant 1:100 1D4B DSHB, Iowa City, IA, USA 
Lamp-2, CD107b, H4B4 1:1,000 SBA-9840-01 Southern Biotech, Birmingham, AL, 
USA 
MLKL 1:1,000 SAB2103620 Sigma-Aldrich, Munich, Germany 
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Target and clone Used 
dilution  
Article number Company 
primary antibodies:    
PARP-1 1:1,000 #9542 Cell Signaling Technology, Danvers, 
MA, USA 
PGAM5, K-16 1:1,000 sc-161156 Santa Cruz Biotechnology, 
Heidelberg, Germany 
Rab5 1:1,000 #3547 Cell Signaling Technology, Danvers, 
MA, USA 
Rab5 1:300 sc-598 Santa Cruz Biotechnology, 
Heidelberg, Germany 
RIPK1 1:1,000 
or 
1:100 
610459 BD Biosciences, Heidelberg, 
Germany 
RIPK3, human 1:1,000 PAB0287 Abnova, Heidelberg, Germany 
RIPK3, murine 1:1,000 PRS2283 Sigma-Aldrich, Munich, Germany 
TNFα 1:1,000 sc-8301 Santa Cruz Biotechnology, 
Heidelberg, Germany 
TNF-R1 1:1,000 sc-8436 Santa Cruz Biotechnology, 
Heidelberg, Germany 
TRAIL-R1, HS101 1:100 ALX-804-297 Alexis Biochemicals, Lörrach, 
Germany 
TRAIL-R2, HS201 1:100 ALX-804-298 Alexis Biochemicals, Lörrach, 
Germany 
V5 1:5,000 P/N 46-0705 Invitrogen, Darmstadt, Germany 
    
secondary antibodies:    
biotin rat anti-mouse IgG1 1:50 553441 BD Biosciences, Heidelberg, 
Germany 
donkey anti-rabbit Alexa Fluor® 555 
IgG (H+L) 
1:200 A-31572 Life Technologies, Darmstadt, 
Germany 
goat anti-mouse Alexa Fluor® 555 
IgG (H+L) 
1:200 A-31572 Life Technologies, Darmstadt, 
Germany 
goat anti-mouse IgG2b-horseradish 
peroxidase (HRP) 
1:2,500 sc-2062 Santa Cruz Biotechnology, 
Heidelberg, Germany 
secondary antibodies, alkaline 
phosphatase (POD)-coupled 
1:10,000  Jackson Immuno Research 
Laboratories, West Grove, PA, USA 
 
4.1.5 Cell lines 
The murine fibrosarcoma cell line L929Ts is a TRAIL-sensitive sub line of the L929 cell line derived 
in the laboratory of Dieter Adam (Christian-Albrechts-University, Kiel, Germany) and has been 
described earlier (Thon et al. 2006). L929sA cells were kindly provided by Peter Vandenabeele 
(Ghent University, Ghent, Belgium) and have been described previously (Vanhaesebroeck et al. 
1992). Wild-type and RIPK3-deficient mouse embryonic fibroblasts (MEFs) as well as murine 
NIH3T3 cells naturally expressing RIPK3 have been previously described (Sosna, Voigt et al. 2014). 
Cells deficient for RIPK3 expression and transfectants stably expressing murine green fluorescent 
protein (GFP) fusions to wild-type or kinase-defective murine RIPK3 in the vector pEGFP-N1 (Takara 
Bio Inc., Mountain View, CA, USA) were generated and provided by Francis Ka-Ming Chan 
(University of Massachusetts Medical School, Worcester, MA, USA), together with human Jurkat I42 
acute leukemia T cells deficient for FADD but additionally stably transfected with TNF-R2 (Chan et 
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al. 2003). Hamster embryonic kidney cells constitutively expressing the simian virus 40 (SV40) large 
T antigen (HEK293T), MCF-7, HeLa, L929ATCC and wild-type Jurkat cells (clone E6-1) were 
obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Immortalized 
MEFs deficient for caspase-7 expression and their wild-type counterparts were kindly provided by 
Stefan Schütze (Christian-Albrechts-University, Kiel, Germany). These MEFs were originally 
generated by Richard Flavell (Yale School of Medicine, New Haven, CT, USA). MEFs lacking 
SPPL2a or SPPL2b or SPPL2a/b and wild-type cells as control were generated and kindly provided by 
the group of Bernd Schröder (Christian-Albrechts-University, Kiel, Germany). Presenilin-1/2-deficient 
MEFs were a gift from Paul Saftig (Christian-Albrechts-University, Kiel, Germany) and have been 
described (Herreman et al. 1999). Immortalized wild-type and JNK1/JNK2 double-deficient MEF 
were a kind gift from Roger Davis (University of Massachusetts Medical School, Worcester, MA, 
USA). Wild-type, cathepsin D-deficient, and cathepsin D-deficient MEF stably transfected with the 
pro-cathepsin D cDNA have been previously described (Heinrich et al. 2004). Primary lung fibroblasts 
from JNK1- and JNK2-deficient mice and their wild-type littermate controls were prepared in the 
laboratory of Dieter Adam (Christian-Albrechts-University, Kiel, Germany). Human gall bladder 
adenocarcinoma (Mz-ChA-1), pancreatic adenocarcinoma (Colo357, PancTu-I, Panc89, A818-4, 
Pt45P1), gastric adenocarcinoma (MKN-28) and non-small cell lung carcinoma (KNS-62) cell lines 
have been described (Egberts et al. 2007; Sipos et al. 2003; Kurdow et al. 2005; Juhl et al. 1997). The 
leukemia-derived U-937, CCRF-CEM, pancreatic BxPC-3, colorectal HT-29, ovary adenocarcinoma 
SK-OV-3 and malignant melanoma-derived SK-MEL-28 cancer cells were originally obtained from 
ATCC and were, as well as Mz-ChA-1, Colo357, PancTu-I, Panc89, A818-4, Pt45P1, MKN-28 and 
KNS-62, a gift from Holger Kalthoff (Christian-Albrechts-University, Kiel, Germany). HEK293T and 
all MEFs were cultivated in DMEM supplemented with 10 % (v/v) FCS, 50 µg/mL penicillin and 
streptomycin each and 50 µM β-mercaptoethanol in 0.9 % (w/v) NaCl. Mz-ChA-1, KNS-62, U-937 
and HT-29 were maintained in RPMI 1640 medium supplemented with 10 % (v/v) heat-inactivated 
FCS and 1 mM sodium pyruvate. L929, NIH3T3 and Jurkat cells were cultivated in a mixture of 
Click’s/RPMI 1640 medium (50/50 % (v/v)), supplemented with 10 % (v/v) heat-inactivated fetal calf 
serum (FCS), 2 mM L-glutamine, 50 µg/mL penicillin and streptomycin. All described cell lines were 
maintained in a humidified incubator containing 5 % (w/v) CO2 at 37 °C. 
For passaging, cells were detached, using phosphate buffered saline (PBS) supplemented with  
0.5 % (v/v) trypsin and 0.2 % (v/v) EDTA every two to four days and re-seeded in fresh medium. For 
functional assays (to preserve the integrity of cell surface molecules), cells were alternatively detached 
with accutase. For long-term storage, cell lines were re-suspended in FCS with 10 % (v/v) DMSO and 
frozen in liquid nitrogen. 
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4.2 Methods 
4.2.1 Cytotoxicity assays 
4.2.1.1 Trypan blue staining 
To determine the amount of dead cells (when measuring ceramide levels), cells were pelleted and re-
suspended in PBS. An aliquot of the cell suspension was added to the same volume of 0.4 % (v/v) 
trypan blue staining solution and applied onto a Neubauer counting chamber. Live cells with an intact 
cell membrane did not absorb trypan blue and were scored separately from dead (blue) cells. 
4.2.1.2 Measurement of intracellular ATP levels 
The loss of intracellular ATP was measured as a marker for cell death. Intracellular ATP content was 
determined with the Cell-Titer GLO® Assay Kit following the instructions of the manufacturer. 
4.2.1.3 Crystal violet staining 
For determination of cell viability by crystal violet staining, cells were seeded onto flat-bottom 96-well 
plates. After stimulation as indicated in the figure legends, adherent cells were washed twice with PBS 
and stained with crystal violet solution (0.5 % (w/v) crystal violet, 4 % (w/v) formaldehyde,  
30 % (v/v) ethanol, and 0.17 % (v/v) NaCl) for 10 min at 37 °C. The staining solution was carefully 
washed away with tap water and the cells were dried at 50 °C for 1 h. Stained cells were dissolved in 
33 % (v/v) acetic acid and the absorbance of the staining was measured in a microplate reader at 
570 nm. 
4.2.1.4 Propidium iodide staining 
For flow cytometric analysis of cell death (e.g. loss of membrane integrity), cells were seeded in 12-
well plates at 70 % confluence. Suspension cell lines (U-937 and Jurkat T cells) were stimulated 
immediately whereas adherent cells were left to attach over night. After treatment, adherent 
(detachment with accutase) and detached cells were collected followed by centrifugation at 400 x g for 
5 min at 4 °C. The cell pellet was washed once in cold PBS/5 mM EDTA, resuspended in PBS/EDTA 
containing 2 µg/mL propidium iodide (PI), and analyzed for loss of membrane integrity on a 
FACSCalibur flow cytometer at red fluorescence. 
For every flow cytometric measurement, 10,000 cells were examined and cellular debris was excluded 
from the analysis. All values for loss of membrane integrity were calculated as 100 % minus PI-
negative intact, alive cells to account for disintegrated dead cells that have lost their PI staining again 
due to diffusion. 
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4.2.2 Clonogenic survival assays 
The analysis of clonogenic survival of cells was carried out as described by Franken and coworkers 
(Franken et al. 2006). Briefly, after treatment, 1,000 viable cells were re-suspended in RPMI 1640 
supplemented with 10 % FCS and 1 mM sodium pyruvate and plated into 6-well plates, cultured for 
7 days, and stained with crystal violet staining solution (see 4.2.1.3) for 10 min at 37 °C. The 
remaining staining solution was washed away and plates were dried at 50 °C. Colony formation  
(>10 cells) was determined from pictures taken with a digital camera (Lumix DMC-FS10, Panasonic, 
Wiesbaden, Germany). Non-adherent U-937 cells were alternatively analyzed for their ability to form 
colonies in soft agarose by mixing treated cells with 2 mL of 0.4 % (w/v) Sea Plaque agarose in RPMI 
1640 supplemented with 10 % FCS and 1 mM sodium pyruvate. This cell suspension was then 
transferred into a 6-well plate containing 3 mL of a 1 % (w/v) peqGOLD agarose underlayer in 
complete medium in each well. Cells were incubated for 7 days at 37 °C. Again, colony formation 
(>10 cells) was determined from pictures taken with a digital camera. For this purpose, cells were 
stained with 1 mL of 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide (MTT; 2.5 mg/mL 
in PBS) for 2 h at 37 °C to allow metabolization of MTT to blue MTT-formazan. 
4.2.3 Transfection 
All used constructs and siRNAs are listed in 4.1.3. 
4.2.3.1 Nucleofection 
L929Ts cells were transfected with 150 pmol siRNA using the Amaxa® Cell line Nucleofector™ kit 
V according to manufacturer’s instruction. Briefly, 1 x 106 cells per transfection were pelleted and re-
suspended in 100 µL room temperature (RT) solution V. The cell suspension was combined with 
either 150 pmol siRNA or 10-20 µg DNA and transferred into a cuvette. The transfection was applied 
with Nucleofector® Program T-20 and cells were gently transferred into 6-well plates containing pre-
warmed media for 24-72 h. 
HT-29 cells were transfected as above using the Amaxa® Cell line Nucleofector™ kit R according to 
the manufacturer’s standardized protocols. 
4.2.3.2 Electroporation 
U-937, HEK293T and L929Ts cells were transfected using electroporation with an electroporation 
device from Bio-Rad. Depending on the purpose of the transfection, 2-10 x 106 cells were pelleted and 
dissolved in 200 µL cell specific medium without supplements and mixed with the desired siRNA 
(150 pmol) or DNA (10 µg). The mixture was transferred into a 0.2 µm pre-warmed cuvette and 
placed into the electroporation device. The parameters for electroporation were optimized for each cell 
line and depicted in table 3. 
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Table 3: Electroporation settings for U-937, HEK293T and L929Ts cells. 
Cell line Settings 
U-937 155 V 
1000 µF 
resistance [Ω]: ∞ 
HEK293T 110 V 
pulse length: 25 ms 
L929Ts 280 V 
960 µF 
resistance [Ω]: ∞ 
 
4.2.3.3 Reverse transfection with siPORT™ Amine Transfection Agent 
The transfection with siPORT™ Amine Transfection Agent is polyamine-based and was utilized for 
HT-29 cells. For reverse transfections, 3 x 103 cells were utilized per transfection reaction in 96-well 
plates. For 12-well plates, 3 x 104 cells were used per transfection. For each 96-well plate transfection 
reaction, 9.4 µL OptiMEM® reduced serum media and 0.6 µL siPORT™ Amine solution (1:16 (v/v)) 
was incubated for 10 min at RT. Meanwhile, 2 µM siRNA (1 µL) was diluted in 9 µL OptiMEM®. 
After incubation, diluted siRNA and siPORT™ Amine solution were mixed and incubated for further 
10 min and thereafter placed in 96-well (for viability assay; see 4.2.1.2) or 12-well plates (volumes 
were ten times multiplied respectively; for further Western blot analysis see 4.2.11) before the cell 
suspension was added. After 72 h post-transfection, either cellular extracts were prepared or cells were 
stimulated as indicated. 
For each transfection reaction, the efficiency of the down-regulation was analyzed by Western blot 
analysis either for the protein of interest or control siRNAs. 
4.2.3.4 Stable transfection of L929Ts cells 
Stable transfection of L929Ts cells with pEF6.V5/His.aSMasewt or myc-DDK-tagged PGAM5 was 
performed either by nucleofection or electroporation (see 4.2.3.1 and 4.2.3.2). The expression plasmid 
of PGAM5 already contains a neomycin resistance cassette, whereas pEF6.V5/His.aSMasewt does not. 
Cells were transfected with 10 µg PGAM5-FLAG or a mixture of 2 µg of BMGNeo and 20 µg of V5-
A-SMase plasmid. The transfected cells were transferred into fresh complete media over night. Further 
cultivation of transfected cells was performed in 14 cm cell culture plates at 1:5 (v/v) dilution in fresh 
media supplemented with 1 mg/mL G418 to select resistant transfectants. After approximately two 
weeks of cultivation with routine media change, cell colonies were visible. These sub clones were 
detached with sterile filter paper pieces soaked with PBS supplemented with 0.5 % (v/v) trypsin and 
0.2 % (v/v) EDTA and transferred into 6-well plates. The cell clones were expanded and analyzed via 
Western blot for stable expression of the desired protein. 
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4.2.4 High-throughput RNA interference screen procedure with HT-29 cells 
For a high-throughput RNA interference (RNAi) screen, the Silencer Human Druggable Genome 
siRNA Library V3 was used. From this siRNA library the respective 560 genes encoding protease 
siRNAs were selected and transferred to 96-well plates generating a human protease siRNA library. 
HT-29 cells (3,000 cells per well in 96-well plates) were reverse-transfected with three individual 
siRNAs per target gene (final concentration: 20 nM) using siPORT™ Amine Transfection Agent (see 
4.2.3.3) and a multidrop cell dispenser (Freedom Evo 200 robotic platform). After 72 h, cells were 
stimulated for 20 h with TNF, zVAD-fmk and cycloheximide (CHX) or left unstimulated and 
intracellular ATP levels were measured (see 4.2.1.2). The experimental set up is depicted in Figure 5. 
Figure 5: High-throughput siRNA screen for proteases participating in necroptosis. (A) The pipetting scheme for a 
Tecan Freedom Evo 200 robotic device and (B) the schematic diagram of the first screen is shown. HT-29 cells were reverse 
transfected with protease siRNA. After 72 h, necroptosis was induced by 100 ng/mL TNF, 20 µM zVAD-fmk and 5 µg/mL 
CHX. ATP levels were measured 20 h after stimulation. The complementary siRNA screen was performed in collaboration 
with the group of Philip Rosenstiel (Christian-Albrechts-University, Kiel, Germany). 
Abbreviations: adenosine-5'-triphosphate (ATP), cycloheximide (CHX), high temperature requirement protein A2 
(HTRA2), receptor-interacting serine-threonine protein kinase (RIPK), tumor necrosis factor (TNF), TNF-receptor 1 (TNF-
R1), benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD-fmk). 
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For data analysis, values of all plates were color-coded and manually inspected for systematic bias 
(e.g. row or rim effects) and/or inappropriate knock-down efficiency (i.e. the viability of either RIPK3 
or TNF-R1 siRNA-transfected controls was less than twofold of the overall median calculated for each 
plate). Plates that did not meet these criteria were repeated before further analysis. Stimulation 
intensities (fold induction) were calculated by dividing unstimulated through stimulated treatment. 
Individual fold inductions were normalized to the median of the corresponding 96-well plate. Genes 
with normalized fold-induction values ≥ 1.5 or ≤ -1.5 were considered to be candidate genes (hits). 
The described RNAi screen was performed in collaboration with Gunnar Jacobs (PopGen, Kiel, 
Germany) and the group of Philip Rosenstiel (Christian-Albrechts-University, Kiel, Germany). 
4.2.5 Staining of cell surface molecules 
4.2.5.1 Internalization studies of TNF-R1 
The cell surface expression of TNF-R1 was detected by fluorescence based labeling of the receptor 
and flow cytometric analysis. U-937 cells were centrifuged at 100 x g for 10 min and washed twice 
with PBS. Cells were re-suspended in PBS to a final concentration of 4 x 106 cells/mL and cooled 
down to 4 °C. 50 µL of the washed and cold cell suspension was pre-incubated with zVAD-fmk or 
dynasore as indicated in the figure legends. After pre-incubation, cells were incubated with 400 ng 
ligand TNF60-Fc for 1 h on ice. Internalization of TNF60-Fc bound TNF-R1 complexes was achieved 
by incubation of the cell suspension at 37 °C for various time-points. The reaction was stopped by 
immediately cooling down on ice. To stain the receptor/ligand complexes still retained at the cell 
surface, the cell suspension was incubated with 1 µg of Protein G-Alexa Fluor® 488 for at least 
30 min at 4 °C in the dark. Thereafter, cells were washed twice with 1 x RDF1 buffer (provided by the 
TNFα Kit from R&D) to minimize background staining and to remove unreacted Protein G-Alexa 
Fluor® 488. Cells were fixed in 0.2 mL of 3 % (w/v) paraformaldehyde (PFA) in PBS for final flow 
cytometric analysis at green fluorescence. 
For control, the fluorescence of cells was measured which were incubated with Protein G-Alexa 
Fluor® 488 alone. 
4.2.5.2 Cell surface staining of TRAIL receptors 
To detect cell surface expression of TRAIL receptors (DR4 and DR5), a total of 4.5 x 105 U-937 cells 
were collected in a ‘V’-bottom 96-well assay plate, washed once with washing buffer containing  
1 % (w/v) bovine serum albumin (BSA) and 0.1 % (v/v) NaN3 in PBS and centrifuged at 200 x g for 
4 min at 4 °C. The cells were incubated with 10 µg/mL anti-TRAIL-R1 or anti-TRAIL-R2 mouse 
monoclonal antibodies in washing buffer for 1 h at 4 °C in a humidified chamber, washed twice with 
ice-cold washing buffer and incubated with anti-mouse biotin-conjugated secondary antibodies for one 
additional h at 4 °C. After two washing steps, cells were incubated with phycoerythrin-conjugated 
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streptavidin for further 15 min at 4 °C, washed twice and fixed in 150 µL PBS containing 1 % (w/v) 
PFA and transferred into 0.6 mL flow cytometric tubes. Samples were stored at 4 °C for further flow 
cytometric analysis.  
For control, the fluorescence of cells was measured which were incubated with iso-type matched 
antibodies IgG1 and incubated with anti-mouse biotin-conjugated secondary antibodies and 
phycoerythrin-conjugated streptavidin. 
4.2.6 Caspase activity assay 
Measurement of caspase-3 and -8 activities was based on the reaction of the enzymes with a specific 
fluorogenic substrate. Following treatment, adherent and detached cells were collected and lysed in a 
lysis buffer (10 mM HEPES pH 7.4, 142 mM KCl, 5 mM MgCl2, 1 mM EGTA, 0.2 % (v/v) NP40, 
1 mM dithiothreitol (DTT), 2 mM Pefabloc). Cytosolic extracts equilibrated with 1 mM dATP and 
10 µM cytochrome c for 1 h at 30 °C (to activate caspases) served as positive control. To measure 
caspase-3 activity, 100 µM ac-zDEVD-afc (benzyloxycarbonyl (ac)-Asp-Glu-Val-Asp-7-
aminotrifluoromethylcoumarin (afc)) diluted in 100 µL caspase buffer containing 20 mM Pipes pH 
7.2, 100 mM NaCl, 10 mM DTT, 1 mM EDTA, 0.1 % (w/v) CHAPS and 10 % (w/v) sucrose was 
added to 10 µL cytosolic extracts (5-20 µg protein, depending on the enzymatic activity) and 
incubated at 37 °C for distinct time-points. For measuring caspase-8 activity, 100 µM ac-z-IETD-afc 
(ac-Ile-Glu-Thr-Asp-afc) was added to the caspase buffer. The release of afc was measured as 
emission at 505 nm upon excitation at 405 nm using a fluorimeter equipped with a thermo stated 
microplate reader. 
4.2.7 Intracellular ceramide quantification 
For measurement of ceramide generation, 1 x 107 cells per treatment and time-point were seeded onto 
14 cm culture plates. After treatment, the supernatant and already detached cells were collected and 
the reaction was stopped by washing cells with ice-cold PBS. Adherent cells were detached by 
treatment with accutase, collected, and pooled with the supernatant followed by centrifugation at  
400 x g for 5 min at 4 °C. The cell pellet was re-suspended in PBS and the cell number was counted 
(see 4.2.1.1). After counting, cells were washed twice in PBS and pelleted for either storage at -80 °C 
or immediate processing. 
Lipid extraction with methanol/chloroform was performed at 4 °C according to the method of Bligh 
and Dyer (1959). Briefly, the cell pellet was re-suspended in 2 mL autoclaved Milli-Q water and 4 mL 
methanol (1:2 (v/v)) and transferred into a 14 mL conical glass tube. Subsequently, the mixture was 
homogenized with an ultrasonic disintegrator for 16 x 5 sec with 10 sec intervals between each 
sonication step. After sonication, 2 mL chloroform were added and the samples were again 
homogenized for 16 x 5 sec as described above. Samples were centrifuged for 10 min at 2,800 x g. 
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The upper phase was transferred into a 40 mL conical glass tube with 3 mL autoclaved Milli-Q water 
and 6 mL chloroform (1:2 (v/v)). For re-extraction, the lower and interphase were supplemented with 
1 mL autoclaved Milli-Q water and 4 mL methanol (1:4 (v/v)), immediately sonicated for a second 
cycle as described above and centrifuged at 2,800 x g for 10 min. The resulting supernatant was 
pooled with the separately stored upper phase from the previous step and again centrifuged at  
2,800 x g for 10 min. After centrifugation, the resulting lower organic phase - containing the extracted 
lipids - was transferred to a new glass tube and evaporated under 1 bar N2 at 37 °C. Dried lipids were 
re-suspended in a mixture of chloroform/methanol (9:1 (v/v); recommended amount: 50 µL for a total 
of 1 x 107 cells). In parallel, for chromatographic separation of the lipids, thin layer chromatography 
plates were pre-run with chloroform/methanol (2:1 (v/v)) and dried for at least 30 min at 80 °C. The 
chromatography chamber was equilibrated with a solvent containing dichloromethane/acetic 
acid/methanol (100:5:2 (v/v)) for 1 h at RT. 50 µL of each sample and ceramide standards (1 nM, 
2.5 nM and 5 nM; mostly composed of N-stearoylsphingosine) were diluted in chloroform/methanol 
(9:1 (v/v)), and applied onto the plate. The plate was run in the chromatography chamber with 
dichloromethane/acetic acid/methanol until the migration front had arrived at 1 cm below the upper 
end of the plate. After chromatography, the plate was dried for 10 min at 180 °C. For charring of the 
resolved lipids, the plate was submerged into a bath of 10 % (v/v) copper sulphate and 8 % (v/v) 
ortho-phosphoric acid for 15 sec at RT, dried for 2 min at 100 °C and charred by heating to 180 °C 
until lipid bands became visible. The plate was scanned and analyzed using the Molecular Dynamic 
Personal Densitometer SI and the program ImageQuant 5.2. Different ceramide species containing 
ester-linked fatty acids with 16 and 18 carbon atoms were identified by comparison with the applied 
co-migrating ceramide standards. 
4.2.8 A-SMase activity assay 
The measurement of A-SMase activity in cell lysates was described previously (Edelmann et al. 
2011). Briefly, cells were detached with accutase, cooled down with cold medium and pre-incubated 
with zVAD-fmk and various stimuli indicated in the figure legends. After pre-incubation, the cell 
suspension was incubated with 100 ng/mL TNF for 1 h and internalization was induced by switching 
the temperature from 4 °C to 37 °C for a specific time kinetic. Internalization was stopped by washing 
cells twice with ice-cold PBS. Cell pellets were stored at -80 °C. 
Prepared samples were kindly analyzed for A-SMase activity by Supandi Winoto-Morbach (Christian-
Albrechts-University, Kiel, Germany). Concisely, cell pellets were washed twice with PBS and diluted 
in A-SMase assay buffer (250 mM sodium acetate, 1 mM EDTA, 0.1 % (v/v) Triton X-100, pH 5.0) 
and lysed by sonication for 4 x 1 sec on ice. The A-SMase activity was measured using N-methyl-
[14C]-sphingomyelin (0.5 µCi/mL, 0.55 Ci/mmol) as a radioactively labeled substrate. A range from 
0.5-2 µg of protein was incubated with the substrate for 2 h at 37 °C in a total volume of 50 µL. 
Radioactivity of enzymatically liberated radioactive phosphocholine was extracted with  
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750 µL chloroform/methanol (2:1 (v/v)) and 250 µL of autoclaved Milli-Q water. The radioactive 
aqueous phase was mixed with liquid scintillator (Aquasafe 300 plus) and measured in a β-counter. 
4.2.9 Preparation of cellular extracts 
After removal of the supernatant, adherent cells were washed once with pre-warmed PBS and 
harvested after detaching with trypsin/EDTA in PBS or accutase. Detached cells were pelleted by 
centrifugation at 400 x g for 5 min at RT and washed twice with cold PBS. Suspension cells were 
immediately pelleted by centrifugation as described above and washed twice with cold PBS. Cells 
were lysed for 10 min on ice in cold TNE lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1 % (v/v) 
NP-40, 3 mM EDTA) supplemented with 10 µg/mL of a protease inhibitor cocktail. Lysates were 
centrifuged at 20,000 x g at 4 °C and the supernatants were stored at -20 or -80 °C until further 
analysis. 
4.2.10 Protein quantification 
Protein concentrations were measured using either the sensitive BCA-Protein Assay Kit according to 
the manufacturer’s instructions or alternatively, a ready to use Coomassie Blue G-250 based reagent. 
Here, 1 mL of staining solution was mixed with 1-5 µL cellular extracts and incubated for 5 min in a 
polystyrene cuvette (10 x 4 x 45 mm). Absorbance was measured at 595 nm with a spectrometer. BSA 
was used as a standard (working range = 0.2 to 1.0 mg/mL). 
4.2.11 SDS-PAGE and Western blot analysis 
For one-dimensional separation of proteins by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE), gels were either purchased ready-to-use from Bio-Rad or poured 
according to standard protocols (Laemmli, 1970). Samples were diluted in 5 X sample buffer  
(10 % (v/v) β-mercaptoethanol, 125 mM Tris-HCl pH 6.8, 4 % (w/v) SDS, 20 % (v/v) glycerol, 
0.02 % (w/v) bromophenol blue) to a final volume of 25 µL and denatured by boiling for 3 min at 
100 °C. After loading the samples onto the gel, a constant electric current of 25 mA per gel was 
applied for 1 h at RT. The separated proteins were then transferred by wet blotting at 4 °C according to 
standard procedures (Harlow and Lane, 1988). Afterwards, the blotted membrane was placed in 
blocking buffer (5 % (w/v) milk-powder in PBS and 0.1 % (v/v) Tween 20) for 1 h at RT under 
constant gentle agitation. Proteins were detected by incubation with specific primary antibody (see 
table 2) over night at 4 °C. Excess of primary antibody was removed washing with PBST (PBS with 
0.1 % (v/v) Tween 20). Subsequently, POD or HRP-conjugated secondary antibodies (1:10,000 
diluted in blocking buffer) were added for 60 min at RT under constant rocking. Followed by further 
washing steps with PBST, the membrane was developed using LumiGLO™ Western blotting reagent. 
The reactive proteins were detected by exposure on an X-ray film for 10 seconds to 60 min. For 
densitometric analysis, the X-ray film was scanned and analyzed using the program ImageJ (Wayne 
Rasband, National Institutes of Health, Bethesda, MD, USA). 
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4.2.12 Two-dimensional PAGE (2D-PAGE) 
To increase the resolution of a one-dimensional PAGE, proteins were alternatively separated in two 
dimensions by isoelectric focusing (IEF) prior to conventional SDS-PAGE. After harvesting, cells 
were lysed as described before (4.2.9). If needed, protein precipitation was done by addition of  
10 % (v/v) trichloroacetic acid (TCA) to the protein lysate and incubation for 30 min on ice, followed 
by centrifugation at 10,000 x g at 4 °C for 20 min. After removal of the supernatant, the pellet was 
washed with ice-cold acetone and the sample was again centrifuged. The supernatant was removed, 
the pellet was air dried and re-suspended in 2D-lysis buffer (7 M urea, 2 M thiourea, 30 mM Tris  
pH 8.5, 4 % (w/v) CHAPS). 
The two-dimensional gel electrophoresis was principally performed as described (O’Farrel, 1975) with 
technical assistance by Melanie Nebendahl and Benjamin Schönbeck (Christian-Albrechts-University, 
Kiel, Germany). Briefly, the supernatant containing the solubilized proteins was recovered after 
centrifugation for 20 min at 20,000 x g at 4 °C. Proteins (250 µg) were centrifuged at 180,000 x g, 
4 °C for 20 min, diluted in 2D-lysis buffer, and applied by cup-loading onto 24 cm non-linear pH 3-11 
IPG gel strips (re-hydrated in DeStreak Solution for 10 h at RT) for approximately 65 kVh. The 
second dimension, separating the proteins by their mass, was performed on 26 x 20 cm large  
12.5 % (w/v) SDS gels after reduction and alkylation using the Ettan DALTsix large vertical 
electrophoresis system. The gel was mounted on a non-backed gel frame and scanned on a Typhoon 
Trio imager. Subsequently, the gels were fixed with 40 % (v/v) ethanol and 10 % (v/v) acetic acid for 
at least 5 h and stained for proteins over night with Flamingo™ Fluorescent gel stain and scanned at 
red fluorescence. The obtained images were analyzed using Image Master 6.0 software. Protein spots 
were selected depending on the experimental setup and were picked using the Ettan spot picker unit 
equipped with a 2 mm picking head and further prepared for mass spectrometry (MS) analysis (see 
4.2.14). 
4.2.13 Two-dimensional difference gel electrophoresis (2D-DIGE) 
The 2D-DIGE method was utilized to compare two samples, labeled with fluorescent dyes, to see 
changes in protein abundance, expression and differential cleavage within one gel. This technique is 
based on the above described 2D-PAGE and was described first in 1997 (Unlü et al.). For 2D-DIGE 
analysis, either whole cell lysates or magnetically enriched receptor containing vesicles were used 
whose preparation is described in section 4.2.15.4. 
The 2D-DIGE technique was kindly performed by Melanie Nebendahl and Benjamin Schönbeck 
(Christian-Albrechts-University, Kiel, Germany) essentially as described before (Schmidt et al. 2009). 
Protein samples prepared in other buffer systems were either de-salted using Zeba™ Spin Desalting 
Columns (74 kDa MWco) or immediately diluted in 2D-lysis buffer. The supernatant was removed 
after centrifugation for 20 min at 20,000 x g at 4 °C. The same amount of protein per sample 
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(maximum 50 µg) was labeled with 400 pmol of the fluorescent dyes Cy 3 or Cy 5 in 
dimethylformamide (DMF, pH 8.5) for 30 min in the dark on ice. The reaction was stopped by 
quenching the labeling reaction with 1 µL 10 mM lysine for 10 min on ice. The differentially labeled 
samples were pooled with the same amount of unlabeled protein of each sample, centrifuged at 
180,000 x g, 4 °C for 20 min and further processed as described in 4.2.12. 
The in-gel fluorescence was scanned on a Typhoon Trio imager to detect Cy 3 and Cy 5 specific 
emission. The detection of differentially labeled protein spots was performed using in silico analyses 
tools included in the DeCyder 6.5 software. To stain whole separated proteins, the gel was stained with 
Flamingo™ Fluorescent gel stain and again mounted on a non-backed gel frame, scanned and 
analyzed using Image Master 6.0 software. Differentially labeled spots were picked using the Ettan 
spot picker unit equipped with a 2 mm picking head and further processed as described in the next 
section. 
In order to verify that the picked spots had been picked from their correct locations, all 2D-gels were 
scanned again after the picking procedure.  
4.2.14 In-gel tryptic digestion and MALDI-TOF/TOF MS analysis 
Picked gel spots were washed with ultra-pure water, 50 mM ammonium bicarbonate (ABC) in  
50 % (v/v) methanol, 70 % (v/v) acetonitrile (ACN), and dehydrated in pure ACN. The gel pieces 
were dried by evaporation of ACN in a SpeedVac centrifuge and rehydrated with 100 ng porcine 
sequencing-grade trypsin in 25 mM ABC at 37 °C over night. For peptide extraction, 20 µL of  
0.1 % (v/v) trifluoroacetic acid (TFA) in ACN was added and the samples were sonicated for 15 min. 
The supernatant was collected and the gel spots were again incubated with 20 µL of 0.1 % (v/v) TFA 
in ACN for 10 min. Both supernatants were combined and dried in a SpeedVac centrifuge. The 
samples were reconstituted in 0.8 µL MALDI matrix solution containing 3.2 mg/mL α-cyano-4-
hydroxycinnamic acid in 65 % (v/v) ACN/0.1 % (v/v) TFA and spotted onto MALDI targets (Opti-
TOF; 384 Well Insert). 
MS measurements and analysis thereof was performed by members of the Systematic Proteomics and 
Bioanalytic Unit of the Christian-Albrechts-University (Kiel, Germany), especially by Bart van den 
Berg, Tomas Koudelka and Andreas Tholey. 
Spectra were acquired on an AB SCIEX MALDI-TOF/TOF 5800 mass spectrometer in positive ion 
mode. For MS measurements, 2,000 shots were accumulated in the mass range of 800 – 4,000 m/z. 
Default calibration was performed using 4700 Proteomics Analyzer Standard Kit, while MS 
measurements were calibrated internally using trypsin, matrix and contaminant peaks (842.509, 
877.034 and 2,807.315 m/z) and smoothed using a FFT Poison-Denoise algorithm. Precursor selection 
for tandem MS/MS analysis was achieved using the 4000 Series Explorer Software (AB SCIEX) with 
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acquisition of the 20 most intense precursors (S/N > 20) beginning with the strongest first. All MS/MS 
spectra were acquired with 1 KV collision energy at ambient air (CID medium: 1.25 x 10-6 Torr) using 
3,000 laser shots per precursor. MS/MS post processing involved smoothing using the Savitsky-Golay 
algorithm with 7 points across the peak and a polynomial order of 4. For peptide identification, 
MALDI-TOF/TOF MS/MS raw files were searched using AB SCIEX GPS software (Version 3.6, 
build 332) with the following pre-filter settings: only peaks within a mass range from 60 Da to the 
precursor mass minus 35 Da and S/N ratio above 10 were used. Spectra were searched with Mascot 
against the Swissprot database (downloaded 15.02.2011) using either Homo sapiens as a taxonomy 
filter (20,254 sequences) with precursor tolerance of 30 ppm or Mus musculus as a taxonomy filter 
(16,345 sequences) and precursor tolerance of 50 ppm and the following parameters for both: MS/MS 
tolerance - 0.3 Da; two missed cleavages allowed. Oxidation (M) was set as variable modification, 
while carbamidomethylation (C) was set as fixed modification. Proteins were considered identified 
when either two peptides were identified with a confidence interval ≥ 99 % (p < 0.01) or three peptides 
≥ 95 % (p < 0.05). 
4.2.15 Protein enrichment and analysis 
4.2.15.1 Immunoprecipitation 
For immunoprecipitation, 1 mg cellular extracts from stimulated L929Ts cells over-expressing V5-A-
SMase were incubated with 2 µg anti-V5 monoclonal antibodies over night on ice. The immune 
complexes were incubated with 20 µL GammaBind G-sepharose for 1 h at 4 °C with constant shaking 
and were washed three times with TNE lysis buffer at 450 x g for 5 min at 4 °C. The 
immunoprecipitated proteins were diluted in 2 X sample buffer (see 4.2.11) and boiled for 3 min at 
100 °C and analyzed by SDS-PAGE. The gel was fixed with 40 % (v/v) ethanol and 10 % (v/v) acetic 
acid for at least 5 h and stained for proteins over night with Flamingo™ Fluorescent gel stain and 
scanned at red fluorescence on a Typhoon Trio imager for red fluorescence. The obtained image was 
analyzed using Image Master 6.0 software. Protein bands were labeled with the help of the spot 
picking device for selecting native and cleaved protein bands for further MS analysis via electrospray 
ionization (ESI; see below). 
4.2.15.2 Electrospray ionization 
The method described below was kindly performed by Tomas Koudelka (Christian-Albrechts-
University, Kiel, Germany). 
For in-gel labeling and digestion, bands corresponding to native and cleaved A-SMase were excised 
from the Flamingo™ stained SDS-PAGE gel, cut into 2 mm3 gel pieces and de-stained using  
50 mM HEPES (pH 8.0), 30 % (v/v) ACN in 50 mM HEPES with shaking. Gel pieces were dried 
down after incubation with ACN using vacuum centrifugation for 15 min. The samples were reduced 
using 10 mM DTT in HEPES for 45 min at 56 °C and the free cysteine residues alkylated using 
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55 mM iodoacetamide in HEPES for 30 min in the dark at RT. Prior to labeling, gel pieces were 
washed with 50 mM HEPES and then dehydrated by incubating samples for 15 min with ACN 
followed by 15 min of vacuum centrifugation. Free amino groups (N-terminus and lysine residues) 
were labeled by incubating samples with 30 mM formaldehyde and 15 mM sodium cyanoborohydride 
at 25 °C over night. Any excess reagent was quenched by the addition of 100 mM ABC for 30 min. 
Gel bands were further de-stained as described above but with HEPES exchanged for ABC. Samples 
were digested with either trypsin or chymotrypsin (50 ng) at 37 °C over night. Digested peptides were 
extracted using 1 % (v/v) formic acid (FA), 50 % (v/v) ACN in 1 % (v/v) FA and 100 % (v/v) ACN. 
Samples were dried in a vacuum centrifuge and re-suspended in 3 % (v/v) ACN in 0.1 % (v/v) TFA. 
To eliminate potential protein carryover samples were acquired by running the lower molecular weight 
protein bands first followed by the higher molecular weight bands. In addition, 1-2 wash runs were 
performed between measurements. 
Nano-high performance liquid chromatography (HPLC)-mass spectrometry was performed on a 
Dionex U3000 nano-LC system coupled online to an Orbitrap LTQ Velos mass spectrometer. Samples 
were desalted for 6 min (Acclaim PepMap100 C-18, 300 µm I.D. x 5 mm, 5 µm, 100 Å) at a flow rate 
of 30 µL/min using 3 % (v/v) ACN, 0.1 % (v/v) TFA. An Acclaim PepMap100 C-18 column (75 µm 
I.D. x 150 mm, 3 µm, 100 Å) was used for analytical separation at a flow rate of 300 nL/min using 
buffers A (0.05 % w/v FA) and B (80 % (v/v) ACN and 0.04 % (w/v) FA). The elution used gradient 
steps of 5-12 % B (6-7 min), 12-55 % B (7-42 min) and 55-90 % B (42-47 min) followed by an 
isocratic wash (90 % B, 47-57 min) and column re-equilibration (5 % B, 57-70 min). MS scans were 
acquired in the mass range of 300 to 2000 m/z at a resolution of 60,000. The five most intense signals 
were subjected to collision-induced dissociation (CID) and higher-energy collisional dissociation 
(HCD) fragmentation using a dynamic exclusion of 120 sec and a repeat count of 3 MS/MS. For this, 
the following parameters were applied: minimum signal intensity: 1000, isolation width: 3.0 Da, 
charge state: ≥2, HCD resolution: 7500, normalized collision energy of 35 and 40 for CID and HCD, 
respectively. 
For database searching, HCD and CID MS spectra were searched separately using various database 
search algorithms via the Proteome Discoverer software (version 1.3 and 1.4): Sequest, Mascot and 
MS Amanda against the reviewed and canonical mouse database (downloaded 13.03.2013) with 
common contaminants (http://www.thegpm.org/crap/), peptide-N-glycosidase F (P21163), 
ribonuclease (P61824), and human A-SMase (P17405) appended to the database (16,737 sequences). 
Data were searched with 7-10 ppm MS tolerance and a 0.5 Da and 0.02 Da fragment tolerances for 
CID and HCD spectra, respectively. For samples digested with trypsin, spectra were searched with 
semi-Arg-C specificity with a maximum of two-missed cleavages allowed, while samples digested 
with chymotrypsin were searched with either semi-chymotryptic specificity (three-missed cleavages 
allowed) or no-enzyme specificity. Carbamidomethylation of cysteine residues (+ 57.021 Da) and 
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dimethylation on lysine (+28.031 Da) were set as fixed modifications while oxidation (+ 15.995 Da) 
on methionine residues and dimethylation (+28.031 Da) on the N-terminus were set as dynamic 
modifications.  
4.2.15.3 Purification of TNF ligands 
For the production of TNF ligands, 2 x 106 HEK293T per transfection cells were transiently 
transfected with 10 µg TNF-ligand DNA via electroporation (see 4.2.3.2). After electroporation, cells 
from three parallel transfections were pooled into 100 mL pre-warmed antibiotic free FreeStyle® 
medium and cultivated over night in an incubator with 5 % (w/v) CO2 at 37 °C. The next day, 
50 µg/mL penicillin and 50 µg/mL streptomycin were added. After two days of cultivation, the 
supernatant was collected, sterile filtrated and supplemented with 10 µg/mL of a protease inhibitor 
cocktail. The cells were further cultivated with fresh FreeStyle® medium containing  
50 µg/mL penicillin and streptomycin each and 1 mg/mL G418 to select for transfected cells. After 
three more days of cultivation, the supernatant was collected, sterile filtrated and supplemented with 
10 µg/mL of a protease inhibitor cocktail. Both supernatants were pooled and stored at 4 °C until 
further enrichment of the soluble ligands with a Hi Trap™ Protein G HP 1 mL column. The ligands 
were purified according to the manufacturer’s protocols. The protein concentration of the purified 
ligands was measured using BCA Protein Assay and the biological activity of TNFwt-Fc or TNF60-Fc 
was always tested in cytotoxicity assays using L929Ts cells (see 4.2.1.4). 
4.2.15.4 Preparation of magnetically labeled TNF receptors and isolation of TNF receptor 
magnetic fractions 
A system based on ligand-specific immunomagnetic labeling of cell surface receptors for purification 
and characterization of TNF receptor magnetic fractions was utilized via a free-flow magnetic 
chamber (HOKImag 1, invented by Tchikov and Schütze, 2008; now manufactured by HOOCK 
GmbH, Kiel). The method was recently described (Tchikov et al. 2014). This immunomagnetic 
separation was continuously advanced throughout this doctoral thesis and therefore three different 
homogenization procedures were used (A-C, see below). Preparations were either analyzed by 
Western blot or by 2D-DIGE analysis with technical assistance from Vladimir Tchikov and Jürgen 
Fritsch (Christian-Albrechts-University, Kiel, Germany; contributions are indicated in the figure 
legends). 
For the cultivation and preparation of cells, human U-937 and murine L929Ts cells were grown to 
70 % confluence. For detachment, adherent L929Ts cells were incubated with PBS/3.5 mM EDTA for 
10 min at 37 °C. Subsequently, cells were collected with a cell scraper, pooled, centrifuged at 400 x g 
for 5 min at 4 °C and 1 x 108 cells per time-point were diluted in 1 mL ice-cold PBS. U-937 cells  
(1 x 109) were washed once with cold PBS at 100 x g for 10 min at 4 °C and diluted in 1 mL PBS. The 
following preparation was performed permanently at 4 °C unless otherwise stated. U-937 cells were 
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pre-treated with 50 µM zVAD-fmk for 30 min. TNF receptors on the surface of L929Ts or U-937 cells 
were labeled either with 100 ng/mL TNFwt-Fc (L929Ts cells) or TNF60-Fc (U-937 cells) by 
incubation for 20 min. Thereafter, 25 µL of protein G magnetic beads was mixed with 1 mL of the cell 
suspension for another 1 h (for preparation of whole cell lysates for 2D-DIGE analysis this step was 
excluded). Unbound magnetic beads were washed at 350 x g with PBS. Synchronized internalization 
of the TNF receptors was induced by adding 5 mL pre-warmed media without supplements, shifting 
the incubation temperature from 4 °C to 37 °C followed by incubation at 37 °C for indicated time-
points. The reaction was stopped by adding 30 mL ice-cold PBS. Cells were pelleted by centrifugation 
at 250 x g for 4 min and washed once with homogenization buffer (HB; 15 mM HEPES, 250 mM 
sucrose and 0.5 mM MgCl2 at pH 7.4). For homogenization, three different methods were used:  
(A) ultra-sonication, (B) mechanical homogenization using a douncer device and subsequent removal 
of mitochondria from the samples by iodixanol density barrier centrifugation (done with the help of 
Jürgen Fritsch) or (C) mechanical homogenization with glass beads (done by Vladimir Tchikov). 
A) The cell pellets were re-suspended in 1 mL HB supplemented with 10 µg/mL protease 
inhibitor cocktail and 12.5 units benzonase, lysed at 4 °C using a Branson W-450 sonication 
device equipped with a cup-resonator. The cells were sonicated for 15 sec (duty cycle: 
constant, output control: 2.5) and centrifuged for 4 min at 600 x g. The supernatant was 
collected and the pellet was again sonicated as above and pooled with the collected 
supernatant. The homogenate was centrifuged at 600 x g for 5 min. Subsequently, 
approximately 850 µL of the supernatant were either loaded to the HOKImag 1 device or 
further prepared without magnetic particles as whole cell lysates for 2D-DIGE analysis. 
B) Alternatively, homogenization was performed mechanically using douncer devices to induce 
shear forces. The cell pellets were re-suspended in 1 mL HB supplemented with  
10 µg/mL protease inhibitor cocktail and transferred to two 15 mL dounce tissue grinders 
performing mechanical homogenization with 5 strokes each. The homogenate was centrifuged 
at 1,500 x g for 5 min, the supernatant was collected and the remaining pellet was again 
homogenized. The supernatant and homogenate were pooled and centrifuged. After 
centrifugation, the resulting post-nuclear supernatant was carefully overlaid on top of  
750 µL of a 16 % (v/v) iodixanol solution on the bottom of a 4 mL centrifuge tube. 
Subsequently, samples were centrifuged at 150,000 x g for 1 h in a swing-out rotor (SW60Ti) 
without brake. The fraction with light organelles (milky ring) was collected for magnetic 
separation as described below and the fraction at the bottom of the tube (referred to as 
mitochondrial fraction) was collected for further Western blot analysis. 
C) Homogenization using a homogenization device with glass beads was described previously 
(Tchikov and Schütze, 2008). The samples were incubated with glass beads on a vortex device 
for 5 min before the homogenate was centrifuged and the remaining pellet again 
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homogenized. After repeating the homogenization procedure three times, supernatants were 
collected, pooled and subjected to magnetic separation. 
The post-nuclear supernatant obtained by either of the above methods was submitted to magnetic 
separation of TNF-R1 magnetic fractions in the magnetic separation device HOKImag 1. Hereby, the 
magnetically labeled material was soaked in free-flow plastic tubes of 5 mm in diameter and  
0.1 mm thin walls which were placed in the magnetic gap serving as column connected to a peristaltic 
pump. After incubation of the lysate in the magnetic field for 1-2 h, the column was washed with 
approximately 30 mL HB. This flow-through suspension was collected and is referred to as non-
magnetic fraction throughout this doctoral thesis. The magnetic TNF-R1-containing membrane 
fractions were eluted using 0.5 mL HB and a plunger of a 1 mL syringe and sedimented at 20,000 x g 
for at least 30 min. The subsequent analysis of the membrane fractions was either conducted by 
conventional Western blot or 2D-DIGE analysis following MALDI-TOF/TOF analysis. 
4.2.16 Microscopy 
4.2.16.1 Documentation of cell morphology 
For visualization of cell morphology, images from unfixed cells were taken using an Axiovert 10 
microscope and a DS-5M-L1 digital sight camera system. 
4.2.16.2 Immunofluorescence analysis of suspension cells 
For immunofluorescence (IF) analysis of TNF receptor localization in human cells, U-937 cells were 
attached onto coverslips and surface receptors were stained with a ligand/Protein G-Alexa Fluor® 
488-complex. For this, HCl-pre-treated glass coverslips were washed twice with PBS and coated with 
a 1:5 (v/v) dilution of poly-L-lysine/PBS for 30 min at 37 °C. The coverslips were again washed twice 
with PBS and 1 x 106 U-937 cells were seeded onto the coated coverslips to allow adherent growth for 
30 min at 37 °C. The coverslips with attached cells were pre-incubated with 50 µM zVAD-fmk for 
30 min at 37 °C. After pre-incubation, coverslips were cooled down on ice and washed once with ice-
cold PBS. Meanwhile, 400 ng TNF60-Fc was incubated with 0.5 µL/slide Protein G-Alexa Fluor® 
488 in the dark at RT for 1 h. For surface labeling of TNF-R1, 100 µl of the ligand/fluorochrome 
mixture was incubated with one coverslip in a humidified dark chamber at 4 °C for 1 h. Then, the 
coverslips were washed twice with cold PBS. To permit receptor internalization, the coverslips were 
incubated at 37 °C for indicated times in 2 mg/mL TRITC-Dextran diluted in RPMI 1640 media 
without supplements. After stopping internalization with cold PBS, the cells were fixed with 
4 % (w/v) PFA for 40 min at 4 °C. After two washes with PBS, coverslips were mounted in ProLong 
Gold Antifade plus DAPI mounting medium onto slides. Slides were dried and kept dark at RT until 
analysis by confocal laser scanning microscopy. 
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4.2.16.3 Immunofluorescence analysis of adherent cells 
For IF analysis of TNF-R1 localization in murine cells, 1 x 105 L929Ts cells were attached to 
coverslips over night. Coverslips with attached cells were placed on ice to cool down and washed once 
with ice-cold PBS. In parallel, 400 ng TNFwt-Fc ligand was incubated with 0.5 µL Protein G-Alexa 
Fluor® 488 in the dark. Further processing was performed as described in 4.2.16.2. 
For analysis of the co-localization of TNF-R1 with other proteins of interest, L929Ts cells were 
seeded onto HCl pre-treated glass coverslips to allow adherent growth over night. The cells were 
incubated with 100 ng/mL biotinylated TNF in combination with 240 ng/mL streptavidin Alexa 
Fluor® 488 (Kit from R&D Systems) for 1 h on ice. To allow receptor internalization, coverslips were 
transferred into pre-warmed media and incubation was carried out at 37 °C for defined times indicated 
in the figure legends. The reaction was stopped by replacing medium with ice-cold PBS and the 
coverslips were washed twice with ice-cold PBS. For fixation, coverslips were incubated with freshly 
prepared 4 % (w/v) PFA in PBS for 30 min on ice. Fixed cells were washed with PBS, permeabilized 
20 min with 0.1 % (w/v) saponin/ 0.2 % (w/v) BSA in PBS and washed again with PBS. The specific 
primary antibodies (see table 2) were diluted in PBS and incubated with the coverslips for 1 h in a 
humidified chamber at 4 °C. Coverslips were then washed two times with PBS and incubated with 
Alexa Fluor® 555-conjugated specific secondary antibodies (1:200 in PBS) for 1 h at 4 °C in the dark. 
After two washes with PBS, the coverslips were mounted in mounting medium as described before 
(4.2.16.2), dried and kept dark at RT until analysis by confocal laser scanning microscopy. 
4.2.17 Transformation of E. coli and plasmid purification 
For the transformation of a plasmid into bacteria, 100 µL chemically competent Escherichia coli XL1 
blue (prepared in the laboratory of Dieter Adam, Christian-Albrechts-University, Kiel, Germany) and 
10 ng of plasmid DNA were incubated on ice for 30 min. After a temperature shift to 42 °C for 45 s, 
cells were transferred into 1 mL pre-warmed SOC medium (2 % (w/v) Bacto-tryptone, 0.5 % (w/v) 
yeast extract, 10 mM sodium chloride, 0.25 mM potassium chloride pH 7.0) and incubated at 37 °C 
for 45 min with continuous shaking at 250 rpm. Afterwards, cells were plated on lysogeny broth (LB) 
agar plates (1 % (w/v) Bacto-tryptone, 0.5 % (w/v) Bacto-agar, 1.5 % (w/v) yeast extract,  
10 mM sodium chloride) with 1 mg/mL ampicillin or kanamycin. Cells containing the 
ampicillin/kanamycin resistance-encoding plasmid were able to grow over night at 37 °C. Colonies 
visible on the plates were inoculated in 5 mL LB medium (1 % (w/v) Bacto-tryptone, 0.5 % (w/v) 
yeast extract, 170 mM sodium chloride pH 7.2) with 1 mg/mL ampicillin/kanamycin at 37 °C and 
250 rpm for approximately 4 h. This pre-culture was transferred to 200 mL fresh LB medium 
containing 1 mg/mL antibiotic over night at 37 °C and 250 rpm. Plasmid purification was conducted 
using the Qiagen Plasmid Maxi Kit according to manufacturer’s instructions. Quantification of 
plasmid DNA was performed using a NanoDrop® spectrometer. 
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4.2.18 Statistical analysis 
When experiments were performed at least with three technical replicas, results are shown as means  
+/- standard deviation. For determination of statistical significance (at least three independent 
experiments), Student’s t-test was employed when comparing controls versus one treatment regime 
assuming differences in standard deviation (statistical analysis program: Excel 2010). A P value of ≤ 
0.05 was considered statistically significant. 
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5. Results 
New model cell lines to study regulated necrosis: U-937 and HT-29 cells 
The most extensively studied model cell line for regulated necrosis initiated by the ligands TNF or 
TRAIL is the murine fibroblast cell line L929 (Strelow et al. 2000; Thon et al. 2005, 2006; Sosna and 
Voigt et al. 2013; Sosna, Voigt et al. 2014). In addition, cell systems such as murine NIH3T3 and 
human Jurkat T cells have been previously characterized regarding their ability to undergo regulated 
necrosis (Thon et al. 2005, 2006; Sosna and Voigt et al. 2013; Sosna, Voigt et al. 2014). To extend the 
repertoire of characterized human cell lines undergoing regulated necrosis, two further cell lines, HT-
29 and U-937 were studied with regard to their ability to undergo necroptosis elicited by TNF or 
TRAIL. Subsequently, it was intended to use them as model systems in studies to identify proteases 
and protease substrates which protect from or enhance TNF- and TRAIL-induced regulated necrosis. 
In a first set of experiments, U-937 cells were analyzed for the presence of the corresponding cell 
surface death receptors TRAIL-R1, and TRAIL-R2. A corresponding analysis for TNF-R1 was not 
performed, since almost every cell type in the human body, with the exception of red blood cells, is 
known to express TNF-R1 (Aggarwal and Natarajan, 1996). As shown in Figure 6A, U-937 cells 
highly express TRAIL-R2. TRAIL-R1 was only marginally expressed, similar to results obtained in 
HT-29 cells which also express high levels of TRAIL-R2 and low levels of TRAIL-R1 (Voigt, Master 
Thesis, 2010). Furthermore, the ability of TNF as well as TRAIL to induce regulated necrosis was 
determined in HT-29 and U-937 cells. Cell death was measured by flow cytometric analysis of 
propidium iodide (PI) fluorescence, an indicator for loss of membrane integrity. Since treatment with 
both cytokines, TNF and TRAIL, activates caspase-dependent apoptosis in most cell systems, the 
inhibition of caspases is required when studying necroptosis. Therefore, TNF or TRAIL was always 
used in combination with the broad spectrum caspase inhibitor zVAD-fmk to suppress any caspase 
activity. If required, the protein biosynthesis inhibitor cycloheximide (CHX) was added to additionally 
sensitize the cells towards cell death (Holler et al. 2000). As shown in Figure 6B, both U-937 and HT-
29 cells showed a clear sensitivity to TNF/zVAD/CHX- or TRAIL/zVAD/CHX-induced cell death. 
The pharmacological inhibition of necroptosis by Nec-1 (Degterev et al. 2008) protected both cell 
lines from TNF- and TRAIL-induced cell death, demonstrating that U-937 and HT-29 cells indeed 
undergo necroptosis when treated with TNF/zVAD/CHX or TRAIL/zVAD/CHX. Morphological 
analysis revealed that both cell lines displayed an exclusively necrotic cellular morphology when 
treated with TNF/zVAD/CHX or TRAIL/zVAD/CHX, in contrast to the apoptotic membrane blebbing 
seen in controls for apoptosis (TNF/CHX or TRAIL/CHX treatment, Figure 6C). 
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Figure 6: Treatment with TNF/zVAD/CHX or TRAIL/zVAD/CHX elicits necroptosis in U-937 and HT-29 cells. (A) 
Flow cytometric analysis of cell surface expression of TRAIL-R1 and TRAIL-R2. Blue lines: specific monoclonal antibodies 
for the respective receptors, red lines: isotype matched control antibodies. Representative results of one out of two 
experiments performed are shown. 10,000 cells were analyzed for each measurement. (B) Cells were treated with 100 ng/mL 
TNF or TRAIL in combination with 20 µM (HT-29) or 50 µM (U-937) zVAD-fmk and non-toxic concentrations of CHX (U-
937: 0.1 µg/mL; HT-29: 5µg/mL). After 24 h, loss of membrane integrity was measured as a marker for cell death by flow 
cytometric analysis of PI-negative and -positive cells. The error bars represent the standard deviation (SD) of two 
independent experiments with three measurements each. (C) Micrographs show the necrotic cellular morphology (black 
arrows). U-937 and HT-29 cells were stimulated for 8 h with TNF/zVAD/CHX or TRAIL/zVAD/CHX to induce necroptosis 
as in (A) or as a control without zVAD-fmk to induce apoptosis (white arrows). The micrograph of U-937 cells stimulated 
with TRAIL/CHX was taken after 5 h stimulation because of the high cell death rate. Scale bar: 100 µm. 
Subsequently, further hallmarks of necroptosis were investigated in U-937 cells. During caspase-
dependent apoptosis, the mature 116-kDa PARP-1 protein is inactivated by caspase-3-mediated 
cleavage, resulting in an 89-kDa PARP-1 cleavage product (Lazebnik et al. 1994). To provide 
additional evidence that TNF/zVAD/CHX elicits necroptosis rather than caspase-dependent apoptosis, 
U-937 cells were left untreated or stimulated with TNF/zVAD to induce necroptosis. As a positive 
control to induce apoptosis, cells were treated with TNF alone. As shown in Figure 7A, the 89-kDa 
cleavage product was not detected in U-937 cells undergoing necroptosis in response to TNF/zVAD, 
only in TNF-treated, apoptotic cells. To further verify that caspases were not activated during 
TNF/zVAD treatment, activation of caspase-3 and -8 was determined directly by measuring the 
cleavage of the fluorogenic substrates zDEVD-afc (caspase-3 substrate) or zIETD-afc (caspase-8 
substrate). As can be seen in Figure 7B, TNF/zVAD did not activate caspase-3 and -8, whereas the 
TNF-treated apoptotic control did (black triangles, Figure 7B), demonstrating that PCD induced by 
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TNF/zVAD was caspase-independent. For HT-29 cells, identical results had been obtained during 
independent studies in the laboratory (Sosna, Voigt et al. 2014; Voigt et al. 2014). 
Figure 7: Characterization of necroptosis elicited by TNF in U-937 cells. (A) Cellular extracts were prepared after U-937 
cells were treated with 100 ng/mL TNF and 50 µM zVAD-fmk or with TNF alone (to induce apoptosis) for the indicated 
time-points. Western blots were generated from whole cell lysates incubated with an antibody detecting the full length 
(116 kDa) and the apoptotic cleavage fragment of PARP-1 (89 kDa). Arrows indicate the position of the full-length protein 
and the 89 kDa cleavage product (present only in apoptotic lysates treated with TNF alone). (B) U-937 cells were left 
untreated or were stimulated for 4 h as above. Subsequently, activation of caspases-3 and -8 was determined in 1 µg cellular 
extracts by measuring cleavage of the fluorogenic substrates (zDEVD-afc and zIETD-afc) over 120 min. 
Since in previous studies ceramide had been identified as an important mediator of regulated necrosis 
(Thon et al. 2005), the impact of ceramide on TNF- and TRAIL-induced necroptosis was also 
investigated in U-937 and HT-29 cells. As shown in Figure 8, TNF/zVAD/CHX as well as 
TRAIL/zVAD/CHX treatment resulted in an accumulation of intracellular ceramide in both cell lines. 
Figure 8: Intracellular ceramide levels of U-937 and HT-29 cells increase in response to treatment with 
TNF/zVAD/CHX or TRAIL/zVAD/CHX. Cells were left untreated or stimulated with 100 ng/mL TRAIL or TNF with 
20 µM (HT-29) or 50 µM (U-937) zVAD-fmk and 0.1 µg/mL (U-937) or 5 µg/mL (HT-29) CHX for 8 h (U-937) or 24 h 
(HT-29) before intracellular ceramide levels were determined in duplicate by means of thin layer chromatography with 
subsequent charring. Original data from the chromatography plate (C16 and C18 ceramide species) are shown below the 
diagram. Trypan blue staining was in parallel performed to measure loss of membrane integrity and is shown above the bar 
graphs. Data show representative results of two independent experiments. 
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Conclusion: U-937 and HT-29 cells can undergo necroptosis 
The above described observations implicate that human HT-29 cells as well as U-937 cells can 
undergo necroptosis elicited by either TNF or TRAIL. U-937 cells showed typical hallmarks of 
necroptosis, similar to previous studies in HT-29 cells (Sosna, Voigt et al. 2014; Voigt et al. 2014). 
Furthermore, U-937 and HT-29 cells showed an increase in ceramide levels when treated with 
TNF/zVAD/CHX and TRAIL/zVAD/CHX, suggesting that ceramide may act as a mediator of 
necroptosis also in these human tumor-derived cell lines. Because of the results obtained here, U-937 
and HT-29 cells were used for further experiments throughout this thesis. 
5.1 TNF and PARP-1 elicit distinct routes to regulated necrosis 
TNF and MNNG can kill cells by regulated necrosis 
Murine fibrosarcoma L929 cells die exclusively by regulated necrosis when treated with TNF 
(Vercammen et al. 1998a; Strelow et al. 2000; Thon et al. 2005). In response to DNA-alkylating 
agents such as MNNG, it was reported that L929 cells also die by necrosis rather than by apoptosis 
(Yu et al. 2002; Xu et al. 2006). To validate that TNF and MNNG do not elicit caspase-dependent 
apoptosis in L929 cells, caspase-3 activity measurements were conducted as an indicator for caspase-
dependent apoptosis through both the extrinsic and the intrinsic pathway. As shown in Figure 9A, 
three L929 sublines (TRAIL-sensitive L929Ts cells, L929 cells obtained from ATCC (L929ATCC) 
and TNF-hypersensitive L929sA cells) did not display any caspase-3 activity after treatment with TNF 
or MNNG. Accordingly, unlike TNF/CHX-treated positive controls, none of the three L929 sublines 
showed membrane blebbing after TNF or MNNG stimulation, which is a morphological hallmark of 
apoptosis (Figure 9B). Therefore, both TNF and MNNG induce cell death through necrotic pathways 
rather than through apoptosis in the three L929 cell lines utilized for the study presented here. 
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Figure 9: TNF and MNNG elicit regulated necrosis in L929 cells. (A) L929Ts, L929ATCC and L929sA cells were left 
untreated or were treated with 100 ng/mL TNF for 5 h, or were treated with 0.5 mM MNNG for 15 min and were then 
incubated with fresh medium without MNNG for another 5 h. Cells treated with 100 ng/mL TNF and 2 µg/mL CHX served 
as a positive control for induction of apoptosis. Subsequently, activation of caspase-3 was determined in 1 µg of cellular 
extract by measuring cleavage of the fluorogenic substrate zDEVD-afc over 120 min. (B) Micrographs show the morphology 
of the cells treated as above for the indicated time-points. White arrows mark cells that show apoptotic membrane blebbing 
after treatment with TNF/CHX. Black arrows indicate necrotic-like morphology of cells in response to TNF or MNNG. Scale 
bar: 100 µm. 
MNNG but not TNF causes rapid activation of the PARP pathway 
The activation but not the cleavage of PARP-1 is required for necroptosis (Sosna, Voigt et al. 2014). 
Interestingly, observations that had been obtained during independent studies in the laboratory show 
that TNF and MNNG activate PARP-1 with distinct kinetics (Sosna, Voigt et al. 2014). 
Hyperactivation of PARP-1 results in a rapid depletion of intracellular NAD+ levels (Yu et al. 2002) 
and, as a direct consequence, also in the depletion of intracellular ATP levels (Vandenabeele et al. 
2010). Therefore, ATP levels were compared to the progression of cell death after treatment with TNF 
or MNNG. In the three L929 sublines, MNNG treatment caused a rapid depletion of intracellular ATP 
levels within 1 h. Furthermore, the rapid loss of ATP clearly occurred earlier than the loss of 
membrane integrity (which was measured as a marker for cell death), proving that MNNG treatment 
induces a rapid activation of PARP-1 (Figure 10A). This was in contrast to TNF-induced necroptosis, 
where ATP levels decreased at later time-points and concurrently with cell death (Figure 10A), 
suggesting that the depletion of ATP levels is rather an accompanying factor of TNF-induced cell 
death than an initial inducer of necroptosis. To further corroborate the distinct activation of PARP-1 
after MNNG or TNF treatment, the repertoire of cell lines was extended to Jurkat and HT-29 cells, 
yielding essentially the same results as in the three L929 sublines (Figure 10B). 
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Figure 10: MNNG but not TNF(/zVAD/CHX) induces rapid ATP depletion. (A) L929Ts, L929ATCC and L929sA cells 
were stimulated with 100 ng/mL TNF, or with 0.5 mM MNNG for 15 min and subsequent incubation with fresh medium 
without MNNG for the indicated time-points. Subsequently, their intracellular ATP content and loss of membrane integrity 
(as a marker of cell death) were analyzed. (B) HT-29 and Jurkat cells were stimulated with MNNG as above, or with 
100 ng/mL TNF with addition of 20 µM (HT-29) or 50 µM (Jurkat) zVAD-fmk and 2 µg/mL (Jurkat) or 5 µg/mL (HT-29) 
CHX. Subsequently, intracellular ATP levels and loss of membrane integrity were measured at the indicated time-points. For 
better comparison and for clarity of presentation, the percentage of intact, large PI-negative cells that still retain their 
membrane integrity is shown. Representative data from one out of two experiments are shown and error bars indicate the SD 
from three measurements. 
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In summary, the late depletion of intracellular ATP levels during TNF-induced necroptosis implicates 
that individual components of the PARP pathway are activated as a secondary consequence during 
necroptosis rather being the cause of necroptotic cellular disintegration. This is in contrast to the rapid 
depletion of ATP following PARP-1 activation by DNA-alkylating agents such as MNNG, suggesting 
that TNF-induced necroptosis and the hyperactivation of PARP-1 represent two distinct routes to 
regulated necrosis. 
Inhibition of the PARP pathway does not protect from TNF-induced necroptosis 
To unravel the role of the PARP pathway in TNF-induced necroptosis, the impact of pharmacological 
inhibitors of PARP-1 was analyzed in L929Ts cells, murine NIH3T3 fibroblasts, and in human Jurkat 
and HT-29 cells. The PARP-1 inhibitors 3-AB, PJ-34 and olaparib impaired MNNG-induced regulated 
necrosis, but not TNF-induced necroptosis in any of the four cell lines analyzed (Figure 11), 
suggesting that inhibition of PARP-1 activation does not protect from TNF-induced necroptosis. 
However, PJ-34, as the only exception, reduced TNF-induced necroptosis in L929Ts cells. This effect 
was not seen with any other PARP-1 inhibitor used in this study. Moreover, two independent studies 
reported unspecific activities of PJ-34 (Madison et al. 2011; Antolin et al. 2012), indicating that the 
observed effect in L929Ts cells is most likely unspecific. 
In the laboratory, additional results were obtained substantiating that the inhibition of the PARP 
pathway does not protect from TNF-induced necroptosis. For example, PARP-1 down-regulation by 
RNA interference in L929Ts and Jurkat cells resulted in reduced MNNG-induced regulated necrosis 
whereas TNF-induced necroptosis was not affected. Moreover, PARP-1-deficient MEFs displayed a 
clear protection from MNNG-, but not TNF-induced regulated necrosis (Sosna, Voigt et al. 2014). 
Figure 11: PARP-1 inhibitors affect MNNG-induced regulated necrosis but not TNF-induced necroptosis.
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Figure 11: continued. Necroptosis was induced in L929Ts, NIH3T3, Jurkat and HT-29 cells in the absence or presence of 
the PARP1-inhibitors 3-AB (2.5 mM), olaparib (L929: 1 µM; NIH3T3, Jurkat: 50 nM; HT-29: 2 µM) or PJ-34 (20 µM) by 
treatment with 100 ng/ml TNF for 24 h (L929Ts, HT-29), 16 h (NIH3T3) or 20 h (Jurkat) with addition of 20 µM (NIH3T3, 
HT-29) or 50 µM (Jurkat) zVAD-fmk and 2 µg/ml (Jurkat) or 5 µg/ml (HT-29) CHX. In parallel, cells were treated with 
1 mM MNNG for 15 min and further incubated for 16 h with fresh medium with or without addition of 3-AB, olaparib or  
PJ-34. Subsequently, loss of membrane integrity was analyzed by flow cytometry. Representative data from one out of two 
experiments are shown. The error bars represent the SD of three parallel measurements. 
The hyperactivation of PARP-1, the resulting depletion of intracellular NAD+ and ATP pools, 
mitochondrial dysfunction and AIF translocation also involves the activation of JNK (Vandenabeele et 
al. 2010). To further elucidate the involvement of JNK in necroptosis, TNF-induced necroptosis was 
analyzed after pharmacological inhibition of JNK or in a direct genetic approach using primary lung 
fibroblasts from JNK1- or JNK2-deficient and immortalized MEFs from JNK1/JNK2 double-deficient 
mice. The inhibition of JNK with the specific JNK inhibitor III did not protect L929Ts cells from 
TNF-induced necroptosis, even at concentrations at which the JNK inhibitor III itself induced 
cytotoxicity (Figure 12A). Similar to the pharmacological inhibition, in the direct genetic approach, 
neither primary lung fibroblasts from JNK1- or JNK2-deficient nor MEFs from JNK1/JNK2 double-
deficient mice were protected from TNF-induced necroptosis (Figure 12B). The obtained results 
suggest that JNK do not participate in TNF-induced necroptosis, which is in contrast to their reported 
role in the PARP pathway (Xu et al. 2006). 
Results 
62 
 
Figure 12: JNK do not participate in TNF-induced necroptosis. (A) L929Ts were left untreated or were treated with 
100 ng/mL TNF for 16 h in the presence of increasing concentrations of JNK inhibitor III. Loss of membrane integrity was 
analyzed by flow cytometry in triplicates. (B) Left panel: Primary lung fibroblasts (LF) from wild-type (WT), JNK1- 
(JNK1 -/-) and JNK2-deficient (JNK2 -/-) mice or immortalized MEFs from JNK1/JNK2 double-deficient (JNK1/2 -/-) mice 
were left untreated or were treated with 100 ng/mL TNF and 20 µM zVAD-fmk in the presence or absence of 2 µg/mL CHX 
for 18 h. Loss of membrane integrity was analyzed by flow cytometry. The error bars represent the SD of three parallel 
measurements. Right panel: Control Western blots were performed to verify presence or absence of endogenous JNK1 
and/or JNK2. Actin served as a loading control. 
Cathepsin and calpain proteases are further components of the PARP pathway (Artus et al. 2010). 
During TNF-induced necroptosis, caspase inhibitors, like zVAD-fmk, but neither individual nor 
combined application of inhibitors for calpain or cathepsin proteases affect the death response 
(Vercammen et al. 1998a, Thon et al. 2005, 2006). This is in line with results obtained in the study 
presented here analyzing proteolytic events during necroptosis, because treatment of U-937 cells with 
inhibitors of the cysteine proteases cathepsin L (zFF-fmk), cathepsin B/L (zFA-fmk) as well as the 
broad spectrum calpain/cysteine protease inhibitor E-64 did not protect from TNF-induced necroptosis 
(see 5.2.1; Figure 15A). Furthermore, wild-type and cathepsin D-deficient MEFs showed no 
differences in the necroptotic response to TNF/zVAD/CHX (Figure 13). Cathepsin D-deficient MEFs 
were not protected from MNNG-induced regulated necrosis, identical to their wild-type counterparts 
or to cathepsin D-deficient MEFs ectopically re-expressing cathepsin D (Figure 13), suggesting that 
cathepsin D plays no role in either TNF-induced necroptosis or the PARP pathway. 
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Figure 13: Cathepsin D plays no role in either TNF-induced necroptosis or the PARP pathway. Wild-type (WT), 
cathepsin D-deficient (CD -/-), and CD -/- MEFs stably retransfected with the pro-cathepsin D cDNA (CD -/-CatD) were 
incubated for 14 h with 100 ng/mL TNF in combination with 20 µM zVAD-fmk and 5 µg/mL CHX or with 1 mM MNNG 
for 30 min and further incubated for 16 h with fresh medium without MNNG. Subsequently, loss of membrane integrity was 
determined by flow cytometry. Representative data from one out of three experiments are shown and error bars indicate the 
SD from three measurements. 
Altogether, the experiments obtained in the study presented here suggest that TNF-induced necroptosis 
is not affected by inhibition of PARP-1 and components of the PARP pathway. 
Inhibition of necroptosis does not protect from PARP-1-induced regulated necrosis 
In a reverse approach, the effect of the inhibition of one crucial component of TNF-induced 
necroptosis on the PARP pathway was analyzed. RIPK3 is such a crucial mediator of necroptosis. For 
this purpose, L929Ts, NIH3T3 cells naturally expressing RIPK3 and HEK293T, MCF-7 and HeLa 
cells which lack endogenous RIPK3 expression were analyzed for their ability to undergo TNF-
induced necroptosis and PARP-induced regulated necrosis. In line with the crucial functions of RIPK3 
in necroptosis, L929Ts and NIH3T3 were sensitive to TNF/zVAD-induced necroptosis whereas 
HEK293T, MCF-7 and HeLa cells were resistant to TNF/zVAD/CHX treatment (Figure 14). In 
contrast to necroptosis, both MNNG and MMS, a distinct DNA-alkylating agent and activator of 
PARP-1 (Gassmann et al. 2012), uniformly induced loss of membrane integrity in all analyzed cell 
lines (Figure 14). Further results obtained in the laboratory substantiate that RIPK3 and also RIPK1 
have no essential functions in the PARP pathway (Sosna, Voigt et al. 2014). 
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Figure 14: RIPK3 is a crucial mediator of TNF-induced necroptosis, but not in the PARP pathway. RIPK3-positive 
(L929Ts, NIH3T3) or RIPK3-negative (HEK293T, MCF-7, HeLa) were treated with 100 ng/mL TNF with addition of 20 µM 
(NIH3T3) or 50 µM (293T, MCF-7, HeLa) zVAD-fmk and 1 ng/mL (293T) or 0.25 µg/mL (MCF-7, HeLa) non-toxic CHX 
for 24 h or with 0.5 mM MNNG or 25 mM MMS for 15 min and further incubated for 16 h with fresh medium without 
MNNG or MMS. Treatment with zVAD/(CHX) alone served as a control. Loss of membrane integrity was determined by 
flow cytometry. Representative data from one out of three experiments are shown and error bars indicate the SD from three 
measurements. 
Conclusion: TNF and PARP-1 induce distinct routes to regulated necrosis 
In this part of the study, the two most extensively studied models of regulated necrosis (necroptosis 
and PARP-induced regulated necrosis) were analyzed and revealed that TNF and MNNG can induce 
regulated necrosis in L929 sublines, HT-29, Jurkat, NIH3T3, HeLa, HEK293T and MCF-7 cells. The 
depletion of intracellular ATP levels occurs late during TNF-induced necroptosis, implicating that 
individual components of the PARP pathway are activated as a secondary consequence during 
necroptosis rather being the cause of necroptotic cellular disintegration. This was in contrast to the 
rapid depletion of ATP following PARP-1 activation by MNNG. Moreover, PARP-1 inhibition did not 
alter TNF-induced necroptosis, whereas the MNNG-induced PARP pathway was blocked. The 
interference with further components of the PARP pathway revealed that JNK as well as cathepsin D 
have no role in TNF-induced necroptosis. On the other hand, interference with components of the 
necroptosis pathway (e.g. RIPK3) did not alter the PARP pathway, suggesting that TNF-induced 
necroptosis and PARP-1-mediated regulated necrosis represent two distinct routes to necrotic PCD. 
Further results performed in the laboratory substantiate this hypothesis (Sosna, Voigt et al. 2014). 
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5.2 Proteolysis is crucial for the regulation of TNF-induced necroptosis 
In regulated necrosis, proteolysis of regulator proteins appears to be an important execution 
mechanism among others as described in section 2.2.1.2, but the participating proteases and the 
underlying molecular mechanisms are only marginally characterized. Therefore, in work described in 
this chapter, the focus was put on the identification of new proteins participating in the proteolytic 
regulation during necroptosis primarily induced by TNF/(zVAD/(CHX)). To this end, three different 
approaches were utilized: (a) identification of proteases whose inhibition blocks necroptosis, 
especially serine proteases sensitive to TFCK (N-tosyl-L-phenylalanine chloromethyl ketone; formerly 
abbreviated TPCK; section 5.2.1), (b) RNAi screens to identify proteases which, when down-
regulated, affect TNF-induced necroptosis (section 5.2.2) and (c) detection of new or known proteins 
cleaved during necroptosis by immuno-magnetic enrichment of TNF-R1-containing magnetic vesicles 
in combination with proteomic technologies, e.g. 2D-DIGE and MALDI-TOF/TOF analyses (section 
5.2.3). Furthermore, the analysis of the proteolytic degradation of the potentially pro-necroptotic 
protein (d) PGAM5 and the characterization of the proteolytic maturation/activation of (e) A-SMase 
during necroptosis was addressed and described in sections 5.2.4 and 5.2.5. In the last section (5.2.6) 
of this part of the presented thesis, the investigation of the role of other peptidases such as presenilin 
and the presenilin homologue signal-peptide-peptidase-like (SPPL) during TNF-induced necroptosis 
was investigated. 
5.2.1 Identification of HtrA2/Omi, PSA1, PMPCA and Lon protease as TFCK-sensitive 
 proteases mediating necroptosis 
Inhibition of serine proteases, but not metalloproteases, cathepsin or calpain/cysteine 
proteases protect cells from TNF-induced necroptosis 
In order to investigate which class of proteases substitute for caspases during regulated necrosis, the 
effects of different protease inhibitors on TNF-induced necroptosis were investigated in murine 
(L929Ts, NIH3T3) and human cell lines (U-937, HT-29, Jurkat ATCC and Jurkat I42). In line with 
previous findings (Thon et al. 2005, Sosna and Voigt et al. 2013; Sosna, Voigt et al. 2014) and as 
shown in Figure 15A, inhibitors of the cysteine proteases cathepsin L (zFF-fmk), cathepsin B/L (zFA-
fmk) as well as the broad spectrum calpain/cysteine protease inhibitor E-64 did not protect U-937 cells 
from TNF-induced necroptosis. Surprisingly, the cathepsin B inhibitor Ca-074Me showed protection 
from necroptotic cell death in U-937 cells. This, however, was not observed in other cell lines (Sosna 
and Voigt et al. 2013) or with any of the other cysteine protease inhibitors studied here. It was shown 
that the inhibitor Ca-074Me abrogated staurosporine-induced necrotic cell death in leukemia cells and 
that this is independent of its inhibitory effect on cathepsin B (Mihalik et al. 2004). Moreover, the 
same group reported that the inhibitor Ca-074Me has a cathepsin B-independent target that plays a role 
in necroptosis upstream of lysosomal breakdown (Dunai et al. 2012) which may explain the protective 
effect of Ca-074Me on TNF-induced necroptosis in U-937 cells. 
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Furthermore, pharmacological inhibition of acid proteases (aspartyl peptidases) by pepstatin A showed 
no decrease in the death response to TNF but rather enhanced necroptosis (Figure 15A). In summary, 
these results demonstrate that calpain/cysteine and aspartate proteases are not required for TNF-
induced necroptosis. Treatment of U-937 cells with the proteasome inhibitor MG-132 did not prevent 
the cells from TNF/zVAD-induced necroptosis (Figure 15A). It was also investigated whether TNF-
induced necroptosis is regulated by metalloproteinases. The broad-spectrum inhibitors of matrix 
metalloproteinases, GM6001 and marimastat, neither protected murine L929Ts cells, NIH3T3 cells 
nor human U-937 cells from TNF-induced necroptosis (Figure 15B), additionally arguing against a 
role of metalloproteinases as well as the proteasome and in this form of PCD. 
Figure 15: Inhibition of cathepsin or calpain/cysteine proteases and metalloproteases does not protect U-937 cells 
from TNF-induced necroptosis. (A) U-937 cells were pre-incubated for 2 h with 1 µM z-FF-fmk, 5 µM zFA-fmk or in 
separate experiments with 1 µM Ca-074Me, 20 µM E64, 0.1 µM MG-132 in combination with 50 µM zVAD-fmk and 
subsequent addition of 100 ng/mL TNF for 24 h before cell death was analyzed. For pepstatin A incubation, cells were pre-
incubated for 24 h with or without 100 µM pepstatin A followed by incubation with or without 100 ng/mL TNF and  
50 µM zVAD-fmk for 24 h. Subsequently, loss of membrane integrity was measured by flow cytometry. (B) L929Ts, 
NIH3T3 and U-937 cells were pre-incubated for 2 h with GM6001 and marimastat as indicated and subsequent addition of 
100 ng/mL TNF and 20 µM (L929Ts, NIH3T3) or 50 µM (U-937) zVAD-fmk before cell death was analyzed. The diagrams 
show the percentage of 10,000 analyzed cells losing their membrane integrity. Representative data from one out of two 
experiments are shown and error bars indicate the SD from three measurements. 
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In a next set of experiments, the effect of TFCK, an inhibitor of chymotrypsin-like serine proteases, on 
TNF-induced necroptosis was investigated. As shown in Figure 16, TFCK significantly protected 
murine L929Ts and NIH3T3 cells from TNF-induced necroptosis. Moreover, TFCK significantly 
protected Jurkat cells and its subline I42 as well as HT-29 and U-937 cells from necroptosis elicited by 
TNF (Figure 16). Similar results were obtained with the treatment of Nec-1, suggesting that TFCK can 
block TNF-induced necroptosis (Figure 16). Taken together, these results show clearly that serine 
proteases participate in TNF-induced necroptosis in a cell type- and species-independent manner, 
whereas inhibition of metalloproteinases, calpain/cysteine and aspartate proteases had no major impact 
in this specific form of regulated necrosis. 
Figure 16: TFCK-specific serine proteases have an impact on TNF-induced necroptosis. Cells were stimulated with or 
without 100 ng/mL TNF for 5 (L929Ts), 6 (Jurkat I42), 16 (NIH3T3, HT-29), 20 (Jurkat) or 24 h (U-937) with optional 
addition of 20 (L929Ts, NIH3T3, HT-29, Jurkat I42) or 50 µM (Jurkat, U-937) of the pan-caspase inhibitor zVAD-fmk,  
2 (Jurkat) or 5 µg/mL (HT-29) CHX and 50 (L929Ts, NIH3T3, U-937) and 25 µM (Jurkat, Jurkat I42, HT-29) TFCK, or 
50 µM necrostatin 1 (Nec-1; to inhibit necroptosis). Subsequently, the cells were analyzed for loss of membrane integrity by 
means of PI staining and flow cytometry. Asterisks indicate statistical significance (t-test), *** P ≤ 0.001. Representative 
data from three experiments are shown and error bars indicate SD from three parallel measurements. 
Identification of HtrA2/Omi, PSA1 and PMPCA as TFCK-sensitive proteases mediating 
necroptosis 
To identify the TFCK-sensitive serine protease(s) responsible for TNF-dependent regulated necrosis, a 
previously employed approach aiming to affinity-label only a subset of proteases and subsequent 
identification of proteins by means of MS (Egger et al. 2007) was adapted. In an initial experiment, 
L929Ts cells were treated with TNF/zVAD in the presence of cell-permeable active-site-directed 
fluorescently labeled TFCK-derivative (FFCK) to identify serine proteases activated during TNF-
induced necroptosis. Micrographs in Figure 17A show the necrotic-like morphology of cells treated 
with TNF/zVAD in comparison to TNF/zVAD/FFCK-treated cells, the latter being protected from 
necroptosis induced by TNF. Already after 30 min of incubation with FFCK, all cells were completely 
labeled with FFCK (Figure 17B). After 5 h of incubation (a timeframe expected to be sufficient to 
activate the relevant serine protease(s)), lysates from the cells were prepared and separated by SDS-
PAGE. Fluorescence analysis revealed bands only in extracts from cells treated with FFCK but not in 
extracts from control cells demonstrating successful FFCK-labeling of the treated cells and no 
background staining in untreated cells (Figure 17C). 
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Figure 17: Labeling of L929Ts cells with a fluorescent active-site-directed serine protease inhibitor (FFCK). L929Ts 
cells were either left untreated, treated with 100 ng/mL TNF and 20 µM zVAD-fmk or additionally with 50 µM fluorescent 
TFCK-derivate (FFCK) for 5 h. (A) Micrographs show the morphology of unstimulated and stimulated cells. Scale bar: 
100 µm. Black arrows mark necroptotic cells. (B) Flow cytometric analysis of L929Ts cells. Red line: Cells stimulated with 
TNF/zVAD/FFCK as in (A), black line: untreated control cells. 10,000 cells were analyzed for each measurement.  
(C) Cytosolic extracts of cells treated as in (A) were separated with technical assistance by Jürgen Fritsch (Christian-
Albrechts-University, Kiel, Germany) on a 6 - 15 % (v/v) gradient SDS gel, and bands (black arrow) were visualized with a 
scanner at green fluorescence. M: protein size marker. 
To increase the resolution of the FFCK-labeled bands found in the one dimensional SDS gel (Figure 
17), cellular extracts labeled with FFCK were analyzed by 2D-PAGE. L929Ts cells were treated with 
TNF/zVAD and CHX (to enhance necroptosis) for 5 h in the presence of FFCK. Lysates were 
separated by 2D-PAGE. Subsequent scanning for fluorescent signals revealed 128 fluorescently 
labeled protein spots (Figure 18). The labeled protein spots were analyzed by MS, 80 were identified 
with high and 28 with lesser confidence. As described in 4.2.14 proteins were considered identified 
when either two peptides were identified with a confidence interval ≥ 99 % (p < 0.01) or three peptides 
≥ 95 % (p < 0.05). Due to non-specific background binding of FFCK, most of the 108 identified 
proteins turned out to be non-proteases. However, in this first screen, the mitochondrial serine protease 
high temperature requirement protein A2/Omi stress regulated endoprotease (HtrA2/Omi; Q9JIY5) 
was identified with high confidence (Figure 18). The identification of HtrA2/Omi met strict criteria of 
the MASCOT database search. Therefore, and because HtrA2/Omi has been associated with both 
caspase-dependent apoptosis as well as caspase-independent regulated necrosis (Vande Walle et al. 
2010), this serine protease was considered a promising candidate. 
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Furthermore, in the same experiment, the mitochondrial-processing peptidase subunit alpha (PMPCA; 
Q9DC61) was identified which did not meet the high confidence criteria, but at least met the first 
filtering criteria. Experiments to determine the biological relevance of PMPCA and its potential 
association with necroptosis are described in section 5.2.2. The remaining identified proteins were 
non-proteases (data not shown). This might be due to the reported variety of pro- and anti-apoptotic 
effects of the chymotrypsin-like serine protease inhibitor TFCK (King et al. 2004; Rokhlin et al. 
2004). 
Figure 18: HtrA2/Omi is a candidate serine protease involved in necroptosis. L929Ts cells were stimulated with 
100 ng/mL TNF, 20 µM zVAD-fmk and 2 µg/mL CHX in combination with 50 µM fluorescent TFCK-derivate (FFCK) for 
5 h. Subsequently, cell lysates were separated by 2D gel electrophoresis and analyzed for protein spots labeled by FFCK (left 
panel, green), or for all separated protein spots by staining with Flamingo™ Fluorescent gel stain (right panel, red). The 
protein spots were subsequently identified by mass spectrometry. HtrA2/Omi is indicated by arrows. The preparation of the 
2D gel was performed in collaboration with the group of Ottmar Janssen (Christian-Albrechts-University, Kiel, Germany) 
and MALDI-TOF/TOF analyses of the isolated fluorescently labeled protein spots were performed in collaboration with the 
group of Andreas Tholey (Christian-Albrechts-University, Kiel, Germany). 
To additionally identify candidate proteases which may be activated at earlier time-points, the screen 
with murine L929Ts cells was repeated and cellular extracts of cells treated with TNF/zVAD/FFCK 
for 30 min were additionally analyzed. The 2D gel from lysates after 30 min stimulation revealed 157 
fluorescently labeled spots which were isolated and identified by MS. In this screen, 71 proteins were 
identified with high and 20 proteins with lesser confidence. From the proteins with lesser confidence a 
part of the multicatalytic proteinase complex proteasome was identified with 9 peptide counts. This 
proteasome subunit alpha type-1 (PSMA1 or PSA1; Q9R1P4) was recently described to be involved in 
sensitization of bortezomib-resistant leukemia cells (Fang et al. 2012) and was therefore considered a 
promising candidate for further research purposes (see 5.2.2). The remaining identified proteins were 
non-proteases (data not shown). 
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Identification of the ATP-dependent Lon protease as a TFCK-sensitive protease 
mediating necroptosis 
The screen for serine-proteases was extended to a cell line of human origin, i.e. Jurkat I42. This Jurkat 
subline is deficient for FADD and stably transfected with TNF-R2 (Chan et al. 2003) and thus 
susceptible to TNF-mediated cell death in the absence of CHX. Cells were treated with TNF/zVAD to 
induce necroptosis and labeled with FFCK for 30 min and 5 h. MS analysis of 145 proteins labeled 
with FFCK from 30 min and 5 h lysates revealed 88 proteins with high and 16 with lesser confidence. 
In this screen, the mitochondrial ATP-dependent protease Lon (LONM; P36776) was identified in 
lysates from cells treated with TNF/CHX/zVAD/FFCK for 30 min, albeit with low confidence (Figure 
19). The remaining identified proteins from lysates obtained after 30 min and 5 h stimulation were 
non-proteases (data not shown). Since the mitochondrial ATP-dependent Lon protease has been 
already associated with tumorigenesis mediated by the generation of ROS (Cheng et al. 2013), it was 
further analyzed as well (see section 5.2.2). 
Figure 19: Identification of the mitochondrial ATP-dependent protease Lon as a candidate serine protease involved in 
necroptosis. Jurkat I42 cells were stimulated with 100 ng/mL TNF, 20 µM zVAD-fmk in combination with 50 µM FFCK for 
30 min. Subsequently, lysates from cells were separated by 2D gel electrophoresis and analyzed for protein spots labeled by 
FFCK (green). The labeled protein spots were subsequently isolated and identified by mass spectrometry. Lon protease 
(LONM) is indicated by the white arrows. The right picture shows the protein load (Flamingo™ staining for proteins; red) 
after excision of green fluorescent protein spots. The preparation of the 2D gel was performed in collaboration with the group 
of Ottmar Janssen (Christian-Albrechts-University, Kiel, Germany) and MALDI-TOF/TOF analyses of the isolated 
fluorescently labeled protein spots were performed in collaboration with the group of Andreas Tholey (Christian-Albrechts-
University, Kiel, Germany). 
Results 
71 
 
The TFCK-sensitive serine protease HtrA2/Omi regulates necroptosis 
As described above, the identification of HtrA2/Omi met strict criteria of the MASCOT database 
search. Therefore, and because HtrA2/Omi has been associated with both caspase-dependent apoptosis 
as well as caspase-independent regulated necrosis (Vande Walle et al. 2010), this serine protease was 
considered a promising candidate. To investigate whether HtrA2/Omi was indeed involved in the 
execution of TNF-induced necroptosis, the activity of HtrA2/Omi was blocked by pharmacological 
inhibition with the specific inhibitor Ucf-101 (Cilenti et al. 2003). Treatment with Ucf-101 resulted in 
protection of L929Ts, NIH3T3, Jurkat ATCC, Jurkat I42 and U-937 cells from TNF-induced 
necroptosis (Figure 20A). However, HT-29 cells showed only marginal protection from 
TNF/zVAD/CHX treatment when incubated with Ucf-101 (Figure 20A). This might be explained by 
the fact that other serine proteases might substitute for HtrA2/Omi in a cell-type-specific manner. 
Notably, in L929Ts cells treated for 5 h with TNF/zVAD, the combination of Ucf-101 and TFCK did 
not confer a stronger protection from necroptosis (Figure 20B). This observation suggests that both 
inhibitors (Ucf-101 and TFCK) were acting via the same signaling pathway or even both may target 
HtrA2/Omi. 
Since pharmacological inhibitors might have non-specific effects, MEFs derived from HtrA2/Omi-
deficient mice were used for further characterization of HtrA2/Omi in necroptosis. MEFs deficient for 
HtrA2/Omi were fully protected from TNF-induced necroptosis (Figure 20C), validating the results 
with Ucf-101. Taken together, the above described observations confirm that the serine protease 
HtrA2/Omi is indeed a key mediator of TNF-induced necroptosis. 
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Figure 20: The serine protease HtrA2/Omi mediates TNF-induced necroptosis. (A) Cells were left untreated, or were 
pretreated for 2 h with 25 µM (Jurkat ATCC, Jurkat I42) or 50 µM (L929Ts, NIH3T3, HT-29, U-937) of Ucf-101 and further 
incubated for 5 (L929Ts, U-937), 6 (Jurkat I42), 16 (NIH3T3, HT-29), 20 (Jurkat ATCC) or 24 h (U-937) with 100 ng/mL 
TNF, 20 µM (L929Ts, NIH3T3, HT-29) or 50 µM (Jurkat ATCC, Jurkat I42, U-937) zVAD-fmk and 2 µg/mL (Jurkat 
ATCC, U-937) or 5 µg/mL (HT-29) CHX before cell death was analyzed by measuring loss of membrane integrity.  
(B) L929Ts cells were left untreated or were pretreated with either 50 µM Ucf-101, 50 µM TFCK or a combination of both as 
above, followed by stimulation with TNF/zVAD/CHX as outlined above. At the end of the incubation time cells were 
analyzed as above. (C) Wild-type (WT) and HtrA2/Omi-deficient MEFs were stimulated with 100 ng/mL TNF,  
20 µM zVAD-fmk and 1 µg/mL CHX or with zVAD/CHX alone for 16 h before cell death was measured by flow cytometry. 
The diagrams show the percentage of 10,000 analyzed cells losing their membrane integrity. Representative data from one 
out of two experiments are shown and error bars indicate the SD from three measurements. 
Conclusion: HtrA2/Omi is a key component of TNF-mediated necroptosis and PSA1, 
PMPCA and Lon protease are TFCK-sensitive proteases potentially mediating 
necroptosis 
Using multiple murine and human cell systems, it could be shown that inhibition of serine proteases 
by TFCK, but not inhibition of metalloproteases, cathepsin or calpain/cysteine proteases protects from 
TNF-induced necroptosis, suggesting that serine proteases are crucial for TNF-induced necroptosis. To 
identify the corresponding TFCK-sensitive serine protease(s), necroptosis was induced in L929Ts or 
Jurkat I42 cells to activate the relevant proteases in the presence of an active-site-directed 
fluorescently labeled TFCK-derivative. The labeled proteins were resolved by 2D-PAGE, followed by 
analysis via MALDI-TOF-MS and HtrA2/Omi was identified as the most promising candidate (see 
Sosna and Voigt et al. 2013). The importance of HtrA2/Omi in necroptosis was validated by showing 
that pharmacological inhibition or genetic deletion of HtrA2/Omi fully protects from TNF-induced 
necroptosis. In the proteomic screen for TFCK-sensitive proteases that participate in necroptosis, three 
further candidates were identified: Lon protease 1, PSA1 and PMPCA. These proteases were 
investigated with regard to their exact function in the signaling pathways of necroptosis after manual 
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transfection of HT-29 and U-937 cells with the specific siRNA which is shown in the following 
section of the study. 
5.2.2 RNAi screen to identify proteases that regulate necroptosis 
Identification of candidate proteases participating in necroptosis in a robotic high-
throughput RNAi screen 
To identify proteases which protect from or enhance regulated necrosis, a complementary siRNA 
screen of all proteases encoded by the human genome was performed in collaboration with the group 
of Philip Rosenstiel (Christian-Albrechts-University, Kiel, Germany), who provided the siRNA library 
as well as the instrument-based structure, expertise and performed the robotic part of the screens. 
The screen was performed using the human colorectal adenocarcinoma cell line HT-29. The setup of 
the screen was related to previous work from Lipinski et al. (2012) identifying mediators of 
intracellular nucleotide-binding oligomerization domain-2 (NOD2) receptor signaling. The Silencer 
Human Genome siRNA library, Version 3 covering 21,687 human genes with 3 individual siRNAs per 
gene (65,061 siRNAs in total) was used to identify proteases potentially involved in TNF-induced 
necroptosis. The experimental set up is depicted in Figure 5A and 5B and is described in section 4.2.4. 
For control of transfection efficacy, control siRNAs targeting known regulators of necroptosis  
(i.e. RIPK1, RIPK3 as well as TNF-R1) were added to the screen. The down-regulation of these 
control proteins significantly reduced the sensitivity of HT-29 cells to TNF-induced necroptosis 
(Figure 21A). Down-regulation of HtrA2/Omi served as an internal negative control, since it was 
shown that down-regulation of HtrA2/Omi does not affect TNF-induced necroptosis (Sosna and Voigt 
et al. 2013; Figure 21A). Of note, the importance of HtrA2/Omi in necroptosis was validated by 
showing that pharmacological inhibition or genetic deletion of HtrA2/Omi fully protects from TNF-
induced necroptosis (see 5.2.1). 
In the initial screen, 21.25 % of all single siRNA hits passed the threshold (normalized fold-induction 
values ≥ 1.5 or ≤ -1.5). To further narrow down the list and to minimize false positives, the effects of 
down-regulation of the three individual siRNAs per gene were compared. The following rules for 
positive candidate genes were defined: (a) genes that were represented by two or three siRNAs above 
the fold-induction threshold, and (b) genes with a single siRNA above the fold-induction threshold and 
with two other siRNAs pointing in the same direction as the single siRNA passing the threshold. 
Using these rules, 7 proteases were found that conformed to criterion (a), with the strongest effectors 
being caspase-8, cylindromatosis (CYLD) and CFLAR (c-FLIP). Furthermore, 33 proteases met the 
criteria for (b). In total, the first robotic screen identified 40 proteases which, when down-regulated, 
caused increased (37 %) or reduced sensitivity (63 %) to TNF-induced necroptosis (Figure 21B and 
Supplementary Table S1). 
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A second robotic screen was performed using the 40 candidates meeting the described criteria (Figure 
21B and Supplementary Table S1) and the same positive and negative controls. After analysis of the 
results, the list of candidates was narrowed down to 10 proteases with pronounced (and six candidates 
with less pronounced) effects, again identifying CASP8, CYLD and c-FLIP as the strongest effectors 
(Table 4). 
Figure 21: High-throughput siRNA screen for proteases participating in necroptosis. (A) Exemplary control experiment 
using HT-29 cells transfected with either positive control siRNA (RIPK1, RIPK3, TNF-R1) or HTRA2 siRNA (all 20 nM). 
After 72 h, necroptosis was induced by addition of 100 ng/mL TNF, 20 µM zVAD-fmk and 5 µg/mL CHX. ATP levels were 
measured 20 h after stimulation. Fold induction values were calculated by means of normalization of viability to control 
siRNA of HTRA2. (B) In the first screen, a total of 40 candidates met the fold induction threshold and were re-screened in a 
second screen yielding 16 candidate hits. Candidates were divided into positive (down-regulation decreases cell death after 
TNF/zVAD/CHX stimulation compared to control transfected cells) and negative regulators (enhancement of cell death after 
down-regulation). The complementary siRNA screen was performed in collaboration with the group of Philip Rosenstiel 
(Christian-Albrechts-University, Kiel, Germany). 
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Table 4: Proteases identified to have a positive or negative effect on TNF-induced necroptosis. These 16 proteases meet 
the criteria for candidate proteases. Citations linking these proteases to programmed cell death (PCD) are listed in the last 
column. For all proteases identified, the related reference sequence number from the National Center of Biotechnology 
Information and their individual accession number are listed. 
 
Manual validation of candidate proteases and TFCK-sensitive proteases in HT-29 cells 
Subsequently, candidates with a published link to PCD (Table 4) were selected and analyzed for their 
potential to enhance or decrease TNF-induced necroptosis. The third screen was performed manually 
using newly obtained and independent siRNA pools or individual siRNAs (see Table 1) for the  
10 candidates to exclude off-target effects of the formerly utilized siRNAs.  
Again, positive (RIPK3, TNF-R1) and negative controls (commercial non-targeting siRNA and 
HTRA2 siRNA) were present in every experiment. Transfected HT-29 cells, where RIPK3 and TNF-
R1 was down-regulated showed decreased TNF-induced necroptosis whereas cell death was not 
prevented by HTRA2-specific siRNA transfection (Figure 22A). Moreover, lysates of siRNA-
transfected HT-29 cells were analyzed by Western blot and showed successful down-regulation of 
representative positive (RIPK3), negative (HTRA2) controls and exemplarily the candidate protease 
caspase-8 (CASP8; Figure 22B). 
The list of candidate siRNA genes was extended by three further candidates (PMPCA, PSA1 and 
LONM; see section 5.2.1) which were identified during the proteomic screen for TFCK-sensitive 
proteases participating in regulated necrosis. Down-regulation of the proteases DESC, GGT1, PRPF8 
and CFLAR resulted in increased cell death. Down-regulation of CASP8 and CYLD on the other hand 
resulted in decreased cell death (Figure 23). The remaining candidates from the siRNA screen 
(MMP3, MEP1B, YME1L1) showed only marginal effects towards TNF-induced necroptosis when 
compared to control transfected and treated HT-29 cells. Likewise, the transfection of HT-29 cells 
with siRNAs for LONM, PSA1 and PMPCA did not result in enhanced or decreased TNF-induced 
necroptosis (Figure 23). This lack of effects may result from an insufficient reduction of proteolytic 
activity by incomplete down-regulation which might not yet be sufficient to inhibit or enhance the 
Protease Abbreviation Reference sequence Accession Number Link to PCD
A disintegrin and metalloproteinase with 
thrombospondin motifs 18 ADAMTS18 NM_199355 Q8TE60 -
Aminopeptidase Q AP-Q NM_173800 Q6Q4G3 -
ATP-dependent zinc metalloprotease 
YME1L1 YME1L1 NM_139312 Q96TA2 Stiburek et al.  2012
Carboxypeptidase Q CBPQ NM_016134 Q9Y646 -
Caspase-8 CASP8 NM_001228 Q14790 Kaczmarek et al.  2013
CasperFLIP CFLAR NM_003879 O15519 Kaczmarek et al.  2013
Cylindromatosis protein CYLD NM_015247 Q9NQC7 Kaczmarek et al.  2013
Dihydropyrimidinase-related protein 3 DPYL3 NM_001387 Q14195 -
Dihydropyrimidinase-related protein 4 DPYL4 NM_006426 Q14531 Kimura et al. 2011
Dipeptidyl peptidase 8 DPP8 NM_197960 Q6V1X1 -
Gamma-glutamyltranspeptidase 1 GGT1 NM_005265 P19440 Boonyanugomol et al.  2012
Insulysin DIE NM_004969 P14735 -
Meprin 1 beta MEP1B NM_005925 Q16820 Carmago et al.  2002
Pre-mRNA-processing-splicing factor 8 PRPF8 NM_006445 Q6P2Q9 Tapia-Vieyra et al.  2005
Stromelysin-1 MMP3 NM_002422 P08254 Sternlicht et al.  1999
Transmembrane protease serine 11E DESC NM_014058 Q9UL52 Viloria et al.  2007
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death response. To further analyze the effects of the candidate proteases, pharmacological inhibitory 
studies and direct genetic approaches will be required. 
Figure 22: Exemplary control experiment for the validation of candidate proteases in HT-29 cells. (A) Intracellular 
ATP measurement of HT-29 cells transfected with siRNAs specific for either human RIPK3, TNF-R1 (internal positive 
control), HTRA2 (negative control) or control siRNA (siCtr). After 72 h, cells were treated with 100 ng/mL TNF, 20 µM 
zVAD-fmk and 5 µg/mL CHX before intracellular ATP levels were determined after 20 h of stimulation. Error bars show the 
respective SD from five parallel measurements. (B) Control Western blots of transfected (siRIPK3, siHTRA2 and siCASP8) 
but untreated cells were performed to verify down-regulation of the endogenous proteins. Detection of actin served as a 
loading control. Here, the diagram and Western blot analysis show one representative experiment which was performed for 
each siRNA transfection independently. 
Figure 23: Validation of 13 candidate proteases in HT-29 cells. The specific siRNA of the 10 candidates identified from 
the siRNA screen (two separate experiments) and of the three candidates from the TFCK-screen were transfected into HT-29 
cells and stimulated with 100 ng/mL TNF, 20 µM zVAD-fmk and 5 µg/mL CHX for 20 h. Data show relative viability units 
of HT-29 cells normalized to cells transfected with control siRNA. Experiments were repeated three times (CASP8, DESC, 
MMP3, CYLD, GGT1, PRPF8, DPYL4, CFLAR) or four times (MEP1B, YME1L1, LONM, PSA1, PMPCA).Values above 
the grey line indicate candidates whose down-regulation potentiates necroptosis or below the grey line indicate candidates 
that possibly protect from necroptosis when down-regulated. 
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Manual validation of candidate proteases and TFCK-sensitive proteases in U-937 cells 
The validation of candidate proteases was extended to an additional human cell line (U-937 cells) and 
flow cytometry was performed in parallel to ATP level measurements to measure loss of membrane 
integrity as an additional read-out for cell death (Figure 24A,B). Control transfections (RIPK3, TNF-
R1 and HTRA2 as negative control siRNAs) were present in every experiment and revealed 
essentially the same trends as observed in HT-29 cells (Figure 24C,D). The transfection of siRNAs 
targeting the candidate proteases DESC, MMP3, CFLAR and PMPCA showed increased loss of 
intracellular ATP indicating increased cell death (Figure 24A). In addition, these cells showed an 
increased loss of membrane integrity as measured by the incorporation of PI (Figure 24B). U-937 cells 
transfected with siRNA targeting GGT1, PRPF8, DPYL1 and PSA1 likewise showed an increase in 
cell death compared to cells transfected with negative control siRNA (Figure 24B). Remarkably, an 
increase in ATP level was detected in cells transfected with PRPF8 siRNA which is in contrast to the 
flow cytometric measurement (Figure 24A,B). As one possible explanation for this result, the increase 
in ATP levels might be due to cell death unrelated effects because two independent studies reported 
that intracellular levels of ATP can vary in response to cell death unrelated stimuli (Hahn-Windgassen 
et al. 2005; Galluzzi et al. 2011). As a result, measurement of loss of membrane integrity was 
additionally performed to validate the effects of down-regulation of candidate proteases. Cell death 
levels of cells with down-regulated CASP8, CYLD and MEP1B were decreased when determined by 
detection of ATP levels (Figure 24A). This was also true for CYLD siRNA transfected U-937 cells 
determined by PI-staining (Figure 24B). However, CASP8 and MEP1B siRNA transfected U-937 cells 
showed no decrease in loss of membrane integrity, suggesting that the measured ATP depletion 
occurred earlier than the onset of cell death. Down-regulation of LONM and YME1L1 showed no 
effect in both approaches (Figure 24A,B). 
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Figure 24: Validation of 13 candidate proteases in U-937 cells. (A-B) siRNAs of the 10 candidates identified from the 
siRNA screen were transfected into U-937 cells for 48 h. Subsequently, cells were stimulated with 100 ng/mL TNF,  
50 µM zVAD-fmk and 0.1 µg/mL CHX for 24 h. Data show relative viability units of U-937 cells normalized to cells 
transfected with control siRNA either (A) measured by intracellular ATP levels or (B) by flow cytometry measuring PI-
positive cells. Experiments were repeated twice (CASP8, DESC, MMP3, CYLD, GGT1, PRPF8, DPYL4, CFLAR) or three 
times (MEP1B, YME1L1, LONM, PSA1, PMPCA). Values above the grey line indicate candidates whose down-regulation 
potentiates necroptosis or below the grey line indicate candidates that possibly protect from necroptosis when down-
regulated. (C) Exemplary control experiment showing intracellular ATP measurement of U-937 cells transfected with 
siRNAs specific for either human RIPK3, TNF-R1 (internal positive control), HTRA2 (negative control) or control siRNA 
(siCtr). After 48 h, cells were treated with 100 ng/mL TNF, 50 µM zVAD-fmk and 0.1 µg/mL CHX before intracellular ATP 
levels were determined after 24 h of stimulation. Error bars show the respective SD from five parallel measurements.  
(D) Control Western blots of transfected (siRIPK3, siHTRA2 and siCASP8) but untreated cells were performed to verify 
down-regulation of the endogenous proteins. Detection of actin served as a loading control. Here, the diagram and Western 
blot analysis show one representative experiment which was performed for each siRNA transfection independently. 
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The role of meprin β during TNF- and TRAIL-induced necroptosis 
Meprin β (MEP1B), as among 4 other metalloproteases (DPYSL4, PRPF8, MMP3, YME1L1), was 
identified during the siRNA screen as a candidate protease possibly involved in TNF-induced 
necroptosis (Table 4). In initial experiments to further investigate the role of MEP1B in necroptosis, 
HT-29 cells were transiently transfected with plasmids encoding wild-type MEP1B or a proteolytically 
inactive MEP1B mutant (E90A). Cells were stimulated with TNF/zVAD/CHX or TRAIL/zVAD/CHX 
to induce necroptosis. Measuring loss of membrane integrity as well as ATP levels revealed that 
transient overexpression of MEP1B in HT-29 cells leads to increased cell death rates after treatment 
with TNF/zVAD/CHX when compared to non-transfected cells (Figure 25). This effect was only 
marginally seen in cells treated with TRAIL/zVAD/CHX, suggesting differences in the signal 
transduction pathways of TNF- and TRAIL-induced necroptosis. Treatment of cells with 
TNF/zVAD/CHX or TRAIL/zVAD/CHX in combination with Nec-1 was performed as a control and 
verified that transfected HT-29 cells indeed undergo necroptosis (Figure 25). Interestingly, cells 
expressing the inactive MEP1B mutant also showed increased cell death levels after stimulation with 
TNF as well as TRAIL/zVAD/CHX (Figure 25). In conclusion, the analysis of MEP1B function 
suggests that the catalytic activity of MEP1B has protective effects in TNF-induced necroptosis. 
Nevertheless, these preliminary data should be substantiated by loss of gene function studies and by 
studying the effects of MEP1B-specific inhibitors in future experiments. 
Figure 25: Role of MEP1B during necroptosis. HT-29 cells were transiently transfected with wild-type MEP1B or an 
inactive MEP1B mutant (MEP1BE90A) for 72 h before cell death was induced by treatment with either 100 ng/mL TNF or 
TRAIL in combination with 20 µM zVAD-fmk and 5 µg/mL CHX. The addition of 50 µM Nec-1 to TNF/zVAD/CHX- or 
TRAIL/zVAD/CHX-treated cells served as a control for necroptosis. After 20 h, cell death was analyzed by measuring loss 
of membrane integrity (left) and decrease of intracellular ATP levels (right). One out of three experiments is shown. Error 
bars indicate the SD from three parallel measurements. 
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Conclusion: Five novel proteases enhance necroptosis upon down-regulation 
In a complementary siRNA screen of all proteases encoded by the human genome, caspase-8 
(CASP8), CYLD and c-FLIP (CFLAR), proteins that represent key regulators of necroptosis, were 
identified, confirming the functionality of the screen. Subsequently, a second robotic screen was 
performed using the siRNAs of the 40 best candidates and again identifying CASP8, CYLD and 
CFLAR as the strongest effectors. The second screen narrowed down the list of candidates to  
10 proteases with pronounced and six candidates with less pronounced effect. In a third, manually 
performed screen, it could be confirmed that the candidates (CASP8, CYLD, CFLAR, DESC, MMP3, 
GGT1, PRPF8 and DPYL4) affect necroptosis upon down-regulation in HT-29 as well as U-937 cells 
as two independent human systems for necroptosis. However, the precise role of these proteases in cell 
death, and in particular, in necroptosis is still unknown. The down-regulation of MEP1B did not affect 
necroptosis in HT-29 and U-937 cells, but studies of HT-29 cells transiently transfected with plasmids 
encoding MEP1B showed increased cell death rates in TNF-induced necroptosis, suggesting a possible 
role of MEP1B during TNF-induced necroptosis. 
5.2.3 Identification of new proteins that are cleaved or differentially expressed during 
necroptosis as potential candidate regulators of necroptosis 
After binding to its ligand TNF, the internalization of the activated TNF-R1 is an essential prerequisite 
for recruiting the DISC to the TNF-R1 and the initiation of pro-apoptotic signaling. Subsequently, 
TNF-R1-containing vesicles fuse with endosomal compartments containing further signaling 
molecules, leading to the formation of multivesicular bodies which are capable of mediating apoptosis 
(Schneider-Brachert et al. 2004). To analyze such TNF-R1-containing vesicles, an immuno-magnetic 
separation procedure has been utilized in previous studies (Tchikov et al. 2014). In order to enrich and 
identify proteins recruited to or cleaved in the vicinity of the TNF-R1, this immuno-magnetic 
separation procedure was adapted for the isolation of TNF-R1-containing vesicles under necroptotic 
conditions. 
The ligands TNF60-Fc and TNFwt-Fc can induce necroptosis in U-937 and L929Ts cells 
Before TNF-R1-containing vesicles can be enriched with the above described immuno-magnetic 
separation, the TNF-R1 must be prelabeled with Fc-tagged TNF-ligands coupled to Protein G 
magnetic nanoparticles (see 4.2.15.4). In order to test the biological activity of the purified Fc-tagged 
TNF-ligands (Figure 26A; see 4.2.15.3), loss of membrane integrity was measured using murine 
L929Ts and human U-937 cells treated either with commercially available TNF or TNFwt-Fc or 
TNF60-Fc in combination with zVAD-fmk to induce necroptosis (Figure 26B). Although human TNF 
and murine TNF are very homologous, human TNF binds only to murine TNF-R1 (Ameloot et al. 
2001). Therefore, the human TNFwt-Fc ligand was used to trigger necroptosis via TNF-R1 in murine 
L929Ts cells. Because TNFwt-Fc would bind to both human TNF-R1 and TNF-R2 (Tartaglia et al. 
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1993) in human U-937 cells, these cells were analyzed using the ligand TNF60-Fc which binds 
exclusively to the human TNF-R1. As shown in Figure 26B, both cell lines displayed the same levels 
of cell death after treatment with either TNF or the specific TNF-Fc ligands. Therefore, the Fc-tagged 
ligands were used for further studies analyzing TNF-R1 internalization and magnetically enriched 
TNF-R1-containing vesicles. 
Figure 26: Biological activity of TNF ligands. (A) HEK293T cells were transfected with plasmids encoding for TNFwt-Fc 
or TNF60-Fc and the TNF-ligands were purified as described in 4.2.15.3. The supernatant of transfected HEK293T cells 
(input), the different elution fractions (#1-#4) with the respective TNF ligand and the flow-through of the Protein G column 
were separated on a 10 % SDS-gel. The Western blot shows either TNFwt-Fc (upper panel) or TNF60-Fc (lower panel) 
protein levels detected with anti-TNF antibodies. (B) Loss of membrane integrity was measured after 24 h of stimulation with 
either commercially available TNF (100 ng/mL) or 100 ng/mL TNFwt-Fc or TNF60-Fc in combination with  
20 µM (L929Ts) or 50 µM (U-937) zVAD-fmk using flow cytometry. Representative data show three parallel measurements 
and the experiment was repeated three times. Error bars indicate the SD from three parallel measurements. 
TNF-R1 is internalized upon induction of necroptosis 
Next, it was analyzed whether TNF-R1 internalization upon induction of necroptosis occurred in the 
same manner as after induction of apoptosis. For this purpose, U-937 cells were incubated with 
TNF60-Fc with (to induce necroptosis) or without zVAD-fmk (to induce apoptosis) either on ice to 
block endocytosis or at 37 °C for various time-points to permit internalization. After the time-points 
indicated in Figure 27A, cell surface-associated ligands were labeled and the fluorescence intensity 
was measured by flow cytometry. Increasing the temperature to 37 °C resulted in a decrease of 
fluorescence intensity first detected after 5 min and proceeding for up to 60 min (Figure 27A,B; 
apoptosis). Cells pre-incubated with zVAD-fmk also showed a loss of fluorescence intensity (Figure 
27A,B; necroptosis). To confirm that the loss of the fluorescence signal was due to the internalization 
of the TNF-R1, cells were incubated with TNF60-Fc/zVAD and an inhibitor of dynamin-dependent 
Results 
82 
 
endocytosis (dynasore). As shown in Figure 27C, the decrease in fluorescence intensity and therefore 
the internalization of TNF60-Fc was almost completely blocked by dynasore, confirming that TNF-R1 
is internalized during necroptosis. 
Figure 27: Determination of TNF-R1 internalization by flow cytometry. (A) U-937 cells were treated with 100 ng/mL 
TNF60-Fc without (induction of apoptosis) or with pre-treatment with 50 µM zVAD-fmk (to induce necroptosis). Cells were 
kept on ice (0 min; black) or internalization was induced by shifting the cells to 37 °C for 5, 10, 20 (red), 30 and 40 min 
(blue) of internalization. TNF-R1 remaining on the cell surface of U-937 cells was labeled using Protein G-Alexa Fluor® 
488. The fluorescence intensity was measured by flow cytometry. The graphs representing cells measured after 5, 10, 30, 50 
and 60 min are not shown for clarity of presentation. (B) The entire time kinetic was used for calculation of the 
internalization rate normalized to cells kept on ice (0 min). The graph compares the internalization rate of cells undergoing 
necroptosis (white bars) or apoptosis (black bars). (C) U-937 cells were pre-treated with 50 µM zVAD-fmk as above with or 
without 50 µM dynasore. Cells were subsequently treated with 100 ng/mL TNF60-Fc to induce necroptosis for 20 and 
40 min respectively. In all experiments, 10,000 cells were analysed for each measurement. One representative experiment out 
of four is shown. 
Subsequently, the internalization capacity of murine TNF-R1 after induction of necroptosis was 
analyzed in L929Ts cells by confocal microscopy. For this purpose, cells were labeled with 
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biotinylated TNF in combination with streptavidin Alexa Fluor® 488 and counterstained for the 
endosomal marker Ras-related protein 5 (Rab5). Of note, L929 cells die exclusively by regulated 
necrosis when treated with TNF (Vercammen et al. 1998a; Strelow et al. 2000; Thon et al. 2005), 
therefore, no addition of zVAD-fmk was required. Cells kept on ice (0 min) showed clear labeling of 
TNF-R1 on the cell surface, and no TNF-R1 appeared to be internalized. After 15 min incubation at 
37 °C and induction of necroptosis, a small fraction of Rab5-positive endocytic vesicles also contained 
labeled TNF-R1. The number of Rab5 positive, TNF-R1-containing vesicles increased further at later 
time-points (Figure 28), confirming the internalization of TNF-R1 during TNF-induced necroptosis. 
Figure 28: TNF-R1 is internalized upon induction of necroptosis. L929Ts cells were incubated with Biotin-TNF 
(100 ng/mL) in combination with streptavidin Alexa Fluor® 488 (green) at 37 °C for the indicated time-points. Subsequently, 
cells were stained with rabbit-α-Rab5 antibodies followed by Alexa Fluor® 555-donkey-α-rabbit antibodies to stain Rab5 
(red) and the nuclei was stained with DAPI (blue) as described in section 4.2.16.3. A co-localization is indicated by yellow 
staining and representative events were marked with white arrows. Scale bar: 100 µm. 
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Furthermore, the interaction of internalized TNF-R1 and RIPK1 as a crucial mediator of necroptosis 
was analyzed by intracellular co-localization studies. In L929Ts cells, RIPK1 was localized in the 
cytoplasm. After internalization of the TNF-R1 labeled with Biotin-TNF/streptavidin Alexa Fluor® 
488, intracellular co-localization with RIPK1 (10 min; Figure 29) was observed, suggesting that after 
internalization, the TNF-R1 gets in close contact to RIPK1 as a requirement for induction of 
necroptosis. 
Figure 29: Stimulation with TNF leads to co-localization of internalized TNF-R1 with RIPK1. L929Ts cells were 
stimulated with 100 ng/mL biotinylated TNF (Biotin-TNF) in combination with streptavidin Alexa Fluor® 488 (green) for 
10 min at 37 °C. Nuclei were stained with DAPI (blue) and RIPK1 was stained using mouse-α-RIPK1 antibodies and goat-α-
mouse Alexa Fluor®555 (red) as described in section 4.2.16.3. White arrows indicate intracellular co-localization which is 
indicated by yellow staining (merge). Scale bars: 10 µm. 
To investigate the localization of TNF-R1 after TNF-ligand induced necroptosis with the above 
described TNF-Fc ligands, L929Ts cells were labeled with TNFwt-Fc in combination with Protein G-
Alexa Fluor® 488. The internalization was performed in medium with the fluid phase marker TRITC-
Dextran to study endocytosed vesicles. Before internalization was started (0 min), cells showed clear 
labeling of TNF-R1 on the cell surface, and no TNF-R1 appeared to be internalized. After 
internalization was started (37 °C), simultaneous immunofluorescence detection of endocytic vesicles 
and TNF-R1 revealed a time-dependent appearance of TRITC-Dextran-labeled endocytic vesicles 
containing labeled TNF-R1 (Figure 30A). The observation of TRITC-Dextran vesicles containing 
labeled TNF-R1 confirmed that TNFwt-Fc treatment and thus induction of necroptosis leads to the 
internalization of murine TNF-R1 into endocytic vesicles. 
In U-937 cells, the simultaneous detection of endocytic vesicles (TRITC-Dextran positive) and labeled 
TNF-R1 was not possible because the labeling of cells with TRITC-Dextran revealed no signal. 
Nevertheless, before internalization was started (0 min), cells showed clear labeling of TNF-R1 on the 
cell surface. After internalization was started (37 °C), the intensity of labeled TNF-R1 was increased 
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within the cell (Figure 30B). These clusters of TNF-R1 were present already after 10 min of 
internalization and at later time-points, indicating that TNF-R1 is also internalized into endocytic 
vesicles in U-937 cells. 
The above results demonstrated the biological activity of the TNF-Fc ligands and that TNF-R1 is 
internalized upon induction of necroptosis into endocytic vesicles, providing the basis for subsequent 
isolation of the, necroptotic TNF-R1-containing vesicles with the described immuno-magnetic 
separation procedure, and thus for the identification of proteins recruited into or cleaved at the vicinity 
of the TNF-R1 during necroptosis.  
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Figure 30: Immunofluorescence of TNF-R1-localization. (A) L929Ts cells were pre-incubated with 20 µM zVAD-fmk for 
30 min and further 1 h with TNFwt-Fc/Protein G-Alexa Fluor® 488 (green) on ice. Cells were kept on ice (0 min) or 
internalization was induced by incubating cells at 37 °C in the presence of the fluid phase marker TRITC-Dextran (red) for 
the indicated time-points. White arrows indicate fusions of endocytosed vesicles with labeled TNF-R1 which is indicated by 
yellow staining (merge). (B) U-937 cells were pre-incubated with 50 µM zVAD-fmk for 30 min and followed by  
1 h incubation with TNF60-Fc/Protein G-Alexa Fluor® 488 (green) on ice. Cells were kept on ice (0 min) or internalization 
was induced by incubating cells at 37 °C in the presence of the fluid phase marker TRITC-Dextran for the indicated time-
points. The labeling of U-937 cells with TRITC-Dextran revealed no signal and is therefore not shown. Nuclei were stained 
with DAPI (blue). Scale bar: 10 µm. 
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Characterization of necroptotic TNF-R1-containing vesicles in L929Ts cells 
As a prerequisite for the identification of proteins cleaved during TNF-mediated necroptosis by 2D-
DIGE analysis, the magnetically isolated vesicles had first to be characterized at the protein level to 
confirm the successful enrichment of TNF-R1-containing vesicles. For this purpose, the TNF-R1 of 
L929Ts cells was labeled with TNFwt-Fc and magnetic Protein G-coupled micro-beads in the 
presence of zVAD-fmk on ice. TNF-R1 internalization was induced for 10 to 40 min and lysates were 
prepared as described in 4.2.15.4. Subsequently, the magnetic fractions containing potential 
internalized TNF-R1 vesicles were isolated, subjected to SDS-PAGE and analyzed by Western blot 
(Figure 31). As shown in Figure 31A, the commercially available antibody directed against human 
TNF-R1 detected the receptor in the fractions from murine cells only poorly. Since detection of TNF-
R1 is essential for quantification of the magnetic fractions, densitometry analyses were performed to 
quantify the enrichment of TNF-R1-containing vesicles (Figure 31A, lower panel). Western blot 
analysis additionally revealed that the adaptor protein RIPK1 was accumulated in the receptor 
containing vesicles after 10 min of internalization, in line with the necroptotic character of the TNF-
R1-containing vesicles. Moreover, vesicles from different time-points of TNF-R1 internalization 
contained the marker protein of early endosomes, Rab5, as well as the lysosome-associated membrane 
glycoprotein 1 (LAMP-1; Figure 31A), showing that the TNF-R1 was localized in multivesicular 
bodies. As an independent verification of these findings, Figure 31B shows a time kinetic of magnetic 
fractions prepared and measured by means of conventional Western blot which was performed by 
Vladimir Tchikov (Christian-Albrechts-University, Kiel, Germany). In this experiment, Western blot 
analysis of TNF-R1 demonstrated the successful enrichment of internalized magnetically labeled TNF-
R1-containing vesicles, because isolated magnetic fractions contained increasing amounts of Rab5 and 
accumulated the lysosomal protein LAMP-1 with increasing time. As shown in Figure 31B, TNF 
stimulation accumulated both RIPK1 and RIPK3 to the TNF-R1-containing magnetic vesicles with 
rapid and transient kinetics, as expected after the induction of necroptosis. Furthermore, no cleavage of 
caspase-7 and -8 was detected (Figure 31B), consistent with the fact that caspases are not activated 
(and thus not cleaved) during necroptosis. Due to consistently low protein yield during large scale 
isolation and enrichment of TNF-R1 magnetic fractions, 2D-DIGE analyses of magnetic TNF-R1-
containing vesicles from L929Ts cells were not conducted. 
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Figure 31: TNF-dependent accumulation of proteins to necroptotic TNF-R1 magnetic fractions. (A) Magnetic fractions 
harboring TNF-R1-containing vesicles were derived from L929Ts cells after stimulation with 100 ng/mL TNFwt-Fc for the 
indicated times. 3 µg of protein were immunoblotted for presence/accumulation of endogenous TNF-R1, RIPK1, as well as 
Rab5 and LAMP-1 as endosomal and lysosomal markers, respectively. Untreated protein cell extracts were used as control 
(lysate). A quantitative analysis of the x-fold accumulation of the above analyzed proteins is shown below. Values are 
normalized to 0 min. (B) In an independent experiment, the magnetic fractions were prepared and measured by means of 
conventional Western blot by Vladimir Tchikov (Christian-Albrechts-University, Kiel, Germany). Here, protein load was 
adjusted to achieve equal signal intensity of TNF-R1 and thus of equal amounts of TNF-R1-containing vesicles. The TNF-
R1-containing vesicles were immunoblotted for accumulation of endogenous RIPK1, RIPK3, as well as Rab5 and LAMP-1 
and presence of endogenous pro-caspase-7 and -8 and cleaved caspase-8. Asterisk: unspecific band. 
Characterization of necroptotic TNF-R1-containing vesicles in U-937 cells 
In addition to L929Ts cells, magnetic fractions from human U-937 cells were analyzed. To this end, 
TNF-R1-containing magnetic fractions were isolated by a two-step procedure including negative 
selection against mitochondria (described in Tchikov et al. 2014), to enhance the purity of the 
preparation. U-937 cells were pre-incubated with zVAD-fmk to inactivate caspases together with 
TNF60-Fc and Protein G-coupled micro beads for 1 h at 4 °C prior to internalization at 37 °C. 
Internalization was stopped immediately (0 min) or after 5 to 60 min. Preparation of mitochondria-free 
TNF-R1 magnetic fractions was performed with the help of Jürgen Fritsch (Christian-Albrechts-
University, Kiel, Germany). Isolated magnetic TNF-R1 complexes were analyzed by Western blot for 
signature proteins of distinct intracellular compartments. 
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Consistent with the above results from L929Ts cells, the protein Rab5 as a marker for early endosomes 
showed low expression levels at 0 min but was accumulated to the magnetic TNF receptor fractions at 
20 min and remained there up to 60 min (the latest time-point measured; Figure 32). The lysosome-
associated membrane protein LAMP-2 was detectable already at 0 min and showed increased protein 
levels after 20 min, indicating that the TNF-R1-containing vesicle fuse early with lysosomal 
compartments. Likewise, RIPK3 accumulated to the TNF-R1-containing vesicles at 20 min in parallel 
to increased Rab5 and LAMP-2 protein levels (Figure 32). As a consequence of the negative selection 
against mitochondria, the mitochondrial marker protein cytochrome c oxidase subunit 4 (COXIV) was 
not present in the magnetic fractions (Figure 32). 
Figure 32: TNF-dependent accumulation of proteins to the necroptotic TNF-R1 magnetic fractions isolated from U-
937 cells. Magnetic fractions harboring TNF-R1-containing vesicles were derived from U-937 cells after stimulation with 
100 ng/mL TNF60-Fc and 50 µM zVAD-fmk for the indicated times. A two-step procedure to separate contaminating 
mitochondria was performed as described in 4.2.15.4 and with technical assistance of Jürgen Fritsch (Christian-Albrechts-
University, Kiel, Germany). Subsequently, 3 µg of proteins were immunoblotted for presence/accumulation of endogenous 
TNF-R1, RIPK3, as well as Rab5, LAMP-2 and COXIV as endosomal, lysosomal and mitochondrial markers, respectively. 
Untreated protein cell extracts were used as control (lysate). A quantitative analysis of the x-fold accumulation of the above 
analyzed proteins is shown below. Values are normalized to protein levels at 0 min. 
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Proteome analysis of soluble proteins after induction of necroptosis 
To identify proteins differentially expressed or cleaved during TNF-induced necroptosis, a 2D-DIGE 
approach was used. This form of gel electrophoresis overcomes limitations in traditional 
electrophoresis because changes in protein abundance between untreated and treated samples can be 
compared simultaneously. In an initial experiment, all soluble proteins were extracted from U-937 
cells stimulated with TNF60-Fc and zVAD-fmk on ice (0 min) and 20 min at 37 °C. Protein extracts 
from cells stimulated for 20 min were labeled with the fluorescent dye Cy 3, and control extracts were 
labeled with the fluorescent dye Cy 5 and separated by 2D-PAGE. After gel electrophoresis, the gel 
was scanned and the detection of differentially labeled protein spots was performed using in silico 
analysis tools as described in 4.2.13. A total of 142 differentially expressed protein spots with at least 
1.2-fold increased or decreased protein levels were identified. The appropriate threshold was set and 
calculated by the utilized software. After 20 min of TNF60-Fc/zVAD stimulation, 77 (3.8 % of total 
spots) protein spots showed a higher expression, whereas 65 protein spots (3.2 % of total spots) 
showed a lower expression than in control cellular extracts. All differentially expressed protein spots 
were analyzed by means of MALDI-TOF/TOF, and 30 proteins were identified with high confidence. 
The identified proteins were classified based on their x-fold increased or decreased protein levels 
(Appendix Table S2). In the repetition of the above experiment, 89 differentially expressed protein 
spots were detected. For 29 protein spots (1.5 % of total spots) an increased expression after 20 min 
TNF/zVAD stimulation was detected whereas 60 proteins spots (3 % of total spots) showed decreased 
levels compared to untreated samples. 
Furthermore, comparing these two independent 2D-DIGE experiments, one protein, namely cofilin-1 
(CFL-1; P23528) was consistently found to be increased in cellular extracts isolated from cells treated 
for 20 min with TNF60-Fc/zVAD. Protein spots which were consistently decreased were tubulin 
alpha-1B chain (TUBA1B; P68363) and pyruvate kinase isozymes M1/M2 (PKM; P14618). Several 
proteins were found to have inconsistently increased or decreased protein levels in the two 
experiments. These include stathmin (STMN1; P16949), heterogeneous nuclear ribonucleoprotein K 
(HNRNPK; P61978), cAMP-dependent protein kinase type II-alpha regulatory subunit (PKR2; 
P13861), heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1; P22626) and A1 
(HNRNPA1; P09651), Rho GDP-dissociation inhibitor 2 (GDIA2; P52566) and heat shock protein 
beta-1 (HSPB1; P04792). The proteins HSPB1, HNRPK and PKM showed alterations in their 
isoelectric points, possibly a result of post-translational modification or the presence of different 
isozyme species. 
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As the most promising candidate, although having inconsistently increased or decreased protein levels 
in the two experiments, the protein stathmin was identified in one experiment in two distinct protein 
spots of different molecular weight. One of the spots had a molecular weight corresponding to the 
predicted molecular weight of the full-length protein whereas the other spot had a smaller molecular 
weight (Figure 33; Table S2), pointing to a possible proteolytic cleavage during necroptosis. 
Figure 33: Stathmin was identified by 2D-DIGE analysis and is potentially cleaved during TNF-induced necroptosis. 
Example of the protein stathmin identified in two spots with different mass potentially indicating proteolytic cleavage events. 
3D views of stathmin are shown (individual spots marked by a violet boundary; average ratio of expression in brackets). The 
2D-DIGE experiment was performed with technical assistance of Melanie Nebendahl and Benjamin Schönbeck (Christian-
Albrechts-University, Kiel, Germany). The mass spectrometry analysis of isolated proteins was performed by Tomas 
Koudelka (Christian-Albrechts-University, Kiel, Germany). 
Proteome analysis of isolated TNF-R1-containing vesicles after induction of 
necroptosis 
To identify additional candidate proteins that are cleaved in U-937 cells after induction of necroptosis 
with TNF60-Fc/zVAD, a second 2D-DIGE approach was carried out, this time with enriched magnetic 
TNF-R1-containing vesicles to enrich and identify proteins accumulated into or cleaved merely at the 
vicinity of the TNF-R1. For this purpose, in a first experiment, magnetically enriched TNF-R1-
containing vesicles of U-937 cells stimulated with TNF60-Fc/zVAD for 0 and 20 min were isolated 
without depletion of mitochondria and compared by 2D-DIGE as described above for soluble proteins. 
An initial Western blot of total cell lysates, magnetic TNF-R1 fractions and the remaining non-
magnetic flow through showed increased protein levels of the marker proteins Rab5 and LAMP-1 in 
the magnetic fraction, demonstrating the successful enrichment of TNF-R1 endocytic vesicles  
(Figure 34). Furthermore, no caspase-7 was detected in TNF-R1 magnetic fractions, but caspase-7 was 
detected in the non-magnetic flow through, consistent with the fact that caspases are not activated and 
thus not recruited to the TNF-R1 during necroptosis. The lipase A-SMase was shown to be involved in 
necroptosis (Thon et al. 2005) and therefore, the presence of cleaved and thus activated A-SMase was 
also investigated. However, cleaved A-SMase was not found in the TNF-R1 magnetic fractions 
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(Figure 34) but in the non-magnetic flow through, suggesting that A-SMase is not a part of the TNF-
R1 signaling complex in necroptosis. 
Figure 34: Characterization of magnetically isolated TNF-R1-containing vesicles prior to 2D-DIGE analysis. Magnetic 
fractions harboring TNF-R1-containing vesicles were derived from U-937 cells after stimulation with 100 ng/mL TNF60-Fc 
and 50 µM zVAD-fmk on ice (0 min) or for 20 min at 37 °C. Subsequently, 3 µg of protein of each magnetic fraction were 
immunoblotted for presence/accumulation of endogenous TNF-R1, Rab5, LAMP-1, pro caspase-7 and cleaved A-SMase. 
Rab5 and LAMP-1 were detected as endosomal and lysosomal marker, respectively. Untreated protein cell extracts were used 
as control (lysate). The non-magnetic flow-through was also analyzed. 
In the subsequent 2D-DIGE analysis, 252 differentially expressed protein spots with at least 1.2-fold 
increased or decreased protein levels were identified. Protein spots which showed decreased/increased 
intensities of either Cy 3 or Cy 5 (Figure 35) were analyzed by MALDI-TOF/TOF. The mass 
spectrometric analysis identified 21 proteins with increased and 25 with decreased protein levels in the 
fraction of U-937 cells treated with TNF60-Fc/zVAD for 20 min (Table S3). The protein moesin 
(MSN; P26038) was identified as differentially expressed in magnetic TNF-R1 fractions of both 
experiments and one of the spots analyzed had a molecular weight smaller than the theoretical 
molecular weight of the full length protein (Figure 35), suggesting that moesin is cleaved during 
induction of necroptosis. 
A search of the Swissprot database revealed that 27 % of the identified proteins were of mitochondrial 
origin, indicating that the membranes contained in the magnetic fractions might form contact sites with 
mitochondria and thereby interact with each other. The resulting heterogeneous membrane fractions 
might interfere with the identification of non-mitochondrial regulated candidate proteins of lower 
protein abundance. Therefore, prior to a new 2D-DIGE experiment, the magnetic TNF-R1 fractions 
were subjected to density-gradient centrifugation to avoid mitochondria contaminations (with 
technical assistance of Jürgen Fritsch, Christian-Albrechts-University, Kiel, Germany). A Western blot 
analysis of the TNF-R1/zVAD magnetic fractions was performed to validate the purity of the 
preparations and showed no mitochondrial protein COXIV expression (Figure 36A). The mitochondria 
free preparations were also subjected to 2D-DIGE analysis as described above. The 2D-DIGE analysis 
resulted in 112 spots with differentially expressed proteins. The spots with at least 1.5-fold increased 
or decreased protein levels were identified (Figure 36B). The protein spots were again analyzed by 
MALDI-TOF/TOF. The mass spectrometric analysis identified 6 proteins with increased  
Results 
93 
 
and 4 proteins with decreased levels in the fraction containing TNF-R1 vesicles which were isolated 
from cells stimulated with TNF60-Fc/zVAD for 20 min (Table S3). 
Comparing these two different 2D-DIGE experiments (Figure 35 and 36B; Table S3), two 
dehydrogenases (inosine-5’-monophosphate dehydrogenase 2 (IMPDH2; P12268) & D-3-
phosphoglycerate dehydrogenase (PHGDH; O43175)) were consistently found to be increased in 
TNF-R1 fractions isolated from cells treated 20 min with TNF60-Fc/zVAD. The peroxisome enzyme 
catalase (CAT; P04040) showed lower expression in both 2D-DIGE experiments (Table S3). Protein-
disulfide-isomerase A6 (PDIA6; Q15084) and alpha-enolase (ENO1; P06733) showed differential 
expression patterns in the two independent 2D-DIGE experiments, possibly due to inter-gel variations. 
The protein spots of ENO1 showed alterations in their isoelectric points, possibly a result of post-
translational modification or the presence of different isozyme species. The above identified proteins 
are involved in either regulating the energy metabolism of a cell (IMPDH2, PHGDH, PDIA6, CAT) or 
they are components of the cytoskeleton (ENO1, MSN), suggesting that during necroptosis, a change 
in the energy metabolism as well as a reorganization of the cytoskeleton occurs. 
Figure 35: 2D gel and examples of spots identified after TNF60-Fc/zVAD stimulation in isolated TNF-R1 magnetic 
fractions. Left panel: 2D gel analysis of magnetic fractions harboring TNF-R1-containing vesicles were derived from U-937 
cells after stimulation with 100 ng/mL TNF60-Fc and 50 µM zVAD-fmk on ice (0 min, labeled with Cy 5, red) or for 20 min 
(labeled with Cy 3, green) at 37 °C. The threshold was set to 1.2 (change in protein expression). Similar protein spots (yellow 
in the overlay): 1189 (82.5 %), increased protein spots (green): 149 (10.3 %) and decreased protein spots (red): 103 (7 %). 
Differentially expressed proteins were isolated and analyzed by mass spectrometry. The white square indicates the position of 
the enlarged pictures on the right. Right panel: Example of the protein moesin identified in two spots with different mass 
potentially indicating proteolytic cleavage events. 3D views of Moesin are shown (individual spots marked by a violet 
boundary; average ratio of expression in brackets). The 2D-DIGE experiment was performed with technical assistance of 
Melanie Nebendahl and Benjamin Schönbeck (Christian-Albrechts-University, Kiel, Germany). The mass spectrometry 
analysis of isolated proteins was performed by Tomas Koudelka (Christian-Albrechts-University, Kiel, Germany). 
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Figure 36: Western blot of mitochondria-free necroptotic TNF-R1 magnetic and non-magnetic fractions and 2D-
DIGE analysis of the magnetic fractions. (A) Magnetic fractions harboring TNF-R1-containing vesicles were derived from 
U-937 cells after stimulation with 100 ng/mL TNF60-Fc and 50 µM zVAD-fmk on ice (0 min) or for 20 min at 37 °C. A two-
step procedure to remove contaminating mitochondria was performed as described in 4.2.15.4 and with technical assistance 
of Jürgen Fritsch (Christian-Albrechts-University, Kiel, Germany). Subsequently, 3 µg of proteins of each magnetic fraction 
were immunoblotted for presence/accumulation of endogenous TNF-R1, LAMP-1, and COXIV. LAMP-1 and COXIV were 
detected as lysosomal or mitochondrial marker, respectively. Untreated protein cell extracts were used as control (lysate). The 
non-magnetic flow-through was analyzed in parallel. (B) 2D gel analysis of magnetic fractions harboring TNF-R1-containing 
vesicles were derived from U-937 cells after stimulation with 100 ng/mL TNF60-Fc and 50 µM zVAD-fmk on ice (0 min, 
labeled with Cy 5, red) or for 20 min (labeled with Cy 3, green) at 37 °C. A two-step procedure to remove contaminating 
mitochondria was performed as described in 4.2.15.4 and with technical assistance of Jürgen Fritsch (Christian-Albrechts 
University, Kiel, Germany). The threshold was set to 1.5 (change in protein expression). Similar protein spots (yellow):  
1116 (90.9 %), increased protein spots (green): 57 (4.6 %) and decreased protein spots (red): 55 (4.5 %). Differentially 
expressed proteins were isolated and analyzed for their origin by mass spectrometry. The 2D-DIGE experiment was 
performed with technical assistance of Melanie Nebendahl and Benjamin Schönbeck (Christian-Albrechts-University, Kiel, 
Germany). The mass spectrometry analysis of isolated proteins was performed by Tomas Koudelka (Christian-Albrechts-
University, Kiel, Germany). 
All proteins identified in this study are listed in the appendix (Table S2 and S3). 
Conclusion: Proteins are differentially expressed and cleaved during the execution of 
necroptosis 
Taken together, the 2D-DIGE analysis of soluble proteins and magnetically enriched TNF-R1-
containing vesicles identified new proteins with a possible participation in the proteolytic regulation of 
necroptosis. The analysis resulted in differentially expressed proteins (TUBA1B, PKM, CFL-1, 
IMPDH2, PHGDH, CAT) whose up- or down-regulation results in the regulation or breakdown of the 
energy metabolism during necrotic cell death. Furthermore, components of the cytoskeleton (MSN, 
STMN1) were identified as possible substrate proteins for proteolytic cleavage, suggesting a 
proteolytically induced reorganization of the cytoskeleton during necroptosis. 
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5.2.4 The potentially pro-necroptotic protein PGAM5 is constitutively degraded in 
healthy cells 
Necroptosis critically relies on the signaling molecule mixed lineage kinase domain-like (MLKL; Sun 
et al. 2012, Wu et al. 2013). It was proposed that MLKL promotes regulated necrosis upon 
phosphorylation by RIPK3 by PGAM5 and Drp-1, leading to mitochondrial fragmentation (Wang et 
al. 2012). To clarify whether the proteins MLKL, PGAM5 and Drp-1 are also involved in TNF-
induced necroptosis, the murine cell line L929Ts and the human cell line HT-29 were analyzed after 
down-regulation of the above mentioned proteins by RNAi. Down-regulation of PGAM5 and Drp-1 
had no effect on TNF-induced necroptosis although protein expression was clearly decreased in 
Western blots (Figure 37). In contrast, the down-regulation of MLKL reduced TNF-induced necrotic 
cell death, although the down-regulation could not be confirmed by Western blot due to specificity 
problems of the antibody used for this experiment. In summary, the results shown in Figure 37 
identified MLKL as a mediator of TNF-induced necroptosis. This is in line with recent studies 
(Galluzzi et al. 2014b). Based upon the obtained results, an essential role of Drp-1 and PGAM5 in 
necroptosis could not yet be confirmed. As one possible explanation, the reduction of PGAM5 and 
Drp-1 protein levels may have been insufficient to affect TNF-induced necroptosis. 
Figure 37: MLKL is a mediator of TNF-induced necroptosis. Left panel: HT-29 and L929Ts cells were transfected with 
siRNAs specific for human or murine PGAM5, Drp-1 and MLKL, respectively. As a negative control, cells were transfected 
with non-targeting siRNA. After 24 h (L929Ts) or 72 h (HT-29) of transfection, cells were left untreated or were incubated 
with 100 ng/mL TNF in combination with 20 µM (L929Ts) or 50 µM (HT-29) zVAD-fmk and 5 µg/mL (HT-29) CHX. After 
5 h (L929Ts) or 20 h (HT-29), necroptosis was analyzed by measuring the decrease of intracellular ATP levels as a marker 
for cell death. ATP levels are shown relative to control-transfected cells. Error bars indicate the SD from five parallel 
determinations. Right panel: Control Western blots of transfected but untreated cells were performed to verify down-
regulation of the endogenous protein levels. Detection of actin served as a loading control. 
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Wang and coworkers (2012) suggested that upon phosphorylation of MLKL by RIPK3, the long splice 
variant PGAM5L binds to the necrosome followed by binding of the short form of PGAM5 
(PGAM5S). Furthermore, they proposed that PGAM5L might be proteolyzed before binding to 
PGAM5S which then leads to a possible dephosphorylation and activation of Drp-1 and subsequent 
mitochondrial fragmentation (Wang et al. 2012). To further study a possible role of PGAM5 in TNF-
induced necroptosis in cells with strong expression of PGAM5, L929Ts cells were stably transfected 
with a PGAM5-FLAG construct. After induction of cell death by TNF/zVAD, all stably transfected 
clones showed similar cell death rates, when compared to wild-type L929Ts cells (Figure 38). The 
treatment with TNF/zVAD/Nec-1 blocked cell death in all clones, confirming the induction of 
necroptosis. In Western blots, the strongest PGAM5-FLAG expression was detected in clones B11 and 
C47. Therefore, clone C47 (further named L929Ts PGAM5-FLAG cells) was used for all further 
experiments which aimed to characterize the role of PGAM5 in necroptosis. 
Figure 38: L929Ts cell lines overexpressing PGAM5-FLAG. Left panel: Five different L929Ts cell lines from isolated 
cell clones harboring and expressing the protein PGAM5 coupled to a FLAG tag were treated with 20 µM zVAD-fmk alone 
or in combination with 100 ng/mL TNF as well as 50 µM necrostatin 1 (Nec-1) for 5 h and loss of membrane integrity was 
compared to non-transfected wild-type L929Ts cells. One out of two experiments is shown. Error bars show the SD of three 
parallel measurements of 10,000 cells each. Right panel: Western blot of the stably transfected L929Ts cell clones, wild-
type L929Ts and a positive control (HEK293 cells transient over-expressing PGAM5-FLAG (pos.)) shows the expression of 
PGAM5-FLAG either detected with anti-FLAG or anti-PAGM5 antibodies at 35 kDa. Detection of actin served as a loading 
control. Asterisk: nonspecific band. 
Time kinetics of PGAM5 expression during necroptosis of wild-type L929Ts cells and L929Ts 
PGAM5-FLAG cells showed that both endogenous and overexpressed PGAM5-FLAG protein levels 
increased upon induction of necroptosis with TNF/zVAD (Figure 39A). This observation clearly 
demonstrated that the increased expression of PGAM5 is not due to transcriptional or translational 
modifications because expression of PGAM5-FLAG relies on a different promoter than the 
endogenous PGAM5 gene. Rather, the increase of PGAM5 protein levels is possibly caused by an 
inhibition of proteolysis. This possible regulation of PGAM5 by proteases was substantiated by the 
observation that increased levels of PGAM5 were observed when cells were treated with a protease 
inhibitor cocktail alone or in combination with zVAD-fmk to avoid unspecific activation of caspases 
by the inhibitors (Figure 39B). The treatment of cells with the proteasome inhibitor MG-132 and 
zVAD also showed increased PGAM5 levels in Western blots (Figure 39B). This suggests a 
constitutive degradation of the potentially pro-necroptotic protein PGAM5 by unknown proteases in 
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healthy cells, which is blocked upon induction of necroptosis (elevating PGAM5 levels and thus 
possibly facilitating mitochondrial fragmentation). Consistent with this assumption, the TNF/zVAD-
induced increase of PGAM5 was diminished when necroptosis was blocked by Nec-1 (Figure 39B). 
Induction of apoptosis (TNF/CHX treatment) resulted also in an increase of PGAM5 levels indicating 
similar mechanism of the inhibition of the constitutive degradation of PGAM5 after induction of 
apoptosis (Figure 39B). To further narrow down possible protease candidates involved in the 
constitutive degradation of PGAM5, cells were treated with serine protease inhibitors (AEBSF and 
TFCK; Figure 39C) alone or in combination with zVAD-fmk. Western blots of PGAM5 revealed a 
similar increase in PGAM5 protein levels when serine protease as well as caspase activity was 
inhibited. Since the mitochondrial serine protease HtrA2/Omi was shown to be crucial for TNF-
induced necroptosis, PGAM5 expression was also analyzed in the presence of the HtrA2/Omi inhibitor 
Ucf-101 alone or in combination with zVAD-fmk. Western blot analysis revealed a similar increase in 
PGAM5 protein levels when HtrA2/Omi was inhibited by Ucf-101 or Ucf-101/zVAD as in 
TNF/zVAD-treated cellular extracts (Figure 39C), indicating that HtrA2/Omi might be a potential 
physiological regulator of PGAM5. 
 
Results 
98 
 
Figure 39: Serine proteases (HtrA2/Omi) and the proteasome are physiological regulators of PGAM5. (A) L929Ts 
wild-type cells and cells stably expressing the protein PGAM5 coupled to a Flag tag were treated with 100 ng/mL TNF and 
20 µM zVAD-fmk for the indicated time-points. Western blots show the expression of PGAM5-FLAG and PGAM5 at 
35 kDa. (B) L929Ts PGAM5-FLAG cells were left untreated or treated as above for 4 h with TNF/zVAD, TNF/zVAD and 
50 µM necrostatin 1 (Nec-1) or TNF and 2 µg/mL CHX. Furthermore, cells were treated for 24 h with either 20 µM zVAD-
fmk alone, 10 µg/mL protease inhibitor cocktail (protease inh.), with a combination of zVAD and protease inhibitor cocktail, 
or the proteasome inhibitor MG-132 (50 µM) in combination with zVAD-fmk. (C) L929Ts PGAM5-Flag cells were left 
untreated or were treated with zVAD or TNF/zVAD as in (B). Stimulation with 100 µM AEBSF/(zVAD), 50 µM 
TFCK/(zVAD), or 50 µM Ucf-101/(zVAD) was stopped after 24 h. Western blots of cellular extracts were performed using 
anti-FLAG and anti-PGAM5 antibodies. Expression of actin served as a loading control. Asterisk: unspecific band. 
Conclusion: Serine proteases (e.g. HtrA2/Omi) and the proteasome are physiological 
regulators of PGAM5 
In the study presented here, it could be demonstrated that the potentially pro-necroptotic protein 
PGAM5 is constitutively degraded by yet unknown proteases in healthy cells. The levels of both 
endogenous and overexpressed PGAM5 increased upon induction of necroptosis. A similar increase in 
PGAM5 levels was induced by treatment of cells with protease inhibitors such as AEBSF, TFCK and 
MG-132, pointing to serine proteases and the proteasome as physiological regulators of PGAM5. 
Moreover, Ucf-101-treated cells also showed increased PGAM5 levels, suggesting that HtrA2/Omi 
may be involved in the constitutive degradation of PGAM5 in healthy cells. Furthermore, the 
important role of MLKL during necroptosis could be confirmed and was further analyzed during 
TRAIL-induced regulated necrosis in clinically relevant tumor cell lines (see 5.3). 
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5.2.5 Acid sphingomyelinase is proteolytically activated during TNF-induced 
necroptosis 
Activation of A-SMase by TNF/zVAD correlates with the appearance of a 57-kDa 
proteolytic cleavage fragment in L929Ts cells 
Unlike in apoptosis, where caspase-7 and -8 are responsible for the activation of A-SMase (Edelmann 
et al. 2011), the proteolytic maturation and activation of A-SMase in necroptosis must by definition 
occur in a caspase-independent manner and must therefore be mediated by distinct non-caspase 
proteases. In an initial experiment, murine L929Ts, NIH3T3 and human Jurkat I42 and U-937 cells 
were stimulated with TNF/zVAD to induce necroptosis. Afterwards, cells were immediately placed on 
ice and cellular extracts from each time-point were prepared and analyzed for their levels of 
endogenous A-SMase protein (Figure 40A). As a limitation of the analysis, commercially available 
antibodies for A-SMase were only able to detect an A-SMase fragment of approximately 57 kDa 
which corresponds to the cleaved, active form of A-SMase (Ferlinz et al. 1994). Western blot analysis 
revealed a time-dependent increase of the active A-SMase fragment in L929Ts cells (Figure 40A), 
providing first hints that A-SMase cleavage may also occur during necroptosis. Treatment of NIH3T3, 
Jurkat I42 and U-937 cells with TNF/zVAD, showed also effects on endogenous cleaved A-SMase 
levels (Figure 40A), confirming that A-SMase cleavage occurs during necroptosis in a cell-type 
unrelated manner. 
In order to test whether this detected 57-kDa A-SMase fragment was derived from proteolytic 
cleavage of the 72 kDa A-SMase pro-form, murine L929Ts cells were stably transfected with a 
construct coding for a V5-tagged version of the full-length A-SMase. Figure 40B shows that 
overexpression of A-SMase had no positive or negative impact on TNF/zVAD-induced necroptosis. 
Furthermore, stimulation of stably transfected L929Ts cells with TNF/zVAD also revealed a time-
dependent processing of overexpressed A-SMase (72 kDa) to a cleaved 57-kDa form in Western blots 
(Figure 40B). 
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Figure 40: A-SMase is cleaved after TNF/zVAD stimulation. (A) Cells were incubated with 100 ng/mL TNF and 20 µM 
(L929Ts, NIH3T3) or 50 µM (Jurkat I42, U-937) zVAD-fmk on ice and stimulation was stopped immediately (0 min) 
(control) or were stimulated at 37 °C for the indicated time-points. Cell lysates were analyzed for endogenous A-SMase by 
means of Western blot using anti-A-SMase antibodies, which however only recognize the 57-kDa A-SMase cleavage 
product. (B) Left panel: Untransfected and L929Ts cells expressing recombinant V5-A-SMase were stimulated with 
100 ng/mL TNF and 20 µM or in combination with 50 µM necrostatin 1 (Nec-1, to inhibit necroptosis) for 5 h before loss of 
membrane integrity was measured by flow cytometry. 10,000 cells were analyzed in triplicates. The error bars show SD from 
one out of three independent experiments. Right panel: Cells were stimulated as in (A) and a Western blot was performed 
using anti-V5 antibodies, detecting pro-A-SMase-V5 at 72 kDa and the cleavage product of A-SMase-V5 at 57 kDa. Actin 
served as a loading control. 
To analyze if the appearance of the cleaved fragment of overexpressed as well as endogenous A-
SMase was an indicator for activation of A-SMase, cell lysates were analyzed in parallel by Western 
blot for A-SMase cleavage and for A-SMase activity. In stably transfected (V5-A-SMase L929Ts 
cells) as well as untransfected L929Ts cells, induction of necroptosis with TNF/zVAD led to a time-
dependent processing of either overexpressed A-SMase or endogenous pro-A-SMase to a 57-kDa 
fragment (Figure 41; upper panel), which was accompanied by a corresponding increase in enzymatic 
activity (Figure 41, lower panel), suggesting that the proteolytic cleavage after induction of 
necroptosis results in the activation of the A-SMase. 
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Figure 41: Proteolytic activation of A-SMase in necroptosis. V5-A-SMase L929Ts cells (left) or untransfected L929Ts 
cells (right) were treated with TNF/zVAD to induce necroptosis for the indicated time-points. The upper panels show anti-
V5 Western blots for both tagged full length form (pro-A-SMase) and the cleaved active A-SMase form (left). Parallel 
Western blot of endogenous A-SMase from untransfected L929Ts cells showed only the cleaved, active form of endogenous 
A-SMase at 57 kDa (right). Lower panels: In parallel, A-SMase activity was measured. The data shown were obtained from 
three experiments each performed in triplicates. Error bars show the respective SD. Protein levels from one representative out 
of three experiments are shown. A-SMase activity measurements were performed by Supandi Winoto-Morbach (Christian-
Albrechts-University, Kiel, Germany). 
Treatment of untransfected L929Ts cells with Nec-1, Arc39 (an A-SMase-specific inhibitor; Roth et 
al. 2009; Samapati et al. 2012), as well as with TFCK inhibited the proteolytic processing as well as 
the activation of A-SMase during necroptosis (Figure 42). 
Figure 42: TNF/zVAD-induced A-SMase cleavage and activation occurs downstream of RIPK1. L929Ts cells were 
stimulated with TNF/zVAD or in combination with 50 µM necrostatin-1 (Nec-1), 10 µM Arc39 or 50 µM TFCK for the 
indicated time-points. Cell lysates were analyzed for A-SMase activity using N-methyl-[14C]-sphingomyelin as substrate. 
Data were obtained from four independent experiments performed in triplicates. Error bars show SD. The same lysates were 
analyzed for endogenous cleaved A-SMase protein levels by Western blots. Western blots were performed to detect the 
cleaved, active A-SMase at 57 kDa. Detection of actin served as a loading control. Protein levels from one representative out 
of four experiments are shown. A-SMase activity measurements were performed by Supandi Winoto-Morbach (Christian-
Albrechts-University, Kiel, Germany). 
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In further experiments to extend the inhibitor repertoire, L929Ts cells were treated with NSA, a 
pharmacological inhibitor of MLKL (Wu et al. 2013), or with the internalization inhibitor dynasore in 
combination with TNF/zVAD. Both inhibitors fully blocked the activation of A-SMase. Parallel 
Western blots to detect the active, cleaved A-SMase product revealed an inhomogeneous distribution 
pattern (Figure 43). To rule out that this was due to the solvent the inhibitors were dissolved in, cells 
were treated with TNF/zVAD in combination with DMSO. As shown in Figure 43, treatment with 
DMSO had no impact on TNF/zVAD-induced A-SMase activity as well as on the cleavage pattern of 
A-SMase when compared to protein extracts from cells treated with TNF/zVAD alone. This 
observation led to the assumption that the inhomogeneous distribution pattern of cleaved A-SMase in 
extracts from cells treated with NSA or with the internalization inhibitor dynasore in combination with 
TNF/zVAD is not due to the solvent of the inhibitor but is rather a direct effect of the inhibitors used. 
In summary, the obtained results suggest that A-SMase is activated downstream of the internalization 
of the TNF-R1 and downstream of the RIPK1-RIPK3-MLKL complex. Furthermore, the blockage of 
A-SMase activity after treatment with TFCK suggests the possible involvement of serine proteases in 
the regulation of A-SMase activity. 
Figure 43: A-SMase cleavage and activation in L929Ts cells occurs downstream of MLKL and is inhibited by 
dynasore. L929Ts cells were stimulated with TNF/zVAD alone or in combination with 50 µM dynasore or  
1 µM necrosulfonamide (NSA) or 5 µL DMSO (as solvent control) for 0 to 120 min. Cell lysates were analyzed for A-SMase 
activity. Error bars show standard deviations. The same lysates were analyzed for endogenous A-SMase expression. Western 
blots were performed using anti-A-SMase antibodies, detecting the cleaved, active A-SMase at 57 kDa. Protein levels from 
one representative out of two (TNF/zVAD/DMSO), three /TNF/zVAD/NSA) or four (TNF/zVAD and TNF/zVAD/dynasore) 
experiments are shown. A-SMase activity measurements were performed by Supandi Winoto-Morbach (Christian-Albrechts-
University, Kiel, Germany). 
The effector caspase-7 directly interacts with and mediates A-SMase activation during apoptosis 
(Edelmann et al. 2011). To investigate whether caspase-7 has an impact on necroptosis-induced 
proteolytic cleavage and activation of A-SMase, caspase-7 deficient MEFs and wild-type MEFs were 
characterized for A-SMase cleavage and activity under necroptotic conditions. MEFs were incubated 
with TNF/zVAD/CHX to induce necroptosis and as a control with TNF/CHX to induce apoptosis. 
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Treatment with TNF/zVAD/CHX revealed increased sensitivity of MEFs devoid of caspase-7 
compared to wild-type cells. Addition of Nec-1 decreased cell death rates, confirming that 
TNF/zVAD/CHX induces necroptosis in these MEFs (Figure 44A). Furthermore, the results obtained 
showed increased cell death rates of MEFs deficient in caspase-7 compared to their wild-type 
counterparts after induction of apoptosis (TNF/CHX), suggesting that MEFs devoid of caspase-7 a 
generally more sensitive towards cell death. In contrast to L929Ts cells treated with TNF/zVAD (see 
Figures 41, 42, 43) and to wild-type MEFs (Figure 44B), MEFs deficient of caspase-7 did not show an 
increase of A-SMase activity in response to induction of necroptosis (Figure 44B). However, Western 
blot analysis showed increased protein levels of cleaved A-SMase after induction of necroptosis in 
wild-type MEFs whereas only a marginal cleavage of A-SMase was detectable in MEFs deficient in 
caspase-7 (Figure 44C). These observations suggest that the presence of caspase-7 protein might be 
needed for activation of A-SMase during TNF-induced necroptosis and that the caspase-7-deficient 
MEFs utilized in this study might undergo TNF-induced necroptosis via additional effector 
mechanisms independent from A-SMase activation and subsequent ceramide generation. 
Figure 44: A-SMase activity after TNF-induced necroptosis in wild-type and caspase-7 deficient MEFs. (A) Left 
panel: Wild-type MEFs (Caspase-7 +/+) and MEFs devoid of caspase-7 (Caspase-7-/-) were treated with 100 ng/mL TNF and 
1 µg/mL CHX (to induce apoptosis) or in combination with 20 µM zVAD-fmk (to induce necroptosis) for 16 h before loss of 
membrane integrity was measured by PI staining and flow cytometry. 10,000 cells were analyzed for each measurement. One 
out of three experiments is shown. Error bars show the SD from triplicate measurements. Right panel: Western blot to detect 
full length caspase-7 in cellular extracts of wild-type MEFs and caspase-7-/- MEFs. (B) Wild-type MEFs or caspase-7 
deficient MEFs treated with 100 ng/mL TNF, 20 µM zVAD-fmk and 1 µg/mL CHX for 16 h were analyzed for A-SMase 
activity. A-SMase activity measurements were performed by Supandi Winoto-Morbach (Christian-Albrechts-University, 
Kiel, Germany). (C) The same lysates were analyzed for endogenous A-SMase protein levels. Western blots were performed 
using anti-A-SMase antibodies, detecting the cleaved, active A-SMase at 57 kDa. Protein levels from one out of three 
experiments are shown. Detection of actin served as a loading control. 
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Characterization of the 57 kDa A-SMase cleavage product 
To define the proteolytic cleavage site where A-SMase is processed from its precursor to the 57-kDa 
active form, L929Ts cells overexpressing a fusion protein of pro-A-SMase (72 kDa) and the V5 tag 
(2 kDa), pretreated over night with zVAD-fmk to prevent any apoptotic cleavage of A-SMase, were 
stimulated with TNF/zVAD for 30 min to induce necroptosis and processing of A-SMase. 
Unprocessed and processed V5-tagged A-SMase was enriched by immunoprecipitation and lysates 
were separated by SDS-PAGE following Western blots. As shown in Figure 45, there was an 
enrichment of V5-A-SMase protein after immunoprecipitation of A-SMase with its V5-tag. Moreover, 
processed (59 kDa) fragments as well as unprocessed (74 kDa), full-length V5-A-SMase were clearly 
visible. This cleaved 59-kDa protein corresponds to the 57-kDa active A-SMase molecule after 
subtraction of the 2-kDa V5-tag. 
Figure 45: Enrichment of full-length and processed V5-A-SMase. L929Ts cells stably transfected with V5-tagged  
A-SMase were lysed and anti-V5 or anti-RACK antibodies (as a control for specificity, bead control) were used for 
immunoprecipitation (IP). Western blot was performed using anti-V5 antibodies detecting V5-tagged full-length V5-A-
SMase and processed V5-A-SMase fragment (left). As an additional control, V5-A-SMase was also detected in total cell 
lysates. 
To further analyze full-length and processed V5-A-SMase, preparative SDS-gels were loaded with 
immunoprecipitated A-SMase fragments and stained with Flamingo™ Fluorescent gel stain. In 
collaboration with the group of Andreas Tholey (Christian-Albrechts-University, Kiel, Germany) the 
bands corresponding in size to full-length and processed V5-A-SMase were isolated and half of the 
samples were labeled at their N-termini and the other half was left un-labeled. All samples were then 
digested with trypsin and analyzed by means of LC-MS/MS (see 4.2.15.2). Since the N-terminus of 
full-length and processed V5-A-SMase was labeled before digestion with trypsin, peptides identified 
with a labeling can be considered as peptides starting from the N-terminus of either full-length or 
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processed V5-A-SMase. The analyses of extracted V5-A-SMase fragments identified the N-terminus 
of full-length V5-A-SMase with the N-terminus being at A(59)/(60)H (Figure 46; red box). No labeled 
peptides were identified for processed V5-A-SMase products in this first set of experiments (Figure 
46). However, one unlabeled peptide was identified for cleaved A-SMase starting at the proline at 
position P(219)/(220)D, providing evidence that A-SMase is cleaved N-terminal to the site identified 
for cleavage of A-SMase in apoptosis (residue C(250)/(251)D (D253; Edelmann et al. 2011)). 
Figure 46: Sequence coverage of full-length and processed A-SMase during TNF-induced necroptosis. Left panel: 
L929Ts cells stably transfected with V5-tagged A-SMase were treated for 30 min with 100 ng/mL TNF in combination with 
20 µM zVAD-fmk to induce necroptosis. Subsequently, cells were lysed and anti-V5 antibodies were used for 
immunoprecipitation of V5-A-SMase. An SDS-PAGE gel was used for separation of immunoprecipitated proteins (which 
were loaded in five parallel lanes). The gel was stained with Flamingo™ Fluorescent gel stain to visualize protein bands. 
Bands at 74 kDa and 59 kDa were excised and combined, respectively. Right panel: The sequence coverage of full-length 
(pro-A-SMase, upper part) and processed (cleaved A-SMase; lower part) V5-A-SMase is shown. Half of the excised material 
was digested with trypsin (non-labeled; top panel) while the other half was first labeled (at the protein N-terminus and at 
lysine residues, bottom panel) and then digested with trypsin. Green marked sequences are peptides identified with high 
confidence. Red marked amino acids represent known N-linked glycosylation sites. The red box marks the identified N-
terminus of pro-A-SMase at A(59)/(60)H. 
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Since the above described analysis of processed V5-A-SMase under necroptotic conditions provided 
evidence that A-SMase is cleaved at a position distinct from that cleaved during apoptosis, the 
proteolytic processing of V5-A-SMase under apoptotic and necroptotic condition was compared in a 
second set of experiments. For this purpose, full-length V5-A-SMase and processed V5-A-SMase 
fragments were enriched after inducing either apoptosis (TNF/CHX) or necroptosis (TNF/zVAD) and 
were analyzed as above. The preparative SDS-gels stained with Flamingo™ Fluorescent gel stain 
revealed that full-length V5-A-SMase and processed V5-A-SMase fragments isolated from cells either 
undergoing apoptosis or necroptosis had the same molecular weight (Figure 47, left panel). However, 
in the subsequent LC-MS/MS analyses, the reported cleavage site for apoptosis at residue D253 
(Figure 47; blue box; Edelmann et al. 2011) was not detected. In spite of this, un-labeled N-terminal 
peptides starting from L(202)/(203)F were identified, suggesting that the cleavage site of A-SMase 
under apoptotic conditions might be more upstream than previously reported. In contrast to samples 
from apoptotic cells, the analysis of processed V5-A-SMase isolated from necroptotic cells revealed 
un-labeled N-terminal peptides starting from I(201)/(202)L. Overall, the sequence coverage and 
peptides identified in samples from apoptotic and necroptotic cells were very similar (Figure 47, right 
panel), suggesting that cleavage of A-SMase during apoptosis and necroptosis might occur at the same 
sequence or in immediate vicinity. Again, no labeled peptides were identified for processed V5-A-
SMase products in this set of experiments due to detection limits and have so far prevented the 
identification of the exact cleavage site of mature, active A-SMase. 
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Figure 47: Comparison of sequence coverage of processed V5-A-SMase isolated from cells undergoing TNF-induced 
necroptosis or TNF-induced apoptosis. Left panel: L929Ts cells stably transfected with V5-tagged A-SMase were treated 
for 30 min with either 100 ng/mL TNF in combination with 20 µM zVAD-fmk to induce necroptosis (top panel) or with 
5 µg/mL CHX to induce apoptosis (bottom panel). Subsequently, cells were lysed and anti-V5 antibodies were used for 
immunoprecipitation of V5-A-SMase. SDS-PAGE gels were used for separation of immunoprecipitated proteins (which were 
loaded in four parallel lanes). The gels were stained with Flamingo™ Fluorescent gel stain to visualize protein bands. Bands 
at 57 kDa were excised and combined. Right panel: The sequence coverage of processed (cleaved A-SMase) V5-A-SMase is 
shown. Half of the excised material was digested with trypsin (non-labeled; top panel) while the other half was first labeled 
(at the protein N-terminus and at lysine residues, bottom panel) and then digested with trypsin. Green marked sequences are 
peptides identified with high confidence. Red marked amino acids represent known N-linked glycosylation sites. Signal 
peptide of A-SMase is highlighted in grey. The blue box indicates the reported cleavage site of caspase-7 at D253 confirmed 
for apoptosis (Edelmann et al. 2011). 
Conclusion: A-SMase is proteolytically cleaved and activated during necroptosis 
In summary, it was shown for the first time that the levels of the 57-kDa fragment of both endogenous 
and overexpressed A-SMase increased upon induction of necroptosis in multiple cell lines. The 
processing of overexpressed and endogenous A-SMase to a 57-kDa form during necroptosis was 
accompanied by a corresponding increase in its enzymatic activity. Moreover, the study presented here 
shows that Nec-1, NSA as well as TFCK and dynasore inhibit the proteolytic processing as well as the 
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activation of A-SMase during necroptosis, suggesting that A-SMase is activated downstream of the 
RIPK1-RIPK3-MLKL complex, and possibly also downstream of serine proteases. The study of 
caspase-7-deficient MEFs revealed that these cells are able to undergo TNF-induced necroptosis, but 
A-SMase is not activated, suggesting a possible role of non-enzymatic functions of caspase-7 during 
necroptosis. The analysis of the pro- and cleaved form of A-SMase identified the N-terminus of pro-
A-SMase (Figure 46, red arrow), although detection limits have so far prevented the identification of 
the exact cleavage site of mature, active A-SMase. As mentioned above, this cleavage site must be 
distinct from the reported cleavage site where caspase-7 cleaves A-SMase during apoptosis (Edelmann 
et al. 2011; Figure 47, black arrow), because the MS analysis identified peptides that extend N-
terminal of this cleavage site. Interestingly, the comparison of the sequence coverage and peptides 
identified in samples from apoptotic and necroptotic cells suggest that cleavage of A-SMase during 
apoptosis and necroptosis might nevertheless occur within the same sequence or in immediate vicinity. 
5.2.6 The role of presenilin and the presenilin homologue signal-peptide-peptidase-
like (SPPL) during TNF-induced necroptosis 
To investigate if other peptidases are potential regulators of necroptosis induced by TNF, two 
established SPP/SPPL (signal-peptide-peptidase [-like]; Weihofen et al. 2003; Friedmann et al. 2006) 
inhibitors (inhibitor X and (Z-LL)2-ketone), were applied to L929Ts and U-937 cells. Cells were pre-
treated with inhibitor X or (Z-LL)2-ketone for 5 h to ensure optimal inhibitory effects before cell death 
was induced with TNF/zVAD. Treatment with (Z-LL)2-ketone showed no inhibitory effect on TNF-
induced necroptosis in L929Ts and U-937 cells (Figure 48A). On the other hand, the addition of 
inhibitor X slightly diminished TNF-induced necroptosis in murine L929Ts as well as human U-937 
cells (Figure 48A). To further investigate whether SPPL proteins are functionally involved in the 
execution of TNF-induced necroptosis, MEFs from SPPL2a-, SPPL2b- and SPPL2a/b-deficient mice 
were analyzed. Depending on the MEF batches analyzed, MEFs deficient for either SPPL2a or 
SPPL2b or both showed effects on TNF-induced necroptosis (Figure 48B). The analysis of the first 
batch of MEFs showed that SPPL2b- and SPPL2a/b-deficient MEFs were protected from TNF-
induced necroptosis compared to their wild-type counterparts. Unlike batch number one, MEFs from 
SPPL2b- and SPPL2a/b-deficient mice from two additional, distinct batches showed sensitivity 
towards TNF-induced necroptosis (Figure 48B). In spite of this, SPPL2a-deficient MEFs showed 
slight protection from TNF-induced necroptosis compared to the treated wild-type counterparts in 
batch number two and three (Figure 48B). In conclusion, the above described results did not allow to 
define a potential role for SPPLs in TNF-induced necroptosis. 
Inhibitor X is known to specifically bind and inhibit presenilin proteins, which are part of the γ-
secretase protease complex (Dörfler et al. 2001). Based on the effects of inhibitor X on TNF-induced 
necroptosis observed in Figure 48A, MEFs derived from presenilin-1/2-deficient mice were therefore 
included in the characterization of TNF-induced necroptosis. As shown in Figure 48C, in assays 
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investigating TNF-induced necroptosis, presenilin 1/2-deficient cells were fully protected from TNF-
induced necroptosis, confirming the above described results with inhibitor X and pointing to a possible 
role of presenilin in this form of regulated necrosis. 
Results 
110 
 
Figure 48: The role of SPPLs and presenilin in TNF-induced necroptosis. (A) Cells were left without, or were pretreated 
for 5 h with 1 µM inhibitor X or 10 µM (Z-LL)2-ketone. Subsequently, cells were further incubated for 2 (L929Ts) or 24 h 
(U-937) in the presence of 100 ng/mL TNF and 20 (L929Ts) or 50 µM (U-937) zVAD-fmk before cell death was analyzed 
by flow cytometry. (B) Wild-type MEFs and MEFs deficient for SPPL2a (SPPL2a-/-), SPPL2b (SPPL2b-/-) and SPPL2a/b 
(DKO) from three different batches (no. 1-3) were treated with 100 ng/mL TNF and 20 µM zVAD-fmk for 16 h and were 
analyzed as in (A). (C) Wild-type and presenilin-1/2-deficient (P1/2 DKO) MEFs were stimulated for 16 h as in (B) before 
cell death was determined. One out of three experiments is shown. Error bars indicate the SD from three parallel 
measurements. 
5.3 TRAIL-induced necroptosis is a novel approach to eliminate tumor 
cells 
TRAIL can induce regulated necrosis in human tumor cells 
In this part of the study, the ability of TRAIL to induce regulated necrosis in a panel of 14 distinct 
human cancer cell lines of diverse origin was analyzed. To initially characterize the human cancer cell 
lines with regard to their sensitivity to TRAIL-induced regulated necrosis, cells were treated with 
TRAIL/zVAD/CHX. Since treatment with TRAIL normally activates caspase-dependent apoptosis, 
apoptosis was actively inhibited by addition of zVAD-fmk. Furthermore, all cells were additionally 
sensitized with non-toxic concentrations of CHX. As depicted in Figure 49, treatment with 
TRAIL/zVAD/CHX induced regulated necrosis in eight out of 14 tested tumor cell lines. The tumor 
cell lines U-937, Mz-ChA-1, BxPC-3 and HT-29 exhibited the highest sensitivity, followed by 
Colo357, Panc89, PancTu-I and A818-4 cells with decreasing sensitivity levels towards TRAIL-
induced regulated necrosis. The remaining cell lines (CCRF-CEM, MKN-28, SK-OV-3, KNS-62, 
Pt45P1, and SK-MEL-28) displayed only a marginal or no response to treatment with 
TRAIL/zVAD/CHX. The same results were obtained in control assays when regulated necrosis was 
induced with TNF/zVAD/CHX (see Voigt et al. 2014). 
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Figure 49: Induction of regulated necrosis by TRAIL in human tumor cell lines. Cells were treated with 100 ng/ml 
TRAIL in combination with 50 µM zVAD-fmk and non-toxic concentrations of CHX (U-937 0.1 µg/mL; Mz-ChA-1 
2 µg/mL; BxPC-3 1 µg/mL; HT-29 5 µg/mL; Colo357 5 µg/mL; Panc89 1 µg/mL; PancTu-I 10 µg/mL; A818-4 10 µg/mL; 
CCRF-CEM 0.0625 µg/mL; MKN-28 5 µg/mL; SK-OV-3 1 µg/mL; KNS-62 5 µg/mL; Pt45P1 0.1 µg/mL; SK-MEL-28 
10 µg/mL). After 24 h, loss of membrane integrity was measured as a marker for cell death by flow cytometric detection of 
PI-positive cells. Values above the respective columns represent the specific percentage of regulated necrosis (stimulus-
induced minus zVAD/CHX-induced regulated necrosis). The spontaneous cell death in untreated cells is shown for 
comparison. Each bar represent the means of two independent experiments with three parallel determinations each, error bars 
indicate the corresponding SD. Experiments for Mz-ChA-1, BxPC-3, HT-29, Colo357, Panc89, PancTu-I, A818-4, CCRF-
CEM, MKN-28, KNS-62, Pt45P1 and SK-MEL-28 were performed by Stephan Philipp (Christian-Albrechts-University, 
Kiel, Germany). 
Birinapant enhances TRAIL-induced regulated necrosis in human tumor cells 
It has been reported that Smac mimetics can act as enhancers of TNF-induced regulated necrosis (He 
et al. 2009). To test whether Smac mimetics can also enhance TRAIL-mediated regulated necrosis in 
the tested tumor cell lines, five arbitrarily selected sensitive tumor cell lines (U-937, Mz-Cha-1, BxPC-
3, HT-29 and Panc89) and as a control one resistant tumor cell line (KNS-62) were stimulated with 
TRAIL/zVAD/CHX or TNF/zVAD/CHX (as internal control) in the presence of the Smac mimetic 
birinapant. As shown in Figure 50, the addition of birinapant led to a further enhancement of both 
TRAIL- and TNF-induced regulated necrosis in the set of five sensitive tumor cell lines, but not in the 
resistant tumor cell line KNS-62. Furthermore, a ten-fold increase in the concentration of birinapant 
did not further enhance regulated necrosis in the sensitive cell lines or overcome resistance in KNS-62 
cells, indicating that TRAIL- and TNF-induced regulated necrosis is mediated by molecular 
mechanisms which are likewise responsive to Smac mimetics 
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Figure 50: Birinapant enhances TRAIL-induced necroptosis. Cells were treated with 100 ng/ml TRAIL or TNF in 
combination with 50 µM zVAD-fmk and non-toxic concentrations of CHX (U-937 0.1 µg/mL; Mz-ChA-1 2 µg/mL; BxPC-3 
1 µg/mL; HT-29 5 µg/mL; Panc89 1 µg/mL; KNS-62 5 µg/mL) in the presence of the indicated concentrations of the Smac 
mimetic birinapant. After 8 or 24 h of stimulation, regulated necrosis was analyzed by flow cytometric analysis of PI-positive 
cells. Each bar represents the means of two independent experiments with three parallel determinations each, error bars 
indicate the corresponding SD. 
RIPK1, RIPK3 and MLKL are mediators of TRAIL-induced regulated necrosis in the 
examined tumor cell lines 
As described in the introduction (2.2.1.1), regulated necrosis elicited through DRs critically depends 
on the protein kinase RIPK1 and the related downstream kinase RIPK3 (Vanden Berghe et al. 2014). 
To this end, the role of RIPK1 was next validated by pharmacological inhibition in the above selected 
tumor cell lines. The pharmacological inhibition of RIPK1 by Nec-1 protected U-937, Mz-Cha-1, 
BxPC-3, HT-29 and Panc89 cells from both TRAIL- and TNF-induced regulated necrosis (Figure 
51A). Furthermore, the down-regulation of RIPK3 by RNA interference in U-937 and HT-29 cells as 
two sensitive tumor cell lines that express relatively high levels of RIPK3 (see Voigt et al. 2014) 
significantly blocked TRAIL- as well as TNF-induced killing (Figure 51B), suggesting that TRAIL-
induced regulated necrosis likewise occurs via the necroptosis pathway. 
Results 
113 
 
Figure 51: RIPK1 and RIPK3 are mediators of TRAIL-induced regulated necrosis. (A) Cells were left untreated or 
preincubated with 50 µM necrostatin-1 for 2 h before addition of 100 ng/ml TRAIL or TNF in combination with  
50 µM zVAD-fmk and non-toxic concentrations of CHX (U-937 0.1 µg/mL; Mz-ChA-1 2 µg/mL; BxPC-3 1 µg/mL;  
HT-29 5 µg/mL; Panc89 1 µg/mL; KNS-62 5 µg/mL). After 24 h of stimulation, regulated necrosis was analyzed by flow 
cytometric analysis of PI-positive cells. Each bar represents the means of two independent experiments with three parallel 
determinations each. Error bars indicate the corresponding SD. (B) U-937 and HT-29 cells were transfected with siRNAs 
specific for human RIPK3. As a negative control, cells were transfected with an siRNA that does not elicit an RNAi response 
(siCtr). 48 or 72 h after transfection, cells were left untreated or incubated with TRAIL/zVAD/CHX or TNF/zVAD/CHX as 
above. After 24 h of stimulation, regulated necrosis was analyzed by measuring the decrease of intracellular ATP levels as a 
marker for cell death. ATP levels are shown relative to cells transfected with the negative control siRNA but not treated 
(untreated siCtr). Control Western blots of transfected but untreated cells were performed to verify down-regulation of 
endogenous RIPK3. Detection of actin served as a loading control. One out of two experiments with similar results is shown. 
Error bars indicate the SDs from three parallel determinations. Asterisks indicate statistical significance (t-test),  
***P ≤ 0.001. 
It has been reported that phosphorylation of MLKL by RIPK3 is required for RIPK3-dependent 
necroptosis (Vanden Berghe et al. 2014). To clarify whether MLKL is also involved in the TRAIL-
induced killing of tumor cells, MLKL was down-regulated exemplarily in U-937 and HT-29 cells. 
Similar to down-regulation of RIPK3, down-regulation of MLKL significantly reduced TRAIL- as 
well as TNF-induced regulated necrosis in both cell lines (Figure 52A). Furthermore, treatment with 
the MLKL inhibitor NSA resulted in comparable protection from TRAIL- or TNF-induced regulated 
necrosis in the analyzed human tumor cell lines (Figure 52B). 
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Figure 52: MLKL is a mediator of TRAIL-induced regulated necrosis. (A) U-937 and HT-29 cells were transfected with 
an siRNA specific for human MLKL. As a negative control, cells were transfected with non-targeting siRNA (siCtr). 48 or 
72 h after transfection, cells were left untreated or incubated with 100 ng/ml TRAIL or TNF in combination with  
50 µM zVAD-fmk and non-toxic concentrations of CHX (U-937 0.1 µg/mL; HT-29 5 µg/mL). After 24 h of stimulation, 
regulated necrosis was analyzed by measuring the decrease of intracellular ATP levels. ATP levels are shown relative to cells 
transfected with the negative control siRNA but not treated (untreated siCtr). Control Western blots of transfected but 
untreated cells were performed to verify down-regulation of endogenous MLKL. Detection of actin served as a loading 
control. One out of two experiments with similar results is shown. Error bars indicate the SDs from three parallel 
determinations. Asterisks indicate statistical significance (t-test), ***P ≤ 0.001. (B) Cells were treated with  
100 ng/ml TRAIL or TNF in combination with 50 µM zVAD-fmk and non-toxic concentrations of CHX (U-937 0.1 µg/mL; 
Mz-ChA-1 2 µg/mL; BxPC-3 1 µg/mL; HT-29 5 µg/mL; Panc89 1 µg/mL; KNS-62 5 µg/mL) in the presence or absence of 
1 µM necrosulfonamide. After 24 h of stimulation, regulated necrosis was analyzed by flow cytometric analysis of PI-
positive cells. Each bar represents the means of two independent experiments with triplicate measurements. Error bars 
indicate the corresponding SD. 
In summary, RIPK1, RIPK3 and MLKL were identified as mediators of not only TNF-, but also of 
TRAIL-induced regulated necrosis. 
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Ceramide mediates TRAIL/zVAD/CHX- and TNF/zVAD/CHX-induced regulated necrosis 
downstream of RIPK3 
As described above, the lipase A-SMase is activated during necroptosis downstream of the RIPK1-
RIPK3-MLKL complex. Furthermore, recent studies implicated ceramide generated by A-SMase as an 
important mediator of regulated necrosis induced by TRAIL (Thon et al. 2006). However, information 
on the impact of ceramide as a mediator of regulated necrosis in clinically more relevant tumor cell 
systems is currently unavailable. To further substantiate the established role of ceramide, tumor cells 
were treated with Arc39 to inhibit ceramide generation by A-SMase. Arc39 treatment inhibited 
regulated necrosis in U-937, Mz-ChA-1, BxPC-3, HT-29 and Panc89 cancer cells but not in the 
necroptosis-resistant cell line KNS-62 when treated with either TNF- or TRAIL/zVAD/CHX (Figure 
53). 
To investigate the role of RIPK3 not only for TNF-, but also for TRAIL-induced regulated necrosis 
and to study the position of ceramide in the RIPK3-mediated necroptotic signaling cascade, primary 
wild-type MEFs and RIPK3-deficient MEFs were treated with TNF/zVAD/CHX or 
TRAIL/zVAD/CHX to induce regulated necrosis. RIPK3-deficient MEFs but not wild-type MEFs 
were protected from TNF/zVAD/CHX- and TRAIL/zVAD/CHX-induced regulated necrosis. 
Likewise, Arc39 treatment protected wild-type MEFs from TNF- or TRAIL-induced necroptosis as 
did the deletion of RIPK3 in RIPK3-deficient MEFs (Figure 53). Furthermore, RIPK3-deficient MEFs 
were not further protected by Arc39 (Figure 53). 
Figure 53: A-SMase activity is crucial for TRAIL- and TNF-induced regulated necrosis in human tumor cell lines. 
Cells were left untreated or were pre-incubated with 10 µM Arc39 for 2 h before 100 ng/ml of TRAIL or TNF in combination 
with 20 µM (wild-type (WT) or RIPK3-deficient (RIPK3-/-) primary MEFs) or 50 µM zVAD-fmk and non-toxic 
concentrations of CHX (U-937 0.1 µg/ml; Mz-ChA-1 2 µg/ml; BxPC-3 1 µg/ml; HT-29 5 µg/ml; Panc89 1 µg/ml;  
KNS-62 5 µg/ml; MEFs 1 µg/mL) were added. After 16 h (MEFs) or 24 h (all other cell lines) stimulation, cell death was 
analyzed by flow cytometry of PI-positive cells. Each bar represents the means of two independent experiments with three 
parallel measurements each. Error bars indicate the corresponding SD. 
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Moreover, after induction of necroptosis by TNF/zVAD, NIH3T3 cells naturally lacking RIPK3 
(RIPK3-/-) showed a diminished accumulation of intracellular ceramide levels when compared to 
NIH3T3 cells that are stably retransfected with wild-type RIPK3 (RIPK3+/+). Almost identical results 
were obtained in TNF/zVAD-treated NIH3T3 cells stably retransfected with kinase-defective RIPK3 
(RIPK3D161N) (Figure 54). Altogether, the data obtained here suggest that ceramide generated by 
A-SMase acts downstream of RIPK3 as part of the same signal transduction pathway. The remaining 
ceramide accumulation after TNF/zVAD treatment in RIPK3-/- and RIPK3D161N NIH3T3 cells is 
possibly a result of the induction of apoptotic-like caspase-independent cell death pathways rather than 
an induction of necroptosis, because Newton and coworkers recently claimed that the absence of 
RIPK3 drives the signaling pathway towards apoptosis (Newton et al. 2014).  
Figure 54: Ceramide mediates TNF/zVAD-induced regulated necrosis downstream of RIPK3. NIH3T3 cells naturally 
deficient of RIPK3 (RIPK3-/-), NIH3T3 cells stably expressing transfected murine wild-type RIPK3 (RIPK3+/+) or kinase-
defective RIPK3 (RIPK3D161N) were left untreated or were stimulated with 100 ng/mL TNF and 20 µM zVAD-fmk for 18 h 
before intracellular ceramide levels were determined in duplicate. Raw data from the charred thin layer chromatography plate 
(C16 and C18 ceramide species) are shown below the bar graphs. Loss of membrane integrity was determined by trypan blue 
staining and is shown above the respective bars. One out of three representative experiments is shown. 
Induction of regulated necrosis by TRAIL/zVAD/CHX or TNF/zVAD/CHX reduces the 
clonogenic survival of tumor cells 
To determine whether induction of regulated necrosis also can block the capacity of tumor cells for 
unlimited proliferation, measurements of the clonogenic survival were employed for the above 
selected tumor cell lines. As shown in Figure 55, treatment with TRAIL/zVAD/CHX reduced 
clonogenic survival with statistical significance in four out of the five sensitive cell lines (U-937 cells 
showed reduced clonogenic survival which was only slightly above the significance threshold of 0.05 
with P=0.059). Surprisingly, even in the control cell line KNS-62, which had shown resistance to 
TRAIL-induced regulated necrosis in cytotoxicity assays conducted above (see Figure 49), the 
treatment with TRAIL/zVAD/CHX significantly reduced their clonogenic survival. Likewise, 
treatment with TNF/zVAD/CHX led to a reduction of clonogenicity in five out of the six tested tumor 
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cell lines. U-937, HT-29 and Panc89 cells showed a statistically significant reduction. KNS-62 cells 
were only slightly above the significance threshold with P=0.057. Altogether, these data confirm that 
induction of regulated necrosis by TRAIL or TNF can reduce the proliferative potential and thus the 
clonogenicity of tumor cells. 
Figure 55: TRAIL- and TNF-induced regulated necrosis reduces clonogenic survival of tumor cells. Tumor cells were 
treated with 100 ng/ml of TRAIL or TNF in combination with 50 µM zVAD-fmk and non-toxic concentrations of CHX  
(U-937 0.1 µg/ml; Mz-ChA-1 2 µg/ml; BxPC-3 1 µg/ml; HT-29 5 µg/ml; Panc89 1 µg/ml; KNS-62 5 µg/ml). Subsequently, 
their ability to form colonies was analyzed by staining with crystal violet (or by soft agarose cloning for the non-adherent cell 
line U-937) after 7 days (see 4.2.2). Values represent the means from three independently counted wells per condition and 
error bars represent the corresponding SD. Treatment with zVAD/CHX (negative control) served as reference for calculation 
of colony formation as well as of P values. Asterisks indicate statistical significance (t-test), * P ≤0.05, *** P ≤0.001. 
TRAIL-induced regulated necrosis synergizes with chemotherapy in the elimination of 
tumor cells 
The application of TRAIL in combination with chemotherapeutic agents to induce apoptosis in tumor 
cells has been comprehensively investigated (Hellwig and Rehm, 2012). In contrast, a corresponding 
study for the induction of regulated necrosis in synergism with chemotherapeutic agents is not 
available. To alleviate this lack of information, four TRAIL-resistant (Colo357, PancTu-I, MKN-28, 
SK-Mel-28) and the tumor cell line A818-4 which showed only marginal induction of regulated 
necrosis (Figure 49) were analyzed in viability assays after treatment with the chemotherapeutic agents 
cisplatin, etoposide, trichostatin A, 5-fluorouracil, irinotecan, doxorubicin, camptothecin, or paclitaxel 
in combination with TRAIL/zVAD/CHX. The addition of chemotherapeutic agents significantly 
enhanced the cytotoxic effect of TRAIL/zVAD/CHX in four out of five tumor cell lines and in 28 out 
of a total of 40 chemotherapeutic/TRAIL/zVAD/CHX combinations (Figure 56). Notably, the 
cytotoxic response of the cell line A818-4 which had proven only marginally sensitive to 
TRAIL/zVAD/CHX treatment alone (Figure 49) was clearly further enhanced by the addition of 
chemotherapeutics (Figure 56). In summary, the results obtained here demonstrate that TRAIL 
synergizes with chemotherapeutic agents in the induction of regulated necrosis and that this treatment 
can overcome resistance against TRAIL-induced regulated necrosis. 
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Figure 56: TRAIL-induced regulated necrosis synergizes with chemotherapy in the elimination of tumor cells. Cells 
were treated with 100 ng/mL TRAIL, 50 µM zVAD-fmk and non-toxic concentrations of CHX (Colo357, MKN-28 5 µg/mL, 
PancTu-I, SK-Mel-28, A818-4 10µg/mL) with additional application of cisplatin (Cis, 50 µM), etoposide (Eto, 20 µg/ml), 
trichostatin A (Tri, 100 ng/ml), 5-fluorouracil (Flu, 50 µg/ml), irinotecan (Iri, 1 µM), doxorubicin (Dox, 5 µg/ml), 
camptothecin (Cam, 10 µM), or paclitaxel (Pac, 1 µM). After 24 h of incubation, viability was measured by crystal violet 
staining. Treatment with zVAD/CHX (control) served as a reference for the calculation of p values. Viability is shown 
relative to cells treated with zVAD/CHX in combination with the respective chemotherapeutic agent. Asterisks indicate 
statistical significance (t-test), * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. For each cell line, one out of two experiments with 
similar results is shown. Error bars indicate the SD from four parallel determinations. 
Conclusion: TRAIL can induce regulated necrosis in human tumor cells 
The obtained results demonstrate that TRAIL-induced regulated necrosis causes death in eight out of 
14 tumor cell lines and that RIPK1, RIPK3 and MLKL are mediators of not only TNF-, but also of 
TRAIL-induced regulated necrosis. Furthermore, ceramide represents a pivotal factor downstream of 
RIPK3 in the execution of TRAIL- and TNF-induced regulated necrosis because the interference with 
the production of ceramide protected tumor cell lines from necroptosis. The findings also demonstrate 
that the induction of regulated necrosis impairs clonogenic survival of the clinically more relevant 
tumor cell systems employed here and that TRAIL synergizes with chemotherapeutics in killing tumor 
cell lines via regulated necrosis. 
 
Discussion 
119 
 
6. Discussion 
The impact of caspase-independent, non-apoptotic PCD such as necroptosis/regulated necrosis has 
become the focus of international research over the last years. This is particularly true for pathological 
processes which are linked to regulated necrosis, such as hyperacute shock (Cauwels et al. 2003), 
pancreatitis (He et al. 2009; Zhang et al. 2009), cerebral and myocardial ischemia-reperfusion injury 
(Linkermann et al. 2013), Crohn’s disease (Günther et al. 2011), Alzheimer’s disease (Lin and Beal, 
2006) and photoreceptor cell loss (Viringipurampeer et al. 2014). Moreover, pathogens such as HIV, 
vaccinia virus, Shigella and Salmonella (Festjens et al. 2006; Cho et al. 2009) can destruct cells via 
regulated necrosis. The possibility of therapeutic interference with necroptosis/regulated necrosis has 
raised great expectations for the near future. In consequence, a better knowledge of the still 
incompletely understood signaling pathways of the different modes of regulated necrosis, the 
associated components and the distinct executioner mechanisms will facilitate future strategies to 
interfere with damage induced by necroptosis/regulated necrosis (e.g. in shock, pancreatitis, ischemic 
damage or neurodegenerative diseases) to eliminate apoptosis resistant cancers. 
6.1 TNF-induced necroptosis and PARP-1-mediated necrosis elicit 
distinct routes to regulated necrosis 
Future therapeutic interventions, however, require a better knowledge of the signaling pathways of 
regulated necrosis. In previous studies, it was reported that the PARP pathway represents an integral 
part of TNF-induced necroptosis (Los et al. 2002, Vandenabeele et al. 2010). The results obtained in 
the study presented here, however, clearly indicate that TNF-induced necroptosis and the PARP 
pathway represent two distinct routes to regulated necrosis and that they operate separately from each 
other. This was substantiated by the observations that PARP-1 inhibition did not alter TNF-induced 
necroptosis, whereas the MNNG-induced PARP pathway was blocked. 
Furthermore, the hyperactivation of PARP-1 involves the activation of JNK (Vandenabeele et al. 
2010) and in this thesis, the interference with JNK as a further component of the PARP pathway 
revealed that JNK have no role in TNF-induced necroptosis. The revalidated concept that TNF-
induced necroptosis and PARP-1-mediated regulated necrosis are distinct and independent routes to 
regulated necrosis is additionally supported by data of Seok and coworkers who demonstrated that 
JNK activation by DNA-alkylating agents occurs in a TNF-independent manner (Seok et al. 2008). 
Two other and independent studies were also not able to show a link of JNK activation to TNF-
induced necroptosis in multiple cell systems (Lin et al. 2003; Wicovsky et al. 2007). On the other 
hand, a role of JNK in the PARP pathway was recently described based on genetic knockouts and 
pharmacological inhibition studies (Xu et al. 2006). 
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AIF a downstream factor of the PARP pathway was reported to be cleaved by calpains and/or 
cathepsins to yield truncated AIF (tAIF). Subsequently, tAIF relocates from the mitochondria to the 
cytosol and nucleus, where it evokes chromatinolysis and PCD (Artus et al. 2010). The results 
obtained here showed that calpain or cathepsin proteases are not crucial for the induction of TNF-
induced necroptosis in U-937 cells which is in line with previous findings obtained in other cell lines 
(Thon et al. 2005, Sosna and Voigt et al. 2013; Sosna, Voigt et al. 2014). Identical to the results 
presented here, the inhibition of cathepsins B, L, H, or D as further components of the PARP pathway 
(Artus et al. 2010) did not affect TNF-induced necroptosis in murine hepatocytes (Dünstl et al. 2007). 
Furthermore, this thesis shows that cathepsin D-deficient MEFs can undergo TNF-induced 
necroptosis. Of note, cathepsin D-deficient MEF were not protected from MNNG-induced regulated 
necrosis in comparison to their wild-type counterparts or to cathepsin D-deficient MEFs ectopically re-
expressing cathepsin D in the study presented here, suggesting that cathepsin D plays also no role in 
either TNF-induced necroptosis or in the PARP pathway. 
On the other hand, interference with components of the necroptosis pathway (e.g. RIPK3) did not 
impair regulated necrosis elicited by the PARP pathway. In reverse approaches interfering with 
components of TNF-induced necroptosis Xu and coworkers reported that treatment with Nec-1 did not 
protect murine hippocampal HT-22 cells from MNNG-induced regulated necrosis (Xu et al. 2010). 
Furthermore, necroptosis-resistant HeLa cells were still sensitive to MNNG-induced necrosis (Andrabi 
et al. 2006). Moreover, the results obtained in the study presented here and further independent work 
in the laboratory by Sosna and coworkers (Sosna, Voigt et al. 2014) demonstrated that any role of 
RIPK1 or RIPK3 in the PARP pathway cannot depend on signals mediated by TNF-R1. The described 
contribution of RIPK1 and RIPK3 was rather cell-type specific and only of limited impact which is in 
contrast to the essential function of RIPK1 and RIPK3 in TNF-induced necroptosis. These 
observations are also consistent with the studies by Xu et al. (2010) and Chiu et al. (2011) but 
nevertheless, this additional function of RIPK1 and RIPK3 in PARP-1-induced cell death is 
independent from TNF-induced necroptosis. In summary, in TNF-induced necroptosis, RIPK1 and 
RIPK3 play an essential and cell-type-independent role in the initial steps of the death response. In 
contrast to that, their contribution to MNNG-induced regulated necrosis is of limited importance and 
cell-type-specific, and does not occur at the initial, but rather in the late steps of the PARP-pathway. 
In conclusion, this thesis provides a first answer to the question whether there is one core program or 
several independent pathways of regulated necrosis. As a consequence of the results obtained in the 
study presented here, a simultaneous rather than an individual application of highly specific 
necroptosis (e.g. Nec-1 or NSA) and PARP-1 inhibitors (e. g. olaparib) might be the approach of 
choice for the future possibly resulting in an improved treatment of damage induced by regulated 
necrosis (e.g. in shock, pancreatitis, ischemic damage or neurodegenerative diseases). 
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6.2 Identification of proteases and proteolytic substrates involved in 
 TNF-induced necroptosis 
The results obtained in the study presented here demonstrated that the inhibitor of chymotrypsin-like 
serine proteases TFCK significantly protected murine L929Ts and NIH3T3 cells, human Jurkat cells 
and its subline I42 as well as HT-29 and U-937 cells from TNF-induced necroptosis. This is in line 
with a previous study by Vercammen and coworkers showing a protective effect of TFCK on TNF-
induced regulated necrosis in L929 cells (Vercammen et al. 1997), and in summary clearly shows that 
proteolytic processes participate in TNF-induced necroptosis. 
However, the inhibitors of the cysteine proteases cathepsin L (zFF-fmk), cathepsin B/L (zFA-fmk), 
and the broad spectrum calpain/cysteine protease inhibitor E-64 did not protect U-937 cells from TNF-
induced necroptosis. This is in line with previous studies showing that inhibitors of cysteine proteases 
and of calpain/cysteine proteases did not protect L929Ts cells from TNF-induced necroptosis (Thon et 
al. 2005, 2006; Sosna and Voigt et al. 2013). However, during regulated necrosis, cytotoxic 
hydrolases such as Ca2+-dependent calpains destabilize lysosomal membranes (Vanlangenakker et al. 
2008), suggesting that these proteases nevertheless contribute to some extent to cellular events 
associated with regulated necrosis but maybe not specifically in necroptosis. 
In contrast to the other cysteine protease inhibitors utilized, the cathepsin B inhibitor Ca-074Me 
showed protection from necroptosis in U-937 cells. So far this was not observed in other cell lines 
undergoing necroptosis (Sosna and Voigt et al. 2013). Previous studies examining cathepsin B 
functions found that cathepsin B is a component of the TNF-induced apoptotic cell death pathway 
(Guicciardi et al. 2000) and under caspase-inhibiting conditions, cathepsin B was shown to process 
cellular proteins leading to regulated necrosis (Hentze et al. 2003). Furthermore, it was shown that the 
inhibitor Ca-074Me abrogated staurosporine-induced necrotic cell death in leukemia cells and that this 
is independent of its inhibitory effect on cathepsin B (Mihalik et al. 2004). This indicates that the 
inhibitor Ca-074Me has a cathepsin B-independent target that may play a role in necroptosis upstream 
of lysosomal breakdown. The same group found that Ca-074Me protected U-937 cells from 
staurosporine-mediated regulated necrosis by stabilizing the lysosomal compartment and thereby 
preventing rupture of the plasma membrane of the cells (Dunai et al. 2012). 
Treatment of U-937 cells with the proteasome inhibitor MG-132 and the acid protease inhibitor 
pepstatin A did not protect cells from necroptosis elicited by TNF but rather enhanced regulated 
necrosis. MG-132 was shown to reduce the degradation of ubiquitin-conjugated proteins and to 
potentiate TRAIL-induced apoptosis (Sung et al. 2012). In contrast to that, a study by Volbracht and 
coworkers showed that proteasome inhibitors reduce regulated necrosis in neurons (Volbracht et al. 
2001) suggesting that the inhibition of the proteasome has distinct effects in different tissues or cell 
types. Pepstatin A is a well-known inhibitor of aspartic proteases such as pepsin, cathepsin D and 
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cathepsin E. Shacka and coworkers showed that cathepsin D-deficiency induces caspase-independent 
neuron death resulting from the disruption of lysosome function (Shacka et al. 2007). A study 
investigating photoreceptor cell loss showed protective functions of cathepsin D during photoreceptor 
degradation (Chahory et al. 2004). These studies provide indications that non-toxic concentrations of 
MG-132 and pepstatin A have an impact on degradation processes and may therefore potentiate 
necroptotic cell death by inhibiting, e.g. subunits of the proteasome or the aspartic acid protease 
cathepsin D. 
Although metalloproteases are involved in early tumorigenesis and are used as prognostic marker, for 
e.g., lung, colorectal, breast and prostate cancer (Hadler-Olsen et al. 2013), broad spectrum 
metalloproteases inhibitors utilized in this study did not protect from TNF-induced necroptosis, 
suggesting a minor impact of metalloproteases during necroptosis. 
6.2.1 HtrA2/Omi, Lon protease 1, PSA1 and PMPCA are TFCK-sensitive serine 
 proteases identified during necroptosis 
The proteomic screen to discover the TFCK-sensitive serine protease(s) responsible for TNF-
dependent necroptosis identified HtrA2/Omi as a possible mediator of TNF-induced necroptosis. This 
is corroborated by additional results linking HtrA2/Omi and the cysteine protease UCH-L1 to TNF-
induced necroptosis (Sosna and Voigt et al. 2013). The HtrA2/Omi protein is highly conserved and is 
the mammalian homologue of the bacterial HtrA2 endoprotease. Degradation of proteins misfolded 
during cellular stress (e.g. ER stress, heat shock and ischemia/reperfusion) was found to be 
HtrA2/Omi-dependent (Gray et al. 2000). In mouse models, the deletion of HtrA2/Omi has been 
associated with neurodegeneration and Parkinson’s disease (Martins et al. 2004). Neurodegeneration 
was also found in patients harboring mutations in the HtrA2/Omi gene affecting the activity of this 
enzyme (Vande Walle et al. 2008). During apoptosis, HtrA2/Omi is released from the mitochondria 
into the cytoplasm. HtrA2/Omi promotes apoptosis by interacting with the caspase-inhibitor XIAP and 
thereby induces enhanced caspase activity (van Loo et al. 2002). Together with members of the IAPs 
family, the caspase-8 inhibitor phosphoprotein enriched in astrocytes 15 (Pea-15; Trencia et al. 2004) 
and the anti-apoptotic protein HCLS1-associated protein X-1 (HAX-1; Cilenti et al. 2004) are 
substrates of HtrA2/Omi and are cleaved during apoptosis. HtrA2/Omi can not only induce apoptosis 
but it was also reported that HtrA2/Omi can mediate regulated necrosis by its serine protease activity 
upon interleukin-3 deprivation of the mouse pro-B cell line Ba/F3 (Vande Walle et al. 2010), or in 
cytomegalovirus infection (McCormick et al. 2008) and in imatinib mesylate-treated human leukemic 
cells (Okada et al. 2004). However, the molecular details how HtrA2/Omi participates in and which 
substrates are cleaved by HtrA2/Omi during necroptosis are unknown. Only one study, investigating 
substrates cleaved by HtrA2/Omi during regulated necrosis, reports the cleavage and inactivation of 
the substrate RIPK1 by HtrA2/Omi (Vande Walle et al. 2010). Other reports show that, in contrast to 
apoptosis, HtrA2/Omi is not released from mitochondria during TNF-induced necroptosis (van Loo et 
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al. 2002; Blink et al. 2004). This is also consistent with preliminary experiments not detecting 
HtrA2/Omi as part of the necroptotic TNF-R1 signaling complex (data not shown; experiments by 
Vladimir Tchikov, Christian-Albrechts-University, Kiel, Germany). Furthermore, the data in the study 
presented here showed that the pharmacological inhibition of HtrA2/Omi by Ucf-101 or genetic 
deletion of HtrA2/Omi fully protects from TNF-induced necroptosis in a panel of murine and human 
cell lines. In HT-29 cells, protection from TNF-induced necroptosis was less pronounced but 
nevertheless visible when incubated with Ucf-101, suggesting a cell line-specific alteration in the 
signaling pathway. Because HT-29 cells were significantly protected from necroptosis elicited by TNF 
when treated with TFCK, a distinct serine protease might substitute for HtrA2/Omi activity in HT-29 
cells. In addition, the parallel incubation of L929Ts cells with TFCK and Ucf-101 did not result in a 
complete protection of the cells from TNF-induced necroptosis. These observations suggest that both 
inhibitors function by the same signaling pathway and may both bind to HtrA2/Omi or further serine 
proteases are involved in regulated necrosis. Altogether, the above described findings not only 
identified the TFCK-sensitive serine protease HtrA2/Omi as a possible mediator of TNF-induced 
necroptosis but also substantiate the crucial role of HtrA2/Omi in the execution of TNF-dependent 
necroptosis. 
Furthermore, a second TFCK-sensitive serine protease was identified. The mitochondrial  
Lon protease 1 plays a role in protein quality control and in stress response signaling pathways 
(Venkatesh et al. 2012). Furthermore, Lon protease serves as a chaperone for mitochondrial protein 
complex assembly (Rep et al. 1996) and it can bind to DNA or RNA and can thereby modulate 
transcription or translation (Liu et al. 2004). In a previous study, Lon protease down-regulation in 
human lung fibroblasts caused massive apoptosis in the early phase of transfection and this was 
accompanied by ATP depletion caused by severe mitochondrial defects. Subsequently, the cells 
underwent a necrotic type of cell death (Bota et al. 2005). Moreover, Lon protease has already been 
associated with tumorigenesis by ROS production (Cheng et al. 2013). However, in the study 
presented here, the down-regulation of human Lon protease did not result in an increase of TNF-
induced necroptosis in HT-29 and U-937 cells. One possible explanation for this result could be that 
the achieved reduction of Lon protease expression was not sufficient to enhance the death response. 
The characterization of Lon protease action during TNF-induced necroptosis should be further 
investigated by applying specific inhibitors for Lon protease or by utilizing cells completely deficient 
of Lon protease. 
The proteasomal protein proteasome subunit alpha type-1 (PSA1) was also identified as a TFCK-
sensitive serine protease in murine L929Ts cells. Consistent with this finding, several serine protease 
inhibitors, among them TFCK and Pefabloc, have been shown to non-selectively inhibit the 
proteasome which has two chymotrypsin-like active sites (Kisselev et al. 1999; King et al. 2004). The 
identification of proteasomal proteins is in line with a study by Egger and coworkers who found 
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different proteasomal subunits in the TFCK-enriched fraction during a screen for serine proteases 
responsible for ER stress-induced cell death. Moreover, PSA1 was also identified in proteasomal pull-
down experiments performed by Egger and coworkers (Egger et al. 2007), suggesting that the 
identification of PSA1 in this thesis was specific. Down-regulation of PSA1 did not result in inhibition 
or enhancement of TNF-induced necroptosis in HT-29 cells. This is in contrast to U-937 cells where 
down-regulation of PSA1 lead to an increased loss of membrane integrity compared to control 
transfected cells. PSA1 was recently described to be involved in sensitization of bortezomib-resistant 
leukemia cells (Fang et al. 2012), suggesting cell-type and species-specific functions of PSA1 during 
TNF-induced necroptosis. 
The results of the experiments to isolate TFCK-sensitive serine proteases performed during this thesis, 
however also showed that most of the labeled protein spots were non-proteases. This might be due to 
the limited specificity of the chymotrypsin-like serine protease inhibitor TFCK. Notably, the 
mitochondrial-processing metallopeptidase subunit alpha (PMPCA, also abbreviated as MPP-A) was 
also found during the identification of serine proteases responsible for TNF-induced necroptosis, 
although the metallopeptidase PMPCA should not be bound by the serine protease-specific inhibitor 
TFCK. So far, it is unclear whether the identification of PMPCA was unspecific or not. Nevertheless, 
down-regulation of PMPCA in HT-29 and U-937 cells showed an increase in cell death, thus 
suggesting that PMPCA might be a novel protease participating in TNF-induced necroptosis. A 
connection between PMPCA and Lon protease might be possible, because unassembled PMPCA 
subunits are degraded by mitochondrial Lon protease (Ondrovicova et al. 2005). Like Lon protease, 
PMPCA is a quality control enzyme completely degrading misfolded proteins. On the other hand, 
PMPCA can also act as a processing enzyme specifically cleaving mitochondrial proteins with 
regulatory functions during cell death, such as processing of the dynamin-like GTPase optic atrophy 1 
protein (OPA1; Ishihara et al. 2006). 
6.2.2 Five novel proteases enhance TNF-induced necroptosis 
A complementary siRNA screen of all proteases encoded by the human genome identified 10 
proteases with pronounced (and six candidates with less pronounced) effects (see Table 4) which were 
distinct from the identified in 5.2.1 as TFCK-sensitive serine protease(s) responsible for TNF-
dependent necroptosis. Remarkably, the best candidates were caspase-8, CYLD and c-FLIP, proteins 
that represent key regulators of necroptosis (Kaczmarek et al. 2013). The other proteases (DESC, 
GGT1, DPYL4, PRPF8, MMP3) investigated in this study showed enhanced necroptosis upon down-
regulation in HT-29 cells and in U-937 cells. The identification of the above proteases as regulators of 
necroptosis is consistent with the reported functions of these proteases in anti-apoptotic or pro-
tumorigenic processes. In particular, the transmembrane serine protease DESC1 confers tumorigenic 
properties and is upregulated in tumors of different origin (Viloria et al. 2007). The threonine protease 
GGT1 is upregulated by the oncogene K-Ras (and also by TNF). GGT1 enhances the expression of 
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pro-apoptotic molecules and down-regulates the expression of anti-apoptotic molecules, and can 
thereby overcome apoptotic signals (Boonyanugomol et al. 2012). The metalloprotease DPYL4 is a 
target of the tumor suppressor p53 in the apoptotic response to DNA damage (Kimura et al. 2011). 
The metalloprotease PRPF8 shares high homology with ARP2, involved in cell death (Tapia-Vieyra et 
al. 2005) and the matrix metalloproteinase MMP3 participates in tumor initiation (Sternlicht et al. 
1999) and is involved in cancer progression and tissue remodeling (Si-Tayeb et al. 2008). Moreover, 
nuclear MMP3 can induce apoptosis via its catalytic activity (Si-Tayeb et al. 2008). Although down-
regulation of YME1L1 showed no effect in both cell systems (as detected by ATP level measurements 
and flow cytometry), YME1L1 might play a role in regulated necrosis. Like Lon protease 1, YME1L1 
is part of the mitochondrial ATPases associated with diverse cellular activities (AAA) complex. The 
AAA complex exerts peptidase, chaperone-like and translocase activities on the intermembrane space 
side of the inner mitochondrial membrane (Stiburek et al. 2012). One substrate of YME1L1 is the 
dynamin-like GTPase OPA1 (Griparic et al. 2007) which can also be processed by PMPCA (Ishihara 
et al. 2006). OPA1 is localized in the mitochondrial intermembrane space side and during apoptosis 
OPA1 is proteolytically cleaved by AAA, released into the cytosol and causes fragmentation of 
mitochondria (Griparic et al. 2007). However, the precise role of YME1L1 and of the other proteases 
identified here in regulated necrosis, and in particular, in necroptosis is unknown and should be 
investigated in the future. 
Surprisingly, the data obtained by the siRNA screen indicate a differential proteolytic regulation of 
necroptosis by caspase-8 in humans. In the study presented here, caspase-8 down-regulation resulted 
in a protection of human HT-29 cells from TNF-induced necroptosis. Furthermore, the down-
regulation of caspase-8 was also protective in human U-937 cells measuring ATP levels. However, 
protection of U-937 cells after down-regulation of caspase-8 was not observed after PI-staining. This 
observation was not in line with later experiments using individual siRNAs (data not shown), 
suggesting off-target effects of the used mixture of four siRNAs targeting caspase-8 in U-937 cells. 
Nevertheless, the observation that caspase-8 down-regulation protects rather than enhances necroptotic 
cell death elicited by TNF is in contrast to the overall view that caspase-8 suppresses necrosome-
dependent necroptosis (Holler et al. 2000; Cho et al. 2009; He et al. 2009, Zhang et al. 2009). In mice, 
FADD, caspase-8 and FLIPL counteract RIPK1- and RIPK3-dependent necroptosis during 
development, because embryonic lethality in mice lacking FADD or caspase-8 can be rescued by 
RIPK1 or RIPK3 deletion (Kaiser et al. 2011; Oberst et al. 2011; Zhang et al. 2011). Down-regulation 
of caspase-8 or FADD in L929Ts cells potentiated necroptosis elicited by TNF (Vanlangenakker et al. 
2011b). However, interpretation of these studies has to be performed with caution, because they 
present work from murine systems. Unlike mice, humans have two initiator caspases, caspase-8 and 
caspase-10. Human caspase-10 has close homology to human caspase-8 (Fernandes-Alnemri et al. 
1996) and functions as an initiator caspase in DR-mediated signaling (Sprick et al. 2002). Caspase-10 
has overlapping substrate specificities with caspase-8 (Fischer et al. 2006) and similar to caspase-8, 
Discussion 
126 
 
caspase-10 was reported to play a role in viral infection (Takahashi et al. 2006). Kischkel and 
coworkers showed that both caspase-8 and caspase-10 can function independently of each other during 
ligand-induced apoptosis (Kischkel et al. 2001). The reported observations together with the results 
obtained in the study presented here raise the question whether the roles of these two related enzymes 
are redundant or whether they have distinct or complementary functions during necroptosis. Another 
issue which has to be discussed is the fact that the broad spectrum inhibitor of caspases zVAD-fmk 
was always present raising the question why loss of caspase-8 expression still has an impact on 
necroptosis. A study by Kadohara and coworkers could demonstrate that caspase-8 is able to mediate 
the mitochondrial release of pro-apoptotic proteins in a proteolysis-independent manner (Kadohara et 
al. 2008). Accordingly, the protective effect of caspase-8 down-regulation in human cancer cell lines 
during necroptosis might be due to novel scaffolding functions of caspase-8, and maybe caspase-10. 
To investigate the contribution of the identified proteases in regulated necrosis, the metalloprotease 
MEP1B was further characterized. However, in preliminary experiments in the study presented here, 
no effects of the two broad-spectrum metalloprotease inhibitors GM6001 and marimastat were 
observed during TNF-induced necroptosis. Nevertheless, in the study presented here, cell death levels 
were decreased after down-regulation of MEP1B in U-937 cells. On the other hand, this was not 
observed in HT-29 cells, suggesting a cell-type-specific involvement of MEP1B during TNF-induced 
necroptosis. In contrast to that, HT-29 cells transiently transfected with wild-type MEP1B showed 
enhanced cell death rates compared to non-transfected cells after TNF/zVAD/CHX stimulation. Cells 
expressing a catalytically inactive MEP1B mutant also showed increased cell death levels during 
necroptosis. In conclusion, the analysis of MEP1B function suggests that MEP1B plays a role in the 
execution of TNF-induced necroptosis. Nevertheless, these preliminary data should be substantiated 
by loss of gene function studies and by studying the effects of MEP1B-specific inhibitors. 
Furthermore, the role of MEP1B in mediating ischemia-reperfusion injury under caspase-independent 
conditions should be investigated, because meprin inhibition is protective from renal hypoxia-
reoxygenation injury (Carmago et al. 2002) and regulated necrosis is linked to ischemia-reperfusion 
injury (Linkermann et al. 2013). 
6.2.3 Newly identified signaling components of TNF-induced necroptosis 
Cell surface receptors are activated after binding to their ligands, transmit intracellular signals and 
generate a signaling cascade. In the last decade, it has become clear that signal transduction pathways 
may require receptor internalization for signal transduction (McPherson et al. 2001). TNF-R1 
internalization was shown to be essential for the initiation of apoptosis (Schütze et al. 1999; 
Schneider-Brachert et al. 2004). In the presented thesis, the internalization capability of TNF-R1 under 
conditions of caspase-inactivity was confirmed in U-937 cells by flow cytometry. 
Immunofluorescence detection of TNF-R1 in L929Ts and U-937 cells revealed a time-dependent 
appearance of endocytic vesicles harboring the TNF-R1 molecules. In the presented study, immuno-
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magnetic isolation of cell surface TNF-R1 was performed to detect new or known proteins 
differentially expressed or even cleaved during necroptosis. The method allows the monitoring of the 
temporary maturation and distribution of specific proteins involved in intracellular signaling from 
intracellular compartments (Tchikov et al. 2014). The receptors are isolated in their native membrane 
environment in the absence of any detergent and the gentle physical homogenization procedure should 
preserve the morphology and functional integrity of the compartments (Tchikov et al. 2014). The 
analysis of the immuno-magnetically enriched necroptotic TNF-R1 containing vesicles from L929Ts 
and U-937 cells revealed the accumulation of the proteins RIPK1 and RIPK3 to the receptor during 
necroptosis. This is in line with the reported signaling cascade of TNF-induced necroptosis (Vanden 
Berghe et al. 2014). Isolated magnetic TNF-R1 fractions contained Rab5, a marker of early 
endosomes, and accumulated lysosomal proteins. In contrast to apoptosis, TNF/zVAD stimulation 
revealed early accumulation of LAMP proteins within the magnetic TNF-R1 containing vesicles, 
suggesting an early fusion of lysosomes with TNF-R1 containing vesicles during necroptotic cell 
death. However, to clearly prove that the isolated magnetic fractions are intact subcellular 
compartments and are fused at early time-points to lysosomes, the fractions should be analyzed by 
electron microscopy. 
Next, to find protease targets during necroptosis, a 2D-DIGE approach following MS analysis was 
performed. This approach revealed that cofilin-1 (CFL-1) protein levels were consistently increased in 
cellular extracts of U-937 cells undergoing necroptosis. The actin-binding protein CFL-1 disassembles 
actin filaments and reorganizes the cytoskeleton. During cell death, cytoskeleton-associated proteins 
play a role in connecting TNF signaling to actin reorganization. For example, the death-associated 
protein kinase (DAPK) phosphorylates LIM domain kinase 1 and its downstream target CFL-1. Upon 
phosphorylation, CFL-1 possibly acts as a scaffold and as a trigger for actin reorganization and 
detachment of the cell (Ivanovska et al. 2013). During oxidative stress in T cells, CFL-1 is oxidized 
and provokes a stiff actin cytoskeleton and T-cell death. Oxidation of CFL-1 leads to its 
translocation/accumulation to the mitochondria and with that to the execution of regulated necrosis 
(Wabnitz et al. 2010) which possibly explains the finding of increased protein levels of CFL-1 during 
TNF-induced necroptosis in the 2D-DIGE analysis. Furthermore, Wabnitz and coworkers assume that 
oxidized CFL-1 interferes with mitochondrial functions and thus energy depletion does not involve the 
Bcl-2 family (Wabnitz et al. 2010). The 2D-DIGE analysis showed that the major constituent of 
microtubules tubulin alpha-1B chain (TUBA1B) and the glycolytic enzyme pyruvate kinase isozymes 
M1/M2 (PKM) showed decreased protein levels in cells undergoing necroptosis. TUBA1B was found 
to be upregulated in small cell lung cancer tissues (Jeong et al. 2011), suggesting a protective role of 
TUBA1B during cell death. To overcome this protective role, protein levels of TUBA1B might be 
therefore decreased during necroptosis. It was reported that upon translocation of the tumor marker 
PKM to the nucleus, PCD is induced in a caspase-independent manner (Stetak et al. 2007). This might 
explain the low protein levels of PKM after induction of necroptosis in the isolated TNF-containing 
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vesicles (because PKM is already in the nucleus). The protein levels of the two dehydrogenases 
inosine-5’-monophosphate dehydrogenase 2 (IMPDH2) and D-3-phosphoglycerate dehydrogenase 
(PHGDH) were found to be increased in magnetic TNF-R1 fractions isolated from cells undergoing 
necroptosis. Mantle cell lymphoma cells, a rare aggressive type of B-cell non-Hodgkin’s lymphoma, 
are resistant to TRAIL treatment which is associated with a decreased expression of three key enzymes 
of purine nucleotide metabolism, namely purine nucleoside phosphorylase, adenine 
phosphoribosyltransferase and IMPDH2 (Pospisilova et al. 2013). These enzymes have profound 
effects on nucleotide homeostasis and IMPDH2 among others might have pro-necrotic functions 
during regulated necrosis. Resistance to cell death and an increased glucose catabolism are hallmarks 
of cancer. Moreover, cancer cells adapt their metabolic processes to induce rapid cell growth and 
proliferation. PHGDH is involved in the serine biosynthesis pathway and PHGDH protein levels are 
elevated in 70 % of estrogen receptor-negative breast cancers patients. The suppression of PHGDH 
does not affect intracellular serine levels but causes increased α-ketoglutarate levels (Possemato et al. 
2011). However, in the study presented here, PHGDH was found to be upregulated in U-937 cells 
undergoing necroptosis. This is in contrast to the observations that, for example, GLUD1, a 
mitochondrial enzyme converting glutamate into α-ketoglutarate, is hyperactivated by RIPK3 and the 
execution of necroptosis is dependent on the excessive generation of α-ketoglutarate (Mates et al. 
2009). Therefore, the role of PHGDH has to be substantiated by loss of gene function studies and by 
studying the effects of PHGDH-specific inhibitors. The 2D-DIGE analysis revealed that the 
peroxisome enzyme catalase (CAT) showed lower protein levels in necroptotic cells. The rapid 
decomposition of harmful H2O2, a byproduct of many metabolic processes within the cell, is an 
important physiological process to prevent damage of cells and tissues. Yu and coworkers reported 
that caspase inhibition induces catalase degradation and thereby ROS accumulation and non-apoptotic 
PCD (Yu et al. 2006). Since the accumulation of ROS is crucial for the execution of regulated 
necrosis, catalase might be an important substrate for proteolytic cleavage during necroptosis. The 2D-
DIGE proteomic approach provided evidence that the structural constituent of the cytoskeleton moesin 
is a target of proteolytic cleavage. However, at present there are no studies available showing moesin 
cleavage as a result of PCD. Similar to moesin, the cleavage of the protein stathmin should be verified 
by Western blot analysis of cleavage fragments. 
However, only two cleaved proteins were identified and already known protease substrates during 
regulated necrosis such as RIPK1 or Bid (Mocarski et al. 2011; Heibein et al. 2000; Lorenzo and 
Susin, 2007) were not detected by the analysis conducted here. One explanation can be given by the 
kinetics of proteolysis. In response to TNF-induced necroptosis, proteolysis might vary from protein to 
protein and certain proteomic changes might not be detected at the 20 min time-point studied here, but 
could occur earlier or later. Furthermore, some changes in molecular weight of proteins due to 
proteolysis might be masked by other proteins over-represented in the 2D gel and small peptide 
fragments resulting from proteolytic cleavage might be under-represented and excluded. 
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Consequently, the 2D-DIGE analysis should be repeated for further time-points and different protein 
levels, and also should be confirmed by means of quantitative real-time PCR or Western blot. 
Alternatively, the non-gel-based technique iTRAQ (isobaric tag for relative and absolute 
quantification; Ross et al. 2004) could be conducted to study proteomic changes simultaneously at 
different time-points of TNF-induced regulated necrosis. 
In summary, the use of the 2D-DIGE approach revealed insight into cellular events leading to 
necroptosis and identified proteins whose aberrant regulation may contribute to the induction and 
execution of regulated necrosis. The proteins identified here provide exciting new resources to further 
unravel the mechanisms of regulated necrosis caused by TNF stimulation. 
6.2.4 PGAM5 is constitutively degraded under physiological conditions  
Necroptosis critically relies upon the signaling molecule MLKL (Sun et al. 2012, Wu et al. 2013) 
which promotes necroptosis by activating PGAM5 and Drp-1, leading to mitochondrial fragmentation 
(Wang et al. 2012). Remarkably, in the study presented here, down-regulation of PGAM5 and Drp-1 
did not affect necroptosis. This is in line with a study by Remijsen and coworkers showing that down-
regulation of RIPK1, RIPK3 or MLKL diminishes TNF-induced necroptosis in murine cells, whereas 
repression of PGAM5 and Drp-1 has no or only marginal effects on the induction of necroptosis 
(Remijsen et al. 2014). These observations suggest that Drp-1 and PGAM5 are no essential factors for 
TNF-induced necroptosis but may support i.e. mitochondrial fragmentation during necroptosis. 
In apparent contrast to this is the observation that PGAM5 protein levels increased upon induction of 
necroptosis, visualized in the study presented here by Western blot. A similar enrichment of PGAM5 
levels was observed when protease inhibitors were applied, suggesting a constitutive degradation of 
the potentially pro-necroptotic protein PGAM5 by unknown proteases in healthy cells. In further 
experiments, the identity of these proteases could be narrowed down to the family of serine proteases. 
For example, PGAM5 protein levels were increased when HtrA2/Omi was inhibited, indicating that 
HtrA2/Omi is a potential physiological regulator of PGAM5. The proteasome inhibitor MG-132 also 
elevated PGAM5 protein levels, indicating that the proteasome is another physiological regulator of 
PGAM5. A possible explanation for the constitutive degradation of PGAM5 under physiological 
conditions might be that in healthy cells, keeping PGAM5 at low levels most likely prevents 
inadvertent induction of mitochondrial fragmentation and thus necroptosis. In consequence, the 
induction of necroptosis may lead to an increased susceptibility of cells to mitochondrial 
fragmentation by inhibiting PGAM5 degradation. In addition, a recent study by Zhuang and coworkers 
suggested that PGAM5 is cleaved by a non-caspase protease during apoptosis thereby releasing 
PGAM5 from the mitochondria. Once in the cytosol, PGAM5 is shown to be an antagonistic IAP 
substrate (Zhuang et al. 2013). 
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Additionally, the important role of MLKL in necroptosis could be shown in U-937 and HT-29 cells 
and could be extended to clinically relevant tumor cell lines. In this thesis, it could further be 
demonstrated that MLKL is not only involved in TNF-induced necroptotic killing of tumor cells, but 
that it is also involved in TRAIL-induced regulated necrosis. 
6.2.5 A-SMase is proteolytically cleaved during necroptosis 
While there is much evidence implicating ceramide in apoptosis, the question whether ceramide 
represents an essential inducer or is generated in consequence of necroptosis is still subject to debate. 
The study presented here shows for the first time that TNF-induced necroptosis results not only in  
A-SMase activation but also in generation of a 57-kDa protein band in L929Ts cells and a 59-kDa  
V5-tagged A-SMase protein in L929Ts cells expressing V5-A-SMase. The occurrence of two 
molecular forms of A-SMase, a 72 kDa polypeptide and a 57-kDa form, was already described in 1994 
(Ferlinz et al. 1994). The 57-kDa protein bands obtained in the study presented here correlated with A-
SMase induction/activation and this observation is in line with findings by Edelmann and coworkers 
investigating A-SMase cleavage during TNF-induced apoptosis (Edelmann et al. 2011). Furthermore, 
the 59-kDa recombinant cleavage product of V5-A-SMase still carried the C-terminal V5-tag, 
suggesting that A-SMase is proteolytically cleaved to its enzymatically active product at the N-
terminus of the protein. A study by Jenkins and coworkers reported the proteolytic processing of  
V5-A-SMase to a 65 kDa form of A-SMase lacking the C-terminal V5-tag (Jenkins et al. 2011). This 
observation is in direct contrast to the results obtained in the study presented here. In the study by 
Jenkins and coworkers, the C-terminal cleavage of A-SMase was detected in unstimulated cells 
whereas, in the study presented here, cells were stimulated with TNF to induce necroptosis. 
Furthermore, the MS analyses of extracted V5-A-SMase fragments clearly showed that V5-A-SMase 
is cleaved at the N-terminus after TNF-induced necroptosis. Therefore, the detection of a C-terminal 
cleavage fragment of lysosomal A-SMase (Jenkins et al. 2011) might represent a process required for 
lysosomal A-SMase maturation rather than a process involved in TNF-induced activation of A-SMase. 
The observation that A-SMase is cleaved and activated during necroptosis could be further 
substantiated: both necroptosis inhibitors Nec-1 and NSA prevented the proteolytic processing as well 
as the activation of A-SMase during necroptosis. A-SMase activity was also decreased when TFCK or 
dynasore were applied, suggesting that the internalization of the TNF-R1 is required for A-SMase 
cleavage and thus for necroptosis (see 5.2.3). Moreover, cleaved A-SMase was not found in the 
necroptotic TNF-R1 fractions, suggesting that A-SMase is activated downstream of the necrosome 
complex, and possibly cleaved and activated by a yet unknown serine protease. Surprisingly, 
necroptosis-sensitive caspase-7 deficient MEFs did not show A-SMase activity after induction of 
necroptosis. During apoptosis, caspase-8 and caspase-7 sequentially mediate proteolytic activation of 
A-SMase after TNF stimulation (Edelmann et al. 2011). Since overall caspase activity was suppressed 
by the addition of zVAD-fmk in every experimental set-up, the presence of caspase-7 protein rather 
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than its activity might be essential for the activation of A-SMase during TNF-induced necroptosis. 
Caspase-7 plays a crucial role in the execution of apoptosis whereas non-apoptotic functions of 
caspase-7 are, so far, not described (Fan et al. 2005; Lamkanfi et al. 2007). However (although  
A-SMase is the main enzyme responsible for induction of ceramide-mediated necroptosis, see below), 
cell death can be induced by increased ceramide levels also in an A-SMase-independent manner.  
A report by Lafont and coworkers showed that CD95-induced sphingomyelin synthase inhibition leads 
to sphingomyelin decrease and ceramide increase, contributing to cell death. Furthermore, the authors 
could show that sphingomyelin synthase 1 is a putative target for caspase-7 (Lafont et al. 2010). To 
unravel the putative function of caspase-7 during necroptotic activation of A-SMase, ceramide levels 
of caspase-7 deficient MEFs and their wild-type counterparts should be measured after induction of 
necroptosis. Furthermore, the effect on A-SMase activation after re-transfection of recombinant 
caspase-7 in caspase-7 deficient MEFs should be analyzed in the future. 
Under conditions where the classical apoptosis machinery fails, the generation of ceramide may be an 
important backup system enabling a cell to commit suicide by regulated necrosis. In particular, it was 
shown that ceramide consistently accumulates before the onset of necroptosis (Thon et al. 2005). 
Inhibition of ceramide generation by overexpression of acid ceramidase, pharmacological intervention, 
down-regulation or genetic ablation of A-SMase resulted in protection of L929Ts, NIH3T3 and Jurkat 
T cells (Strelow et al. 2000; Thon et al. 2005). A-SMase deficient lung fibroblasts were re-sensitized 
for necroptosis by reconstitution of A-SMase, implicating A-SMase as the main enzyme responsible of 
the accumulation of ceramide after induction of necroptosis (Thon et al. 2005).  
The isolation and analysis of bands corresponding in size to unprocessed and processed A-SMase from 
preparative gels identified the N-terminus of pro-A-SMase being at A(59)/(60)H. The N-terminal 
proteolytic processing at histidine 60 of pro-A-SMase was already described (Schissel et al. 1998). 
Although detection limits have, so far, prevented the identification of the exact cleavage site of 
mature, active A-SMase in necroptosis, the analysis of the 57 kDa band of cleaved A-SMase 
demonstrated that the necroptotic A-SMase fragment extends beyond the putative N-terminal 
apoptotic cleavage site (Edelmann et al. 2011). This suggests that during necroptosis, the cleavage of 
A-SMase must be distinct from the site where caspase-7 cleaves A-SMase during apoptosis. 
Surprisingly, results of the study presented here, revealed that processed A-SMase fragments after 
induction of apoptosis include N-terminal peptides starting from L(202)/(203)F which are upstream of 
the putative cleavage site at D253 found by Edelmann and coworkers (Edelmann et al. 2011). In 
contrast to the suggestion that A-SMase is cleaved during necroptosis at a distinct site, the sequence 
coverage and peptides identified between apoptotic and necroptotic cleaved A-SMase fragments were 
very similar in the study presented here. The putative cleavage site of pro-A-SMase at D253 was 
identified by mutation analysis (Edelmann et al. 2011). However, this cleavage site does not match the 
canonical consensus sequence of caspase-7 and should be revalidated with further analysis of the 
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cleavage fragments by novel MS analysis such as terminal amine isotopic labeling of substrates 
(TAILS; Kleifeld et al. 2011) like processed A-SMase to define the termini of A-SMase via 
quantitative proteomic analyses. 
In summary, a proteolytic activation of A-SMase in response to necroptosis could be confirmed. 
However, the questions which protease cleaves pro-A-SMase during necroptosis and the precise 
location of the N-terminus of cleaved A-SMase still remain open. 
6.2.6 Presenilins are indispensable for TNF-induced necroptosis 
Presenilin proteins belong to a family of multi-pass transmembrane proteins. They are part of the 
catalytic core of the γ-secretase protease complex located in the plasma membrane (Zhang et al. 2013). 
Mice deficient for presenilin-1 show severe defects and die after birth (Shen et al. 1997). Patients with 
familial Alzheimer disease show mutations in their presenilin-1 gene (Menendez, 2004). Down-
regulation of presenilin-1 sensitizes human Hep G2 cells to ER stress-dependent cell death (Száraz et 
al. 2013). In the study presented here, MEFs derived from presenilin 1/2-deficient mice were fully 
protected from TNF-induced necroptosis. This is in line with the observation that the γ-secretase 
protease complex inhibitor X diminished TNF-induced necroptosis in L929Ts and U-937 cells. So far 
no data are available which links presenilins to necroptosis. However, recent studies reported that 
HtrA2/Omi can interact with presenilin-1 in the active γ-secretase protease complex in mitochondria 
(Gupta et al. 2004; Behbahani et al. 2010). This observation is in line with the association of 
HtrA2/Omi protease activity and neurodegenerative disorder, e.g. with a parkinsonian phenotype 
(Martins et al. 2004). Based upon the preliminary results obtained in this thesis, presenilins might 
represent a missing link between HtrA2/Omi activation and execution of necroptosis. 
The Alzheimer’s disease-associated presenilins, the signal peptide peptidase (SPP) and, its 
homologues, the SPP-like peptidases (SPPL) are intramembrane-cleaving proteases (I-CLIPs; Wolfe 
and Kopan, 2004) and members of a group of the GxGD-type aspartyl protease family (Weihofen and 
Martoglio, 2003). Although SPP/SPPLs and presenilins share very limited sequence homologies, they 
exhibit similarities in the cleavage pattern of their substrates, suggesting a common concept of 
intramembrane proteolysis (Fluhrer and Haass, 2007). In the thesis presented here, studying MEFs 
from SPPL2a-, SPPL2b- and SPPL2a/b-deficient mice revealed no conclusive evidence that SPPL2 
proteins play a role in TNF-induced necroptosis, because depending on the MEF batches analyzed, the 
knock-out of either SPPL2a or SPPL2b as well as the double knock-out showed protective effects on 
TNF-induced necroptosis or not. Furthermore, the inhibitor (Z-LL)2-ketone, an established SPP/SPPL 
inhibitor (Friedmann et al. 2006) had no inhibitory effect on TNF-induced necroptosis in L929Ts and 
U-937 cells. The inconclusive results of the different MEF batches might be due to phenotypic 
alterations during immortalization. For example, mutations of the growth-suppressive protein p53 
seem to be a common event in the formation of permanent cell lines (Harvey and Levine, 1991). The 
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p53 tumor suppressor pathway is a central link for nearly all cellular stress responses this include, for 
example, DNA repair, cell cycle arrest, cell death and senescence. Furthermore, p53 regulates PARP-1 
dependent necrosis (Elkholi and Chipuk, 2014). Thus immortalized cell lines with an altered p53 
pathway might have different sensitivities to TNF- or TRAIL-induced cell death pathways. 
Consequently, further experiments have to be conducted investigating other cell systems by down-
regulating or over-expressing SPPL2 proteins to unravel the involvement of SPPL2 proteins during 
necroptosis. A possible link between SPPL proteins and regulated necrosis might be the Mg2+ 
transport pathway within the cell. Preliminary data showed an altered Mg2+ homeostasis in SPPL2a-
deficient mice, possibly as a result in altered cleavage of a member of the transient receptor potential 
channels of the melastatin-like family (TRPM; unpublished observations by Bernd Schröder, 
Christian-Albrechts-University, Kiel, Germany). These ion channels were recently associated with cell 
death. For example, TRPM2 is activated by free radicals and TNF as well as H2O2 stimulation cause 
cell death through a TRPM2-dependent mechanism (Hara et al. 2002). TRPM7 was shown to be a 
downstream target of MLKL, leading to Ca2+ influx and TNF-induced necroptosis (Cai et al. 2014). 
The ion channel TRPM6 is one prominent key player in Mg2+ homeostasis (Ferre et al. 2011) and a 
study by Schmitz and coworkers showed that TRPM7 and its closest homologue, TRPM6 are 
functionally non-redundant but can influence each other’s biological activity (Schmitz et al. 2005). 
Furthermore, deletion of TRPM7 caused growth arrest, Mg2+ deficiency, and cell death in  
B-lymphocytes (Schmitz et al. 2005). TRPM6, being a potential substrate of SPPL2a, has not yet been 
implicated in cell death. The interplay of pro-necroptotic TRPM7 and TRPM6 may also contribute to 
cell death through as yet uncharacterized pathways or through dimerization with either TRPM2 or 
TRPM7. 
6.3 TRAIL induces regulated necrosis in clinically relevant tumor cell 
lines 
The third part of the study presented here provides strong evidence for the suitability of TRAIL-
induced regulated necrosis as a tool to eliminate tumor cells from a wide range of sources. In contrast 
to regulated necrosis, the efficacy of TRAIL in the apoptotic elimination of tumor cells has been 
already demonstrated in clinical trials in patients (Hellwig and Rehm, 2012). Nevertheless, intrinsic 
resistance of tumors against TRAIL-induced apoptosis was found to limit the therapeutic success. 
Therefore, the induction of regulated necrosis by TRAIL would be an additional option to eliminate 
tumor cells that are intrinsically resistant to TRAIL-induced apoptosis. This has, however, been 
investigated only in a very limited number of studies so far. One of those studies has recently reported 
that TRAIL induces necroptosis in the tumor cell lines HT-29 (which was also used in the study 
presented here) and Hep G2 (Jouan-Lanhouet et al. 2012). However, unlike in the study presented 
here, necroptosis occurred only under acidified but not physiologic conditions. Moreover, Jouan-
Lanhouet and coworkers reported that in their system caspase activity is required for cell death (Jouan-
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Lanhouet et al. 2012). This is in contrast to the common molecular mechanisms described for 
necroptosis (Vanden Berghe et al. 2014) and to the observations of the study presented here. 
Furthermore, the study by Jouan-Lanhouet and coworkers showed that their above described findings 
for necroptosis induced by TRAIL do not apply to necroptosis induced by either TNF or CD95 ligand 
(Jouan-Lanhouet et al. 2012), suggesting that conclusions from their study have to be interpreted with 
a certain caution and cannot be generalized for physiologic conditions. Another more encouraging 
study by Hunter and coworkers showed that TRAIL is able to kill small cell lung cancer cells in 
synergy with paclitaxel through a caspase-independent mechanism (Hunter et al. 2011). Furthermore, 
the treatment with TRAIL in combination with lobaplatin, an antitumor platinum drug, had effects on 
the growth of breast cancer cells in vitro by inducing regulated necrosis (Engel et al. 2012). 
Independently, Katz and coworkers reported that combining sorafenib therapy with TRAIL results in 
augmented caspase-independent cell death of malignant pleural mesothelioma cell lines. Furthermore, 
pilot in vivo studies demonstrated promising evidence of the therapeutic efficacy in a xenograft mouse 
model (Katz et al. 2009). The results obtained in the study presented here show that TRAIL-induced 
regulated necrosis is even more effective under conditions that more closely resemble the in vivo 
situation, because TRAIL-induced regulated necrosis clearly interfered with the capacity of the tested 
tumor cell lines for unlimited proliferation in clonogenic survival assays. These observations may 
represent promising new options for the development of future combination therapies for the 
elimination of apoptosis-resistant cancers. Furthermore, the data presented here demonstrate that 
TRAIL-induced regulated necrosis synergized with chemotherapeutic agents such as cisplatin, 
etoposide, trichostatin A, 5-fluorouracil, irinotecan, doxorubicin, camptothecin and paclitaxel and 
enhances the cytotoxic response in the tumor cell lines. In summary, the data obtained here and the 
above mentioned studies provide additional encouragement for the development of future combination 
therapies. 
With regard to unraveling the molecular pathways of TRAIL-induced regulated necrosis, the results 
obtained in the study presented here identified RIPK1, RIPK3 and MLKL as crucial components. 
Furthermore, RIPK3 may represent a possible determinant of susceptibility or resistance of tumor cells 
to TRAIL-induced regulated necrosis (Voigt et al. 2014). In line with this observation, also MLKL 
protein expression was reported to be a prognostic biomarker in patients with pancreatic 
adenocarcinoma, where low expression of MLKL was associated with decreased overall survival of 
the patients (Colbert et al. 2013). Finally, the study presented here confirmed and extended the role of 
ceramide as one of the key mediators of regulated necrosis downstream of RIPK1 and RIPK3 to the 
clinically more relevant tumor cell systems investigated, because treatment with Arc39 suppressed 
TNF- or TRAIL-induced necroptosis in U-937, Mz-ChA-1, BcPC-3, HT-29 and Panc89 cancer cells 
and in MEFs but not in a necroptosis-resistant cell line. There is emerging evidence that A-SMase 
could serve as an important drug target for a variety of diseases. For example, increased A-SMase 
concentrations were found in atherosclerosis, chronic heart failure and depression (Uhlig and  
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Gulbins, 2008). Therefore, the regulation of A-SMase by Arc39 may represent a novel mechanism for 
pharmacological inhibition of the enzyme and the development of combination therapies with TRAIL 
could help to design future strategies to interfere with damage induced by necroptosis/regulated 
necrosis. In line with the crucial function of the kinase RIPK3 in necroptosis, NIH3T3 cells naturally 
lacking RIPK3 displayed a decreased accumulation of intracellular ceramide levels when undergoing 
necroptosis, whereas the stable re-expression of RIPK3 in wild-type cells restored the elevated 
ceramide levels in cells dying by necroptosis. Cells harboring kinase-defective RIPK3 showed slightly 
elevated ceramide levels upon induction of necroptosis. This is possibly a result of the induction of 
apoptotic-like caspase-independent cell death pathways rather than an induction of necroptosis, 
because Newton and coworkers recently claimed that the absence of RIPK3 drives the signaling 
pathway towards apoptosis (Newton et al. 2014). 
With regard to a future application of TRAIL-induced regulated necrosis, still further research is 
required. For future therapeutic application of TRAIL-induced regulated necrosis to eliminate tumor 
cells in patients, strategies for the induction of regulated necrosis need to be adapted to the in vivo 
situation, because the sensitizer CHX used in the study presented here is cytotoxic also to healthy 
tissue. Therefore, future therapies based on the treatment of patients with CHX are not suitable. As a 
possible alternative, He and coworkers showed that Smac mimetics can similarly sensitize cell culture 
models for TRAIL- and TNF-induced regulated necrosis (He et al. 2009). This could be confirmed 
with results obtained in the study presented here showing that the Smac mimetic birinapant similarly 
can act as enhancer of TRAIL- as well as TNF-induced regulated necrosis in tumor cell lines. 
However, in vivo studies showing the efficacy or toxicity of Smac mimetics under conditions of 
regulated necrosis are not available so far. A second possible alternative to CHX might be the 
application of the protein biosynthesis inhibitor homoharringtonine together with TRAIL/zVAD to 
induce regulated necrosis. Clinical studies have already indicated that homoharringtonine is effective 
in treating leukemia such as acute myeloid leukemia or chronic myeloid leukemia (Zhou et al. 1995) 
and in consequence, homoharringtonine has been approved for the treatment of chronic myeloid 
leukemia in patients (Narayanan et al. 2013). Apart from the problems of cytotoxicity of CHX, it must 
also be clarified whether TRAIL or zVAD-fmk treatment is indeed non-toxic in vivo. The study by 
Hellwig and Rehm demonstrated that TRAIL was well tolerated in preclinical models at serum 
concentrations (Hellwig and Rehm, 2012). Furthermore, in two independent studies, the application of 
zVAD-fmk did not show toxicity in vivo, either in a transgenic mouse model of Huntington disease 
(Chen et al. 2000) or a transgenic mouse model of amyotrophic lateral sclerosis (Li et al. 2000). As a 
next step, the possible in vivo toxicity of a joint application of TRAIL and zVAD-fmk has to be 
clarified, as well as in additional combination with chemotherapeutic agents. 
Rapid plasma permeabilization due to necrotic triggers leads to the release of DAMPs from the cell. 
These necrosis-dependent DAMPs can trigger inflammatory responses (Kaczmarek et al. 2013). 
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Accordingly, the release of DAMPs has to be addressed with regard to future therapies, because 
regulated necrosis has been associated with inflammation in several diseases, such as kidney ischemia 
reperfusion or systemic inflammatory response syndrome (Kaczmarek et al. 2013). Hence, it has to be 
addressed whether the death of tumor cells by regulated necrosis is immunogenic. It is also unknown 
whether regulated necrosis as a result may elicit an immune response that might eliminate residual and 
neighboring tumor cells (Vandenabeele et al. 2010). Resolving these questions for TRAIL-induced 
necrosis could thus contribute to an even more effective treatment for cancer patients in the future. 
6.4 Conclusions and biological relevance of the above observations 
Programmed cell death stands out as a critical process for multicellular organisms. This is 
demonstrated by the highly interconnected machinery that ensures its induction, regulation and 
execution. In this present study, it was confirmed that TNF-induced necroptosis and the PARP 
pathway represent two distinct and independent routes to regulated necrosis (Figure 57; see Sosna, 
Voigt et al. 2014). These findings have profound therapeutic implications, because they suggest that 
inhibiting just one of the signaling pathways that lead to regulated necrosis (including e.g. TNF-
induced necroptosis or PARP-1-dependent regulated necrosis) or apoptosis may exert only limited 
cytoprotective effects. As a consequence, a combinatorial strategy that simultaneously inhibits 
multiple signal transduction cascades rather than an individual application of highly specific 
necroptosis (e.g. Nec-1 or NSA) or PARP-1 inhibitors (e.g. olaparib) might be the approach of choice 
for the future, possibly resulting in an improved treatment of damage induced by regulated necrosis 
(e.g. in shock, pancreatitis, ischemic damage or neurodegenerative diseases). Still, future studies 
should address the decryption of the different modes of regulated necrosis to generate profound 
insights into molecular mechanisms of e.g. necroptosis and thus paving the way for its 
pharmacological modulation in the clinic. 
The data presented in this thesis help to decode at least some parts of the molecular pathways involved 
primarily in TNF-mediated necroptosis. Based upon the results obtained in the study presented here, 
the following extensions to the already established models can be proposed. HtrA2/Omi can be 
integrated as a key regulator into the known general signaling pathways of TNF-induced necroptosis 
(see Sosna and Voigt et al. 2013). In this model, binding of TNF to TNF-R1 induces activation of the 
kinases RIPK1, RIPK3, and of MLKL as components of the necrosomal core complex. HtrA2/Omi is 
activated indirectly within the mitochondria and presenilins might represent a missing link between 
HtrA2/Omi activation and execution of necroptosis. As another likely mechanism, MLKL has been 
found to activate the phosphatases PGAM5L/S, which in turn couple to the mitochondrial protein  
Drp-1, and as a mitochondrial attack complex, may cause the subsequent intramitochondrial activation 
of HtrA2/Omi. Furthermore, PGAM5 is constitutively degraded by yet unknown proteases in healthy 
cells. Upon induction of necroptosis, this constitutive proteolysis is inhibited, leading to an increase in 
PGAM5 levels, which may facilitate the fragmentation of mitochondria during necroptosis. In the 
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proteomic screen for serine proteases relevant in necroptosis, in addition to HtrA2/Omi, the proteases 
Lon protease 1, PMPCA and PSA1 were found to be potential candidates (Figure 57). The 
complementary siRNA screen of all proteases encoded by the human genome identified the anti-
apoptotic or pro-tumorigenic proteases DESC, MMP3, GGT1, PRPF8 and DPYL4 in addition to 
caspase-8, CYLD and c-FLIP. However, all identified proteases have to be further investigated with 
regard to their exact function and position in the signaling pathways of necroptosis. The 2D-DIGE 
approach unraveled an enrichment of proteins involved in the cellular energy metabolism (PHGDH, 
IMPDH2) or involved in the structural organization of the cell (CFL-1) during necroptosis. On the 
other hand, the levels of proteins involved in the structural organization of the cell (TUBA1B) or 
involved in the energy metabolism (PKM, CAT) were also decreased. Moreover, moesin, a component 
of the cytoskeleton was identified as a proteolytic substrate during necroptosis (Figure 57). However, 
these results should be further validated in additional biological replicates, and in the future the 
obtained candidates have to be analyzed for their impact on TNF-induced necroptosis. Apart from this, 
the proteolytic activation of A-SMase in response to TNF-induced necroptosis could be confirmed. 
However, the questions which protease cleaves pro-A-SMase and where the N-terminus of cleaved  
A-SMase is precisely localized still remain open. 
The characterization of TRAIL-induced regulated necrosis revealed that it is effective for the 
elimination of various types of tumor cells and that A-SMase and ceramide are critical mediators also 
in this system (Figure 57; Voigt et al. 2014). Similar to TNF-induced necroptosis, studies should aim 
at unraveling the detailed signaling pathways of TRAIL-induced regulated necrosis, as they might be a 
promising target for novel anti-tumor treatments. To this end, more information is needed to fill in the 
“gap” between receptor activation, RIPK1, RIPK3 and MLKL interaction and the observed activation 
of A-SMase and the resulting increase in intracellular ceramide levels. 
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Figure 57: A general model of selected signaling pathways in regulated necrosis based on the results obtained in the 
study presented here. Left: DNA damage induced by DNA alkylating agents such as MNNG or MMS lead to the activation 
of the PARP pathway. The resulting activation of PARP-1 can be efficiently blocked by the specific PARP-1 inhibitors  
3-AB, PJ-34 or olaparib. The activation of PARP-1 culminates in the rapid loss of ATP levels, accompanied by the activation 
of JNK and cathepsins, and subsequently resulting in chromatinolysis and the death of the cell via regulated necrosis. 
Middle: Another distinct pathway of regulated necrosis is necroptosis which can be mediated by e.g. TNF or TRAIL. After 
activation of TNF-R1 by binding of TNF under caspase inhibitory conditions, the necrosome containing phosphorylated and 
activated RIPK1 and RIPK3 is formed. Subsequently, the protein MLKL is activated. This signaling cascade then culminates 
in a yet unknown way in different executioner mechanisms. PGAM5 was shown to be constitutively degraded in healthy cells 
and thus upregulated during TNF-induced necroptosis. During a TFCK-sensitive serine protease screen, the serine protease 
HtrA2/Omi was identified which may be activated by novel mechanisms that involve the activity of presenilins. The TFCK-
sensitive serine protease Lon protease 1 as well as the TFCK-sensitive metalloproteinase PMPCA might also be involved in 
the execution of TNF-induced necroptosis, similar to the proteasomal protein PSA1. The siRNA screen identified, among 
CYLD, caspase-8 and CFLAR, proteases whose down-regulation potentiates (DESC1, GGT1, DPYL4, PRPF8, MMP3) or 
protects (MEP1B) from TNF-induced necroptosis and who thus may be negative or positive regulators of the execution of 
necroptosis. Furthermore, 2D-DIGE analyses of soluble proteins and magnetically enriched TNF-R1-containing vesicles 
revealed that levels of proteins involved in regulating the energy metabolism were either increased (PHGDH, IMPDH2) or 
decreased (PKM, CAT) during TNF-induced necroptosis. Moreover, protein levels of components of the structural 
organization of the cell were increased (CFL-1) or decreased (TUBA1B) or proteins were substrates for proteolytic cleavage 
(moesin). Ceramide generation as another executioner mechanism of TNF-induced necroptosis is initiated by the proteolytic 
maturation/activation of A-SMase by a yet unknown protease. TNF-induced necroptosis can be efficiently blocked by the 
RIPK1 inhibitor Nec-1, the MLKL inhibitor NSA, the serine protease inhibitor TFCK and/or by the HtrA2/Omi inhibitor 
Ucf-101. Right: Likewise, TRAIL-induced necroptosis can be blocked by the addition of Nec-1 or NSA. The addition of 
Smac mimetics can potentiate and thereby positively regulate TRAIL-induced necroptosis in clinically relevant tumor cells. 
Here, ceramide generation is also an important executioner mechanism and recent studies also point to a proteolytic 
maturation/activation of A-SMase during TRAIL-induced regulated necrosis (M. Kähler, Master Thesis, 2013). Question 
marks indicate unknown signaling pathways of proteins. Abbreviations: acid sphingomyelinase (A-SMase), adenosine-5'-
triphosphate (ATP), catalase (CAT), caspase-8 and FADD-like apoptosis regulator (CFLAR), cofilin-1 (CFL-1), 
cylindromatosis (CYLD), transmembrane protease serine 11E (DESC1), dihydropyrimidinase-like 4 (DPYL4), gamma-
glutamyltransferase 1 (GGT1), inosine-5’-monophosphate dehydrogenase 2 (IMPDH2), c-Jun N-terminal kinases (JNK), 
meprin beta (MEP1B), mixed-lineage kinase domain-like (MLKL), metalloproteinase 3 (MMP3), methyl methanesulfonate 
(MMS), 1-methyl-3-nitro-1-nitrosoguanidine (MNNG), necrostatin 1 (Nec-1), necrosulfonamide (NSA), poly(ADP-ribose) 
polymerase (PARP), phosphoglycerate mutase family member (PGAM), D-3-phosphoglycerate dehydrogenase (PHGDH), 
pyruvate kinase isozymes M1/M2 (PKM), mitochondrial processing peptidase alpha (PMPCA), pre-mRNA processing factor 
8 (PRPF8), proteasome subunit alpha type-1 (PSA1), receptor-interacting protein kinase (RIPK), tumor necrosis factor 
(TNF), TNF-receptor 1 (TNF-R1), TNF-related apoptosis inducing ligand (TRAIL), TRAIL-receptor (TRAIL-R), tubulin 
alpha-1B chain (TUBA1B), two-dimensional difference gel electrophoresis (2D-DIGE). 
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8. Appendix 
Table S1: The 40 candidate proteases identified in the first siRNA screen whose down-regulation either positively or 
negatively affects TNF-induced necroptosis in HT-29 cells. These proteases meet rules for candidates as follows: (a) 
protease genes, represented by two or three siRNAs, which after down-regulation either enhanced or reduced TNF-induced 
necroptosis compared to control transfected cells by at least 1.5-fold, or (b) protease genes, represented by a single siRNA, 
whose down-regulation either enhanced or reduced necroptosis by at least 1.5-fold and for which the effects after down-
regulation by the two other siRNAs had the same enhancing or reducing effect on necroptosis (but with fold-induction below 
1.5 and thereby not passing the threshold). Highlighted proteases were also found as candidate hits in the second siRNA 
screen (see 5.2.2). For all proteins, the related reference sequence from the National Center of Biotechnology Information is 
listed. 
 
positive negative positive negative
Protease Reference sequence
ADAM33 NM_025220 x
ADAMTS18 NM_199355 x
aminopeptidase Q NM_173800 x
archaemetzincin1 NM_133463 x
ATPGTP binding proteinlike 2 NM_024783 x
ATPGTP binding proteinlike 3 NM_178563 x
carboxypeptidase A5 NM_080385 x
caspase-8 NM_001228 x
casperFLIP NM_003879 x
cathepsin W NM_001335 x
chymotrypsin C NM_007272 x
cylindromatosis protein NM_015247 x
DESC1 protease NM_014058 x
dihydropyrimidinase-related protein 3 NM_001387 x
dihydropyrimidinase-related protein 4 NM_006426 x
dipeptidylpeptidase 8 NM_197960 x
DNAdamage inducible protein 2 NM_032341 x
epoxide hydrolase NM_000120 x
gammaglutamyltransferase 1 NM_005265 x
gelatinase A NM_004530 x
glutamine-fructose-6-phosphate transamidase 2 NM_005110 x
granzyme A NM_006144 x
insulysin NM_004969 x
kallikrein hK4 NM_004917 x
kallikrein hK6 NM_002774 x
MAP1D methione aminopeptidase 1D NM_199227 x
MASP13 NM_001879 x
meprin beta subunit NM_005925 x
methionyl aminopeptidase I NM_015143 x
neutrophil elastase NM_001972 x
pancreatic elastase II form B NM_015849 x
plasma Glucarboxypeptidase NM_016134 x
polyserase 2 NM_173502 x
PRPF8 NM_006445 x
rhomboid 5 homolog 2 NM_001005498 x
S2P protease NM_015884 x
stromelysin 1 NM_002422 x
thimet oligopeptidase NM_003249 x
tryptase gamma 1 NM_012467 x
YME1like 1 NM_139312 x
(a)
effect after stimulation
(b)
Meeting rules for positive candidates
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Table S2: Soluble proteins differentially regulated after induction of necroptosis which were identified by MS 
analysis. For differential proteome analysis, soluble proteins were extracted from U-937 cells stimulated with TNF60-Fc and 
zVAD-fmk on ice (0 min) and 20 min at 37 °C to induce necroptosis. Protein extracts from cells stimulated for 20 min were 
labeled with the fluorescent dye Cy 3, and control extracts were labeled with the fluorescent dye Cy 5 and separated by 2D-
DIGE. All differentially expressed protein spots were analyzed by means of MALDI-TOF/TOF, and in the first experiment 
30 proteins were identified with high confidence classified based on their x-fold increased or decreased protein levels after 
induction of necroptosis. In the repetition (second experiment) of the above experiment, 89 differentially expressed protein 
spots were detected. For 29 protein spots, increased protein levels after 20 min TNF/zVAD stimulation were detected 
whereas 60 proteins spots showed decreased levels compared to untreated (0 min) samples. Positive values in average ratio 
mean increased amounts of protein levels after induction of necroptosis, compared to untreated samples. Negative average 
ratios indicate decreased protein levels after induction of necroptosis. The accession number for the reference sequence of 
each protein is listed. The protein stathmin with the spot number 2467 and 2469 is a candidate for proteolytic cleavage during 
necroptosis (see Figure S1). The 2D-DIGE experiment was performed with technical assistance of Melanie Nebendahl and 
Benjamin Schönbeck (Christian-Albrechts-University, Kiel, Germany). The mass spectrometry analysis of isolated proteins 
was performed by Tomas Koudelka (Christian-Albrechts-University, Kiel, Germany). 
 
spot no. identified proteins accession number average ratio
Experiment 1
1145 Probable ATP-dependent RNA helicase P17844 1.2293
1162 Heterogenous nuclear ribonucleoprotein L P14866 1.5268
1170 ATPase family AAA domain-containing protein 3B Q5T9A4 1.2437
1193 Heterogeneous nuclear ribonucleoprotein K P61978 -1.2687
1291 Tubulin alpha-1C Q9BQE3 -1.2605
1294 Tubulin alpha-1B chain P68363 -1.308
1303 Tubulin alpha-1B chain P68363 -1.2671
1325 Tubulin alpha-1B chain P68363 -1.2107
1418 Pyruvate kinase isozymes M1/M2 P14618 -1.7399
1428 cAMP-dependent protein kinase type II-alpha regulatory subunit P13861 1.2019
1488 Protein disulfide-isomerase A6 Q15084 1.3049
1639 Actin, cytoplasmic 2 P63261 -1.3389
1724 Heterogenous nuclear ribonucleoprotein A3 P51991 1.2382
1897 Heterogenous nuclear ribonucleoproteins A2/B1 P22626 1.2153
1927 S-formylglutathione hydrolase P10768 -1.282
1947 Heterogenous nuclear ribonucleoprotein A1 P09651 1.214
1951 Heterogenous nuclear ribonucleoprotein A1 P09651 1.3069
1974 ELAV-like protein 1 Q15717 1.3073
2036 40S ribosomal protein S3 P23396 -1.268
2076 Rho GDP-dissociation inhibitor 2 P52566 -1.2841
2110 Phosphoglycerate mutase 1 P18669 1.3754
2123 Heat shock protein beta-1 P04792 1.9526
2126 Heat shock protein beta-1 P04792 -1.8452
2211 Adenine phosphoribosyltransferase P07741 -1.2185
2261 Peptidyl-prolyl cis-trans isomerase B P23284 1.2811
2272 Cofilin-1 P23528 1.3971
2273 Cofilin-1 P23528 1.2384
2283 Stathmin P16949 -1.2725
2294 Peptidyl-prolyl cis-trans isomerase A P62937 1.2322
2295 Nucleoside diphosphate kinase B P22392 1.2404
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Table S2: Continued. 
 
spot no. identified proteins accession number average ratio
Experiment 2
601 Heterogenous nuclear ribonucleoprotein U Q00839 -1.331
791 Alpha-actinin-1 P12814 -1.2283
853 DNA replication licensing factor MCM4 P33991 -1.2152
859 Elongation factor 2 P13639 -1.2129
917 Glycogen phosphorylase, brain form P11216 1.378
1080 Protein transport protein Sec23A Q15436 1.2614
1100 Procollagen galactosyltransferase 1 Q8NBJ5 1.2913
1105 TATA-binding protein-associated factor 2N Q92804 -1.302
1125 Moesin P26039 -1.2084
1226 Plastin-2 P13796 -1.4327
1322 Heterogenous nuclear ribonucleoprotein K P61978 1.3104
1322 Tubulin beta chain P07437 1.3104
1346 Heterogenous nuclear ribonucleoprotein K P61978 -1.2407
1349 Heterogenous nuclear ribonucleoprotein K P61978 -1.377
1355 Heterogenous nuclear ribonucleoprotein K P61978 -1.2114
1366 Phosphoglucomutase-1 P36871 -1.9062
1366 Acyl-CoA synthetase family member 2 Q96CM8 -1.9062
1396 Splicing factor U2AF 65 kDa subunit P26368 -1.2887
1396 Cytoplasmic dynein 1 light intermediate chain Q9Y6G9 -1.2887
1446 Tubulin alpha-1B chain P68363 -1.2435
1465 Pyruvate kinase isozymes M1/M2 P14618 -1.3968
1465 Nicalin Q969V3 -1.3968
1467 Tubulin beta chain P07437 -1.288
1472 Tubulin beta-2C chain P68371 -1.2712
1493 Serine beta-lactamase-like protein LACTB, mitochondrial P83111 -1.3182
1503 Tubulin beta-2B chain Q9BVA1 -1.4021
1504 Tubulin beta chain P07437 -1.2213
1510 Adenylyl cyclase-associated protein 1 Q01518 -1.218
1512 Adenylyl cyclase-associated protein 1 Q01518 -1.4225
1516 Adenylyl cyclase-associated protein 1 Q01518 1.2287
1530 Tubulin beta-2C chain P68371 -1.2569
1532 Pyruvate kinase isozymes M1/M2 P14618 -1.3317
1565 Pyruvate kinase isozymes M1/M2 P14618 -1.2241
1573 cAMP-dependent protein kinase type II-alpha regulatory subunit P13861 -1.2236
1573 Histone-binding protein RBBP4 Q09028 -1.2236
1580 Glutaminase kidney isoform, mitochondrial O94925 -1.2558
1580 Pyruvate kinase isozymes M1/M2 P14618 -1.2558
1583
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily E member 1 Q969G3 -1.0381
1583 Tubulin beta chain P07437 -1.0381
1583 Serine/arginine-rich splicing factor 6 Q13247 -1.0381
1583 cAMP-dependent protein kinase type II-alpha regulatory subunit P13861 -1.0381
1591 Pyruvate kinase isozymes M1/M2 P14618 -1.4774
1688 Septin-7 Q16181 -1.7378
1699 Pyruvate kinase isozymes M1/M2 P14618 1.2977
1738 DAZ-associated protein 1 Q96EP5 -1.9626
1738 Elongation factor 1-alpha 2 Q05639 -1.9626
1783 Flap endonuclease 1 P39748 -1.2501
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Table S2: Continued. 
spot no. identified proteins accession number average ratio
Experiment 2
1800 Actin, cytoplasmic 2 P36261 -1.3143
1911 Heterogenous nuclear ribonucleoprotein D0 Q14103 -1.2239
1913 Serine-threonine kinase receptor-associated protein Q9Y3E4 1.2256
1950 Heterogeneous nuclear ribonucleoproteins A2/B1 P22626 -1.2348
1950 Replication factor C subunit P40938 -1.2348
1979 Heterogeneous nuclear ribonucleoproteins C1/C2 P07910 -1.2041
1979 Glyoxylate reductase/hydroxypyruvate reductase Q9UBQ7 -1.2041
1981 Annexin A2 P07355 -1.2043
1981 Casein kinase II subunit alpha P19784 -1.2043
2001 Glyceraldehyde-3-phosphate dehydrogenase P04406 -1.4635
2023 Ribonuclease H2 subunit B Q5TBB1 -1.2017
2023 Heterogeneous nuclear ribonucleoprotein A1 P09651 -1.2017
2062 Guanine nucleotide-binding G(I)/G(S)/G(T) subunit beta 1 P62879 1.215
2062 Guanine nucleotide-binding G(I)/G(S)/G(T) subunit beta 2 P62873 1.215
2080 Serine/arginine-rich splicing factor 1 Q07955 1.2787
2087 Prohibitin-2 Q99623 1.2682
2128 Phosphatidylinositol transfer protein beta isoform P48739 -1.4339
2128 Phosphatidylinositol transfer protein alpha isoform Q00169 -1.4339
2128 S-formylglutathione hydrolase P10763 -1.4339
2149 Cytochrome c-type heme lyase P53701 1.3478
2149 Cyclin-dependent kinase 1 P06493 1.3478
2164 Proteasome assembly chaperone 2 Q969U7 -1.0069
2165 Translation initiation factor eIF-2B subunit alpha Q14232 1.3218
2165 Actin-related protein 2/3 complex subunit 2 O15144 1.3218
2165 Glucosamine-6-phosphate isomerase 1 P46926 1.3218
2181 Complement component 1 Q subcomponent-binding protein Q07021 -1.3724
2197 Putative elongation factor 1-alpha-like Q5VTE0 -1.2226
2223 Peflin Q9UBV8 1.2091
2223 Acidic leucine-rich nuclear phosphoprotein 32 family member B Q92688 1.2091
2251 Galectin-3 P17931 -1.3358
2277 High mobility group protein B2 P26583 -1.0863
2284 Adenylate kinase 2 P54819 1.6237
2294 Protein NipSnap homolog 1 Q9BPW8 -1.211
2309 Eukaryotic translation initiation factor 4H Q15056 2.6146
2311 Heat shock protein beta-1 P04792 1.6897
2311 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial O75489 1.6897
2313 Heat shock protein beta-1 P04792 -2.8604
2329 Metaxin-2 O75431 -1.2695
2337 GrpE protein homolog 1, mitochondrial Q9HAV7 -2.5753
2351 Translationally-controlled tumor protein P13693 -1.2034
2361 Cysteine and glycine-rich protein 1 P21291 -1.279
2365 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 O96000 -1.7841
2373 Mps one binder kinase activator-like 1B Q9H859 2.4766
2373 Rho GDP-dissociation inhibitor 2 P52566 2.4766
2374 Ubiquitin-40S ribosomal protein S27a P62979 -1.3271
2374 Histone H2A type 1-H Q96KK5 -1.3271
2374 Nucleophosmin P06748 -1.3271
2376 40S ribosomal protein S3a P61247 -1.3644
2430 Uncharacterized protein KIAA1143 Q96AT1 1.2517
2442 Cofilin-1 P23528 1.4223
2447 Sorting nexin-3 O60493 -1.176
2447 Sorting nexin-12 Q9UMY4 -1.176
2449 Destrin P60981 1.3217
2455 Tumor necrosis factor alpha-induced protein 8-like protein 2 Q6P589 -1.404
2460 Nucleoside diphosphate kinase A P15531 -1.3189
2461 Ubiquitin-conjugating enzyme E2 L3 P68036 -1.0153
2463 Eukaryotic translation initiation factor 5A-2 Q9GZV4 1.6478
2467 Stathmin P16949 2.3271
2469 Stathmin P16949 -1.4405
2489 60S ribosomal protein L22 P35268 -1.2124
2489 Dual specificity protein phosphatase 23 Q9BVJ7 -1.2124
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Table S3: Proteins differentially regulated during necroptosis identified by MS analysis. For differential proteome 
analysis, in the first experiment magnetically enriched TNF-R1 containing vesicles of U-937 cells stimulated with TNF60-
Fc/zVAD for 0 and 20 min were isolated without depletion of mitochondria and compared by 2D-DIGE. All differentially 
expressed protein spots were analyzed by means of MALDI-TOF/TOF. The mass spectrometric analysis identified 21 
proteins with increased and 25 with decreased protein levels in the fraction of U-937 cells treated with TNF60-Fc/zVAD for 
20 min. In the repetition (second experiment), prior to 2D-DIGE analysis, the magnetic TNF-R1 fractions stimulated as 
above were subjected to density-gradient centrifugation to avoid contamination with mitochondria. The protein spots were 
again analyzed by MALDI-TOF/TOF. The mass spectrometric analysis identified 6 proteins with increased and 4 proteins 
with decreased levels in the fraction containing TNF-R1 vesicles which were isolated from cells stimulated with TNF60-
Fc/zVAD for 20 min. Positive values in average ratio mean increased amounts of protein levels after induction of 
necroptosis, compared to untreated samples. Negative average ratios indicate decreased protein levels after induction of 
necroptosis. The accession number for the reference sequence of each protein is listed. The 2D-DIGE experiment was 
performed with technical assistance of Melanie Nebendahl and Benjamin Schönbeck (Christian-Albrechts-University, Kiel, 
Germany). The mass spectrometry analysis of isolated proteins was performed by Tomas Koudelka (Christian-Albrechts-
University, Kiel, Germany). 
spot no. identified proteins accession number average ratio
Experiment 1 with mitochondria fraction
349 Hypoxia up-regulated protein 1 Q9Y4L1 1.4146
592 C-1-tetrahydrofolate synthase, cytoplasmic P11586 -1.2063
601 Moesin P26038 1.2082
714 Heat shock protein HSP 90-beta P08238 1.4239
830 Ezrin P15311 -1.2443
845 Moesin P26038 -1.2421
922 Trifunctional enzyme subunit alpha, mitochondrial P40939 1.2192
996 Plastin-2 P13796 -1.2863
1008 Plastin-2 P13796 -1.3026
1009 Plastin-2 P13796 -1.2483
1106 T-complex protein 1 subunit alpha P17987 1.2315
1193 Catalase P04040 -1.2924
1195 Catalase P04040 -1.2491
1203 Calreticulin P27797 1.0358
1272 Prenylcysteine oxidase 1 Q9UHG3 -1.217
1274 D-3-phosphoglycerate dehydrogenase O43175 1.2025
1278 Tubulin beta chain P07437 -1.4212
1280 Inosine-5'-monophosphate dehydrogenase 2 P12268 2.0197
1316 T-complex protein 1 subunit beta P78371 1.204
1329 ATP synthase subunit alpha, mitochondrial P25705 1.2206
1344 ADP-dependent glucokinase Q9BRR6 1.1363
1354 Eukaryotic translation initiation factor 2 subunit 3 P41091 1.2255
1369 ATP synthase subunit beta, mitochondrial P06576 1.2251
1371 ATP synthase subunit beta, mitochondrial P06576 1.3572
1416 Actin-related protein 3 P61158 -1.2959
1440 Protein-disulfide-isomerase A6 Q15084 1.5891
1456 Protein-disulfide isomerase A6 Q15084 -1.4015
1478 Alpha-enolase P06733 -1.6507
1567 Heterogeneous nuclear ribonucleoprotein K P61978 1.2578
1598 Actin, cytoplasmic 2 P63261 -1.2056
1606 Actin, cytoplasmic 2 P63261 -1.3595
1607 Actin, cytoplasmic 2 P63261 -1.2551
1608 Actin, cytoplasmic 2 P63261 -1.3179
1681 Fructose-bisphosphate aldolase A P04075 -1.2993
1775 Annexin A1 P04083 -1.8544
1821 Keratin, type II cytoskeletal 2 epidermal P35908 1.0087
1821 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial P11177 1.0087
1821 Keratin, type II cytoskeletal 1 epidermal P04264 1.0087
1829 L-lactate dehydrogenase B chain P07195 -1.2598
1858 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 P62879 -1.3633
1883 Voltage-dependent anion-selective channel protein P45880 -1.5461
1888 Prohibitin-2 Q99623 1.3515
1939 Annexin A4 P09525 -1.4519
1960 Prohibitin P35232 1.3244
1965 D-beta-hydroxybutyrate dehydrogenase, mitochondrial Q02338 -1.2161
2100 Keratin, type II cytoskeletal 2 epidermal P35908 -1.5863
Experiment 2 without mitochondria fraction
381 Catalase P04040 -2.3861
589 Inosine-5'-monophosphate dehydrogenase 2 P12268 1.7859
710 D-3-phosphoglycerate dehydrogenase O43175 1.677
836 Myosin-lg B0I1T2 1.6536
1271 Protein-disulfide-isomerase A6 Q15084 -2.1127
1319 Septin-7 Q16181 1.6205
1333 Alpha-enolase P06733 1.0232
1340 Alpha-enolase P06733 -1.2494
1348 Alpha-enolase P06733 1.015
1607 Annexin A2 P07355 -1.8261
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